

(19) **DANMARK**

(10) **DK/EP 3710430 T3**



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

- (51) Int.Cl.: **C 07 D 231/08 (2006.01)** **A 61 K 31/4152 (2006.01)** **A 61 K 31/4155 (2006.01)**
A 61 P 3/00 (2006.01) **A 61 P 25/00 (2006.01)** **A 61 P 29/00 (2006.01)**
A 61 P 31/12 (2006.01) **A 61 P 35/00 (2006.01)** **A 61 P 37/02 (2006.01)**
C 07 D 401/12 (2006.01) **C 07 D 403/12 (2006.01)** **C 07 D 405/12 (2006.01)**
C 07 D 409/12 (2006.01) **C 07 D 413/12 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2024-09-09**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2024-07-03**
- (86) Europæisk ansøgning nr.: **18877721.3**
- (86) Europæisk indleveringsdag: **2018-11-15**
- (87) Den europæiske ansøgnings publiceringsdag: **2020-09-23**
- (86) International ansøgning nr.: **IL2018051232**
- (87) Internationalt publikationsnr.: **WO2019097515**
- (30) Prioritet: **2017-11-15 US 201762586195 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV
MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Metabomed Ltd, 18 HaKishon St, 81220 Yavne, Israel**
- (72) Opfinder: **NAKACHE, Philippe, Etzel 19, 81220 Ness Ziona, Israel**
EREZ, Omri, HaRaaz Street 3 apt 8, 7631003 Rehovot, Israel
BOTTI, Simone, HaNassi HaRishon Street 52b apt 32, 7630242 Rehovot, Israel
GOUTOPOULOS, Andreas, 20 Fayette St., Apt 2, Boston, Massachusetts 02116, USA
LABELLE, Marc, 18 Regency Drive, Bedford, New Hampshire 03110, USA
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **ACSS2-INHIBITORER OG FREMGANGSMÅDER TIL ANVENDELSE DERAFT**
- (56) Fremdragne publikationer:
WO-A1-2013/159224
WO-A1-2015/175845
JP-A- H11 291 635
US-A- 3 905 997
US-A- 4 207 317
MARZOUK M.I. et al.: "Synthesis and characterization of novel pyrazolone derivatives", European Journal of Chemistry, vol. 5, no. 1, 31 March 2014 (2014-03-31), pages 24-32, XP055609686,
S. I. EL-DESOKY et al.: "UTILITY OF ISOTHIOCYANATES IN HETEROCYCLIC SYNTHESIS", Sulfur Letters, vol. 25, 5 June 2002 (2002-06-05), - 29 October 2010 (2010-10-29), pages 199-205, XP055609691,
Gaffer, Abdel Fattah, Etman, Abdel Latif: "Synthesis of Thiazolyl-Pyrazolin-5-One Derivatives as Antioxidant Agents", Journal of Heterocyclic Chemistry, vol. 54, no. 1, 14 July 2015 (2015-07-14), pages 331-340,

Fortsættes ...

XP009520847, DOI: 10.1002/jhet.2588

DATABASE CAS 30 September 2015 (2015-09-30), "IH-Pyrazole-4-carboxamide, 1-(4,6-dimethyl-2-pyrimidinyl)-4,5-dihydro-3-methyl-N-[2-(1-methylethyl)phenyl]-5-oxo", retrieved from STN Database accession no. 1808705-10-3

DATABASE CAS 30 June 2015 (2015-06-30), "IH-Pyrazole-4-carboxamide, 1-(2,4-dimethylphenyl)-4,5-dihydro-3-methyl-N-[1-(1-methylethyl)-IH-pyrazol-5-yl]-5-oxo", retrieved from STN Database accession no. 1791350-17-8

DATABASE CAS 25 June 2015 (2015-06-25), "IH-Pyrazole-4-carboxamide, 4,5-dihydro-3-methyl-N-[3-methyl-(phenyl methyl)-IH-pyrazol-5-yl]-5-oxo-1-phenyl", retrieved from STN Database accession no. 1787906-31-3

DATABASE CAS 16 July 2013 (2013-07-16), "IH-Pyrazole-4-carboxamide, 1-(4-fluorophenyl)-4,5-dihydro-3-methyl-5-oxo-N-(tetrahydro-1,1-dioxido-3-fluanyl)", retrieved from STN Database accession no. 1444619-19-5

DATABASE CAS 16 June 2013 (2013-06-16), "IH-Pyrazole-4-carboxamide, 1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-N-(tetrahydro-1,1-dioxido-3-thienyl)", retrieved from STN Database accession no. 1444612-86-5

DATABASE CAS 16 July 2013 (2013-07-16), "IH-Pyrazole-4-carboxamide, 1-(2,4-dimethylphenyl)-4,5-dihydro-3-methyl-5-oxo-N-(tetrahydro-1,1-dioxido-3-thienyl)", retrieved from STN Database accession no. 1444608-50-7

DATABASE CAS 11 April 2013 (2013-04-11), "IH-Pyrazole-4-carboxamide, 4,5-dihydro-3-methyl-5-oxo-N-2-pyridinyl-1-(tetrahydro-1,1-dioxido-3-thienyl)", retrieved from STN Database accession no. 1427938-63-3

DATABASE CAS 15 March 2013 (2013-03-15), "IH-Pyrazole-4-carboxamide, 4,5-dihydro-3-methyl-5-oxo-1-(tetrahydro-1,1-dioxido-3-thienyl)-N-2-thiazolyl", retrieved from STN Database accession no. 1424277-15-5

DATABASE CAS 15 March 2013 (2013-03-15), "IH-Pyrazole-4-carboxamide, 4,5-dihydro-3-methyl-5-oxo-1-(tetrahydro-1,1-dioxido-3-thienyl)-N-1,3,4-thiadiazol-2-yl", retrieved from STN Database accession no. 1424179-52-1

DATABASE CAS 15 March 2013 (2013-03-15), "IH-Pyrazole-4-carboxamide, 4,5-dihydro-3-methyl-5-oxo-N-3-pyridinyl-1-(tetrahydro-1,1-dioxido-3-thienyl)", retrieved from STN Database accession no. 1424083-43-1

DATABASE CAS 14 March 2013 (2013-03-14), "IH-Pyrazole-4-carboxamide, N-1,3-benzodioxol-5-yl-4,5-dihydro-3-methyl-5-oxo-1-(tetrahydro-1,1-dioxido-3-thienyl)", retrieved from STN Database accession no. 1423725-39-6

DATABASE CAS 14 March 2013 (2013-03-14), "IH-Pyrazole-4-carboxamide, 4,5-dihydro-3-methyl-5-oxo-N-phenyl-1-(tetrahydro-1,1-dioxido-3-thienyl)", retrieved from STN Database accession no. 1423670-51-2

DATABASE CAS 14 March 2013 (2013-03-14), "IH-Pyrazole-4-carboxamide, N-(2-chloro-3-pyridinyl)-4,5-dihydro-3-methyl-5-oxo-1-(tetrahydro-1,1-dioxido-3-thienyl)", retrieved from STN Database accession no. 1423624-35-4

DATABASE CAS 7 June 2012 (2012-06-07), "IH-Pyrazole-4-carboxamide, N-[4-(3-fluorophenyl)-2-thiazolyl]-4,5-dihydro-3-methyl-5-oxo-1-(tetrahydro-1,1-dioxido-3-fluanyl)", retrieved from STN Database accession no. 1376380-77-6

DATABASE CAS 7 June 2012 (2012-06-07), "IH-Pyrazole-4-carboxamide, N-(6-ethyl-2-benzothiazolyl)-4,5-dihydro-3-methyl-5-oxo-1-(tetrahydro-1,1-dioxido-3-thienyl)", retrieved from STN Database accession no. 1375980-06-5

DATABASE CAS 30 January 2003 (2003-01-30), "IH-Pyrazole-4-carbothioamide, 1-[4-(4-chlorophenyl)-2-thiazolyl]-4,5-dihydro-5-oxo-N,3-diphenyl", retrieved from STN Database accession no. 483276-32-0

DATABASE CAS 30 January 2003 (2003-01-30), "IH-Pyrazole-4-carboxamide, N-(4-chlorophenyl)-1-[4-(4-chlorophenyl)-2-thiazolyl]-4,5-dihydro-5-oxo-3-phenyl", retrieved from STN Database accession no. 483276-31-9

DESCRIPTION

Description

FIELD OF THE INVENTION

[0001] The present invention relates to novel ACSS2 inhibitors, composition and methods of preparation thereof, and uses thereof for treating viral infection (e.g. CMV), alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), metabolic disorders including: obesity, weight gain and hepatic steatosis, neuropsychiatric diseases including: anxiety, depression, schizophrenia, autism and post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.

BACKGROUND OF THE INVENTION

[0002] Cancer is the second most common cause of death in the United States, exceeded only by heart disease. In the United States, cancer accounts for 1 of every 4 deaths. The 5-year relative survival rate for all cancer patients diagnosed in 1996-2003 is 66%, up from 50% in 1975-1977 (Cancer Facts & Figures American Cancer Society: Atlanta, GA (2008)). The rate of new cancer cases decreased by an average 0.6% per year among men between 2000 and 2009 and stayed the same for women. From 2000 through 2009, death rates from all cancers combined decreased on average 1.8% per year among men and 1.4% per year among women. This improvement in survival reflects progress in diagnosing at an earlier stage and improvements in treatment. Discovering highly effective anticancer agents with low toxicity is a primary goal of cancer research.

[0003] Cell growth and proliferation are intimately coordinated with metabolism. Potentially distinct differences in metabolism between normal and cancerous cells have sparked a renewed interest in targeting metabolic enzymes as an approach to the discovery of new anticancer therapeutics.

[0004] It is now appreciated that cancer cells within metabolically stressed microenvironments, herein defined as those with low oxygen and low nutrient availability (i.e., hypoxia conditions), adopt many tumor-promoting characteristics, such as genomic instability, altered cellular bioenergetics and invasive behavior. In addition, these cancer cells are often intrinsically resistant to cell death and their physical isolation from the vasculature at the tumor site can compromise successful immune responses, drug delivery and therapeutic efficiency, thereby

promoting relapse and metastasis, which ultimately translates into drastically reduced patient survival. Therefore, there is an absolute requirement to define therapeutic targets in metabolically stressed cancer cells and to develop new delivery techniques to increase therapeutic efficacy. For instance, the particular metabolic dependence of cancer cells on alternative nutrients (such as acetate) to support energy and biomass production may offer opportunities for the development of novel targeted therapies.

Acetyl-CoA synthetase enzyme, ACSS2 as a target for cancer treatment

[0005] Acetyl-CoA represents a central node of carbon metabolism that plays a key role in bioenergetics, cell proliferation, and the regulation of gene expression. Highly glycolytic or hypoxic tumors must produce sufficient quantities of this metabolite to support cell growth and survival under nutrient-limiting conditions. Acetate is an important source of acetyl-CoA in hypoxia. Inhibition of acetate metabolism may impair tumor growth. The nucleocytosolic acetyl-CoA synthetase enzyme, ACSS2, supplies a key source of acetyl-CoA for tumors by capturing acetate as a carbon source. Despite exhibiting no gross deficits in growth or development, adult mice lacking ACSS2 exhibit a significant reduction in tumor burden in two different models of hepatocellular carcinoma. ACSS2 is expressed in a large proportion of human tumors, and its activity is responsible for the majority of cellular acetate uptake into both lipids and histones. Further, ACSS2 was identified in an unbiased functional genomic screen as a critical enzyme for the growth and survival of breast and prostate cancer cells cultured in hypoxia and low serum. High expression of ACSS2 is frequently found in invasive ductal carcinomas of the breast, triple-negative breast cancer, glioblastoma, ovarian cancer, pancreatic cancer and lung cancer, and often directly correlates with higher-grade tumors and poorer survival compared with tumors that have low ACSS2 expression. These observations may qualify ACSS2 as a targetable metabolic vulnerability of a wide spectrum of tumors.

[0006] Due to the nature of tumorigenesis, cancer cells constantly encounter environments in which nutrient and oxygen availability is severely compromised. In order to survive these harsh conditions, cancer cell transformation is often coupled with large changes in metabolism to satisfy the demands for energy and biomass imposed by continued cellular proliferation. Several recent reports discovered that acetate is used as an important nutritional source by some types of breast, prostate, liver and brain tumors in an acetyl-CoA synthetase 2 (ACSS2)-dependent manner. It was shown that acetate and ACSS2 supplied a significant fraction of the carbon within the fatty acid and phospholipid pools (Comerford *et. Al.* Cell 2014; Mashimo *et. Al.* Cell 2014; Schug *et al* Cancer Cell 2015*). High levels of ACSS2 due to copy-number gain or high expression were found to correlate with disease progression in human breast prostate and brain tumors. Furthermore, ACSS2, which is essential for tumor growth under hypoxic conditions, is dispensable for the normal growth of cells, and mice lacking ACSS2 demonstrated normal phenotype (Comerford *et. Al.* 2014). The switch to increased reliance on ACSS2 is not due to genetic alterations, but rather due to metabolic stress conditions in the tumor microenvironment. Under normal oxidative conditions, acetyl-CoA is typically produced from citrate via citrate lyase activity. However, under hypoxia, when cells adapt to anaerobic

metabolism, acetate becomes a key source for acetyl-CoA and hence, ACSS2 becomes essential and is, *de facto*, synthetically lethal with hypoxic conditions (see Schug et. Al., Cancer Cell, 2015, 27:1, pp. 57-71). The accumulative evidences from several studies suggest that ACSS2 may be a targetable metabolic vulnerability of a wide spectrum of tumors.

[0007] In certain tumors expressing ACSS2, there is a strict dependency on acetate for their growth or survival, then selective inhibitors of this nonessential enzyme might represent an unusually ripe opportunity for the development of new anticancer therapeutics. If the normal human cells and tissues are not heavily reliant on the activity of the ACSS2 enzyme, it is possible that such agents might inhibit the growth of ACSS2-expressing tumors with a favorable therapeutic window.

[0008] Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar pathogenesis and histopathology but a different etiology and epidemiology. NASH and ASH are advanced stages of non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD). NAFLD is characterized by excessive fat accumulation in the liver (steatosis), without any other evident causes of chronic liver diseases (viral, autoimmune, genetic, etc.), and with an alcohol consumption ≤ 20 -30 g/day. On the contrary, AFLD is defined as the presence of steatosis and alcohol consumption > 20 -30 g/day.

[0009] Hepatocyte ethanol metabolism produces free acetate as its end product which, largely in other tissues, can be incorporated into acetyl-coenzyme A (acetyl-CoA) for use in Krebs cycle oxidation, fatty acid synthesis, or as a substrate for protein acetylation. This conversion is catalyzed by the acyl-coenzyme A synthetase short-chain family members 1 and 2 (ACSS1 and ACSS2). The role of acetyl-CoA synthesis in control of inflammation opens a novel field of study into the relationship between cellular energy supply and inflammatory disease. It has been shown that ethanol enhances macrophage cytokine production by uncoupling gene transcription from its normal regulatory mechanisms through increased histone acetylation, and that the conversion of the ethanol metabolite acetate to acetyl-CoA is crucial to this process.

[0010] It was suggested that inflammation is enhanced in acute alcoholic hepatitis in which acetyl-CoA synthetases are up-regulated and convert the ethanol metabolite acetate to an excess of acetyl-CoA which increases proinflammatory cytokine gene histone acetylation by increased substrate concentration and histone deacetylases (HDAC) inhibition, leading to enhanced gene expression and perpetuation of the inflammatory response. The clinical implication of these findings is that modulation of HDAC or ACSS activity might affect the clinical course of alcoholic liver injury in humans. If inhibitors of ACSS1 and 2 can modulate ethanol- associated histone changes without affecting the flow of acetyl-CoA through the normal metabolic pathways, then they have the potential to become much needed effective therapeutic options in acute alcoholic hepatitis. Therefore, synthesis of metabolically available acetyl-CoA from acetate is critical to the increased acetylation of proinflammatory gene histones and consequent enhancement of the inflammatory response in ethanol-exposed macrophages. This mechanism is a potential therapeutic target in acute alcoholic hepatitis.

[0011] Cytosolic acetyl-CoA is the precursor of multiple anabolic reactions including de-novo fatty acids (FA) synthesis. Inhibition of FA synthesis may favorably affect the morbidity and mortality associated with Fatty-liver metabolic syndromes (Wakil SJ, Abu-Elheiga LA. 2009. 'Fatty acid metabolism: Target for metabolic syndrome'. J. Lipid Res.) and because of the pivotal role of Acetyl-CoA Carboxylase (ACC) in regulating fatty acid metabolism, ACC inhibitors are under investigation as clinical drug targets in several metabolic diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Inhibition of ACSS2 is expected to directly reduce fatty-acid accumulation in the liver through its effect on Acetyl-CoA flux from acetate that is present in the liver at high levels due to the hepatocyte ethanol metabolism. Furthermore, ACSS2 inhibitors are expected to have a better safety profile than ACC inhibitors since they are expected only to affect the flux from Acetate that is not a major source for Ac-CoA in normal conditions (Harriman G et. al., 2016. "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats" PNAS). In addition, mice lacking ACSS2 showed reduced body weight and hepatic steatosis in a diet-induced obesity model (Z. Huang et al., ACSS2 promotes systemic fat storage and utilization through selective regulation of genes involved in lipid metabolism PNAS 115, (40), E9499-E9506, 2018).


[0012] ACSS2 is also shown to enter the nucleus under certain condition (hypoxia, high fat etc.) and to affect histone acetylation and crotonylation by making available acetyl-CoA and crotonyl-CoA and thereby regulate gene expression. For example, ACSS2 decrease is shown to lower levels of nuclear acetyl-CoA and histone acetylation in neurons affecting the expression of many neuronal genes. In the hippocampus such reductions in ACSS2 lead to effects on memory and neuronal plasticity (Mews P, et al., Nature, Vol 546, 381, 2017). Such epigenetic modifications are implicated in neuropsychiatric diseases such as anxiety, PTSD, depression etc. (Graff, J et al. Histone acetylation: molecular mnemonics on chromatin. Nat Rev. Neurosci. 14, 97-111 (2013)). Thus, an inhibitor of ACSS2 may find useful application in these conditions.

[0013] Nuclear ACSS2 is also shown to promote lysosomal biogenesis, autophagy and to promote brain tumorigenesis by affecting Histone H3 acetylation (Li, X et al.: Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis and Autophagy, Molecular Cell 66, 1-14, 2017). In addition, nuclear ACSS2 is shown to activate HIF-2alpha by acetylation and thus accelerate growth and metastasis of HIF2alpha-driven cancers such as certain Renal Cell Carcinoma and Glioblastomas (Chen, R. et al. Coordinate regulation of stress signaling and epigenetic events by ACSS2 and HIF-2 in cancer cells, Plos One, 12 (12) 1-31, 2017).

[0014] WO 2015175845 discloses benzimidazole derivatives that modulate the activity of ACSS2 for therapeutic use.

SUMMARY OF THE INVENTION

[0015] The present invention provides a compound represented by the structure of formula (I):



wherein

A and **B** rings are each independently a single or fused aromatic or heteroaromatic ring system, or a single or fused C₃-C₁₀ cycloalkyl or a single or fused C₃-C₁₀ heterocyclic ring;

R₁ and **R₂** are each independently H, F, Cl, Br, I, OH, SH, R₈-OH, R₈-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁) B(OH)₂, -OC(O)CF₃, -OCH₂Ph, NHC(O)-R₁₀ NHCO-N(R₁₀)(R₁₁) COOH, -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ linear or branched C(O)-haloalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁), C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₅ linear, branched or cyclic alkoxy optionally wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom, C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring, substituted or unsubstituted aryl (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₂** and **R₁** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring;

R₃ is C₂-C₅ linear or branched haloalkyl, CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃, CH₂CH₂CF₃, CF₂CH(CH₃)₂, CF(CH₃)-CH(CH₃)₂, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

R₄ is H, F, Cl, Br, I, OH, SH, R₈-OH, R₈-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀, NHCO-N(R₁₀)(R₁₁), COOH, -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ linear or branched C(O)-haloalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁), C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₅ linear, branched or cyclic alkoxy, C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic

ring, substituted or unsubstituted aryl, (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₃** and **R₄** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring;

R₅ is H, C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched haloalkyl, R₈-aryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

R₆ is H, C₁-C₅ linear or branched alkyl;

R₈ is [CH₂]_p

wherein **p** is between 1 and 10;

R₉ is [CH]_q, [C]_q

wherein **q** is between 2 and 10;

R₁₀ and **R₁₁** are each independently H, C₁-C₅ linear or branched alkyl, C(O)R, or S(O)₂R;

R is H, C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched alkoxy, phenyl, aryl or heteroaryl, or two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring;


m, **n** and **k** are each independently an integer between 0 and 4;

l is an integer between 1 and 4;

Q₁ and **Q₂** are each independently S or O;

or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, *N*-oxide, isotopic variant, PROTAC, pharmaceutical product or any combination thereof.

[0016] In an embodiment, the compound is represented by the structure of formula (II):




wherein

R₁, **R₂**, **R₃**, **R₄**, **R₅**, **R₆**, **R₈**, **R₁₀**, **R₁₁**, **R**, **m**, **n**, **l**, **k**, **Q₁** and **Q₂** are defined as in formula (I); and

$X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9$ or X_{10} are each independently C or N.

[0017] In an embodiment, the compound is represented by the structure of formula (IV):



wherein

R_1, R_2, R_3, R_4 , and R_5 are as defined in formula (I); and

X_3, X_4, X_7 , and X_8 are each independently C or N;

wherein if X_3 is N, then R_4 is absent; and

wherein if X_8 is N, then R_2 is absent.

[0018] In an embodiment, the compound or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, N-oxide, isotopic variants (e.g., deuterated analog), PROTAC, pharmaceutical product or any combination thereof is selected from Table 1a.


[0019] The present invention provides a compound or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, N-oxide, isotopic variants (e.g., deuterated analog), PROTAC, pharmaceutical product or any combination thereof represented by the structures listed in Table 1b.


[0020] In an embodiment, the compound is an Acyl-CoA Synthetase Short-Chain Family Member 2 (ACSS2) inhibitor.

[0021] The present invention also provides a pharmaceutical composition comprising a compound and a pharmaceutically acceptable carrier.

[0022] The present invention provides a compound for use as a medicament.

[0023] The present invention further provides a compound represented by the structure of formula (I):





(I)

wherein

A and **B** rings are each independently a single or fused aromatic or heteroaromatic ring system, or a single or fused C₃-C₁₀ cycloalkyl or a single or fused C₃-C₁₀ heterocyclic ring;

R₁ and **R₂** are each independently H, F, Cl, Br, I, OH, SH, R₈-OH, R₈-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁) B(OH)₂, -OC(O)CF₃, -OCH₂Ph, NHC(O)-R₁₀, NHCO-N(R₁₀)(R₁₁) COOH, -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ linear or branched C(O)-haloalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁), C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₅ linear, branched or cyclic alkoxy optionally wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom, C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring, substituted or unsubstituted aryl (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₂** and **R₁** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring;

R₃ and **R₄** are each independently H, F, Cl, Br, I, OH, SH, R₈-OH, R₈-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀, NHCO-N(R₁₀)(R₁₁), COOH, -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ linear or branched C(O)-haloalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁), C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₅ linear, branched or cyclic alkoxy, C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring, substituted or unsubstituted aryl, (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₃** and **R₄** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring;

R₅ is H, C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched

haloalkyl, R_8 -aryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl (wherein substitutions include: F, Cl, Br, I, C_1 - C_5 linear or branched alkyl, OH, alkoxy, $N(R)_2$, CF_3 , CN or NO_2);

R_6 is H, C_1 - C_5 linear or branched alkyl;

R_8 is $[CH_2]_p$

wherein p is between 1 and 10;

R_9 is $[CH]_q$, $[C]_q$

wherein q is between 2 and 10;

R_{10} and R_{11} are each independently H, C_1 - C_5 linear or branched alkyl, $C(O)R$, or $S(O)_2R$;

R is H, C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched alkoxy, phenyl, aryl or heteroaryl, or two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring;

m , n , l and k are each independently an integer between 0 and 4;

Q_1 and Q_2 are each independently S or O;

or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, N -oxide, isotopic variant, PROTAC, pharmaceutical product or any combination thereof,

for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting cancer in a subject.

[0024] In an embodiment, the cancer is selected from hepatocellular carcinoma, melanoma (e.g., BRAF mutant melanoma), glioblastoma, breast cancer (e.g., invasive ductal carcinomas of the breast, triple-negative breast cancer), prostate cancer, liver cancer, brain cancer, ovarian cancer, lung cancer, Lewis lung carcinoma (LLC), colon carcinoma, pancreatic cancer, renal cell carcinoma and mammary carcinoma, and/or

wherein the cancer is early cancer, advanced cancer, invasive cancer, metastatic cancer, drug resistant cancer or any combination thereof.

[0025] In an embodiment, the subject has been previously treated with chemotherapy, immunotherapy, radiotherapy, biological therapy, surgical intervention, or any combination thereof.

[0026] In an embodiment, the compound is administered in combination with an anti-cancer therapy, such as chemotherapy, immunotherapy, radiotherapy, biological therapy, surgical intervention, or any combination thereof.

[0027] The present invention also provides a compound represented by the structure of formula (I) for use in suppressing, reducing or inhibiting tumor growth in a subject.

[0028] In an embodiment, the tumor growth is enhanced by increased acetate uptake by cancer cells of said cancer, for example:

wherein the increased acetate uptake is mediated by ACSS2, and/or

wherein the tumor cells are under hypoxic stress, or

wherein the tumor growth is suppressed due to suppression of lipid (e.g., fatty acid) synthesis and/or regulating histones acetylation and function induced by ACSS2 mediated acetate metabolism to acetyl-CoA.

[0029] The present invention further provides an in vitro method of suppressing, reducing or inhibiting lipid synthesis and/or regulating histones acetylation and function in a cell such as a cancer cell; or

of suppressing, reducing or inhibiting acetyl-CoA synthesis, such as ACSS2-mediated acetyl-CoA synthesis, from acetate in a cell such as a cancer cell; or

of suppressing, reducing or inhibiting acetate metabolism, such as ACSS2-mediated acetate metabolism, in a cancer cell, optionally wherein the cancer cell is under hypoxic stress,

the method comprising contacting the cell with a compound represented by the structure of formula (I).

[0030] The present invention further provides an in vitro method of binding an ACSS2 inhibitor compound to an ACSS2 enzyme, comprising the step of contacting an ACSS2 enzyme with an ACSS2 inhibitor compound represented by the structure of formula (I), in an amount effective to bind the ACSS2 inhibitor compound to the ACSS2 enzyme.

[0031] The present invention also provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting human alcoholism in a subject,

or for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting a viral infection, such as human cytomegalovirus (HCMV) infection, in a subject, or

for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting alcoholic steatohepatitis (ASH) in a subject, or

for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting non alcoholic fatty liver disease (NAFLD) in a subject, or

for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting non-alcoholic steatohepatitis (NASH) in a subject, or

for use in treating, suppressing, reducing the severity, reducing the risk of developing or


inhibiting a metabolic disorder such as obesity, weight gain, hepatic steatosis and fatty liver disease in a subject, or

for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting a neuropsychiatric disease or disorder such as anxiety, depression, schizophrenia, autism and post-traumatic stress disorder in a subject, or

for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting an autoimmune disease or disorder in a subject.


[0032] In an embodiment, the compound for use in the treatment or in the in vitro method is as defined by claims 1-6.

[0033] In an embodiment, the compound for use in the treatment or in the in vitro method is represented by any of the following structures:




182

;




188

;



189


;



197


;

9




205

;




208

;




210

;



211

;



or

212.

BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The subject matter regarded as the invention is particularly pointed out and distinctly claimed in the concluding portion of the specification. The invention, however, both as to organization and method of operation, together with objects, features, and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanying drawings in which:

Figure 1 depicts a general synthetic scheme for compounds of the invention.

Figure 2 depicts a synthetic scheme for compound **204**.


Figure 3 depicts a synthetic scheme for compound **133**.

Figure 4 depicts an *in-vivo* efficacy study of compound **265** in MDA-MB-468 breast cancer cells xenograft mouse model.

[0035] It will be appreciated that for simplicity and clarity of illustration, elements shown in the figures have not necessarily been drawn to scale. For example, the dimensions of some of the elements may be exaggerated relative to other elements for clarity. Further, where considered appropriate, reference numerals may be repeated among the figures to indicate corresponding or analogous elements.

DETAILED DESCRIPTION OF THE INVENTION

[0036] The present invention provides a compound represented by the structure of formula (I):



wherein

A and **B** rings are each independently a single or fused aromatic or heteroaromatic ring system, or a single or fused C₃-C₁₀ cycloalkyl (e.g. cyclohexyl) or a single or fused C₃-C₁₀ heterocyclic ring (e.g., phenyl, 2-, 3- or 4-pyridine, benzofuran-2(3H)-one, benzo[d][1,3]dioxole, naphthalene, tetrahydrothiophene 1,1-dioxide, thiazole, benzimidazole, piperidine, 1-methylpiperidine, thiophene, imidazole, 1-methylimidazole, isoquinoline);

R₁ and **R**₂ are each independently H, F, Cl, Br, I, OH, SH, R₈-OH (e.g., CH₂-OH), R₈-SH, -R₈-OR₁₀, (e.g., -CH₂-O-CH₃), CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁) (e.g., CH₂-NH₂, CH₂-N(CH₃)₂), R₉-R₈-N(R₁₀)(R₁₁) (e.g., C≡C-CH₂-NH₂), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, NHC(O)-R₁₀ (e.g., NHC(O)CH₃), NHCO-N(R₁₀)(R₁₁) (e.g.,

NHC(O)N(CH₃)₂, COOH, -C(O)Ph, C(O)OR₁₀ (e.g. C(O)O-CH₃, C(O)O-CH(CH₃)₂, C(O)O-CH₂CH₃), R₈-C(O)-R₁₀ (e.g., CH₂C(O)CH₃), C(O)H, C(O)-R₁₀ (e.g., C(O)-CH₃, C(O)-CH₂CH₃, C(O)-CH₂CH₂CH₃), C₁-C₅ linear or branched C(O)-haloalkyl (e.g., C(O)-CF₃), -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁) (e.g., C(O)N(CH₃)₂), SO₂R, SO₂N(R₁₀)(R₁₁) (e.g., SO₂N(CH₃)₂, SO₂NHC(O)CH₃), C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, 2, 3, or 4-CH₂-C₆H₄-Cl, ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₂CH₃, CH₂CF₃), C₁-C₅ linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, O-CH₂-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, 1-butoxy, 2-butoxy, O-tBu), optionally wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom (e.g., O-1-oxacyclobutyl, O-2-oxacyclobutyl), C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy (e.g., OCF₃, OCHF₂), C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C₃-C₈ heterocyclic ring (e.g., thiophene, oxazole, oxadiazole, imidazole, furane, triazole, tetrazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole, protonated or deprotonated pyridine oxide), substituted or unsubstituted aryl (e.g., phenyl) (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl (e.g. methyl, ethyl), OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₂** and **R₁** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, pyridine);

R₃ is C₂-C₅ linear or branched haloalkyl, CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃, CH₂CH₂CF₃, CF₂CH(CH₃)₂, CF(CH₃)-CH(CH₃)₂, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

and **R₄** is H, F, Cl, Br, I, OH, SH, R₈-OH (e.g., CH₂-OH), R₈-SH, -R₈-O-R₁₀, (e.g., CH₂-O-CH₃) CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁) (e.g., CH₂-NH₂, CH₂-N(CH₃)₂), R₉-R₈-N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀ (e.g., NHC(O)CH₃), NHCO-N(R₁₀)(R₁₁) (e.g., NHC(O)N(CH₃)₂), COOH, -C(O)Ph, C(O)O-R₁₀ (e.g. C(O)O-CH₃, C(O)O-CH₂CH₃), R₈-C(O)-R₁₀ (e.g., CH₂C(O)CH₃), C(O)H, C(O)-R₁₀ (e.g., C(O)-CH₃, C(O)-CH₂CH₃, C(O)-CH₂CH₂CH₃), C₁-C₅ linear or branched C(O)-haloalkyl (e.g., C(O)-CF₃), -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁) (e.g., C(O)N(CH₃)₂), SO₂R, SO₂N(R₁₀)(R₁₁) (e.g., SO₂N(CH₃)₂), C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, C(OH)(CH₃)(Ph), ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃), C₁-C₅ linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, O-CH₂-cyclopropyl), C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or

unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C₃-C₈ heterocyclic ring (e.g., thiophene, oxazole, isoxazole, imidazole, furane, triazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole), substituted or unsubstituted aryl (e.g., phenyl), (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₃** and **R₄** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, cyclopentane, imidazole);

R₅ is H, C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, CH₂SH, ethyl, iso-propyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₃), Rs-aryl (e.g., CH₂-Ph), substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted heteroaryl (e.g., pyridine (2, 3, and 4-pyridine), (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

R₆ is H, C₁-C₅ linear or branched alkyl (e.g., methyl);

R₈ is [CH₂]_p

wherein **p** is between 1 and 10;

R₉ is [CH]_q, [C]_q

wherein **q** is between 2 and 10;

R₁₀ and **R₁₁** are each independently H, C₁-C₅ linear or branched alkyl (e.g., methyl, ethyl), C(O)R, or S(O)₂R;

R is H, C₁-C₅ linear or branched alkyl (e.g., methyl, ethyl), C₁-C₅ linear or branched alkoxy, phenyl, aryl or heteroaryl, or two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring;

m, **n** and **k** are each independently an integer between 0 and 4;

l is an integer between 1 and 4;

Q₁ and **Q₂** are each independently S, O;

or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, *N*-oxide, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical product or any combination thereof.

[0037] In some embodiments, A is a phenyl. In other embodiments, A is pyridinyl. In other embodiments, A is 2-pyridinyl. In other embodiments, A is 3-pyridinyl. In other embodiments, A is 4-pyridinyl. In other embodiments, A is naphthyl. In other embodiments, A is benzothiazolyl.

In other embodiments, A is benzimidazolyl. In other embodiments, A is quinolinyl. In other embodiments, A is isoquinolinyl. In other embodiments, A is indolyl. In other embodiments, A is tetrahydronaphthyl. In other embodiments, A is indenyl. In other embodiments, A is benzofuran-2(3H)-one. In other embodiments, A is benzo[d][1,3]dioxole. In other embodiments, A is naphthalene. In other embodiments, A is tetrahydrothiophene1,1-dioxide. In other embodiments, A is thiazole. In other embodiments, A is benzimidazole. In others embodiment, A is piperidine. In other embodiments, A is 1-methylpiperidine. In other embodiments, A is imidazole. In other embodiments, A is 1-methylimidazole. In other embodiments, A is thiophene. In other embodiments, A is isoquinoline. In other embodiments, A is single or fused C₃-C₁₀ cycloalkyl ring. In other embodiments, A is cyclohexyl.

[0038] In some embodiments, B is a phenyl ring. In other embodiments, B is pyridinyl. In other embodiments, B is 2-pyridinyl. In other embodiments, B is 3-pyridinyl. In other embodiments, B is 4-pyridinyl. In other embodiments, B is naphthyl. In other embodiments, B is indolyl. In other embodiments, B is benzimidazolyl. In other embodiments, B is benzothiazolyl. In other embodiments, B is quinoxalinyl. In other embodiments, B is tetrahydronaphthyl. In other embodiments, B is quinolinyl. In other embodiments, B is isoquinolinyl. In other embodiments, B is indenyl. In other embodiments, B is naphthalene. In other embodiments, B is tetrahydrothiophene1,1-dioxide. In other embodiments, B is thiazole. In other embodiments, B is benzimidazole. In other embodiments, B is piperidine. In other embodiments, B is 1-methylpiperidine. In other embodiments, B is imidazole. In other embodiments, B is 1-methylimidazole. In other embodiments, B is thiophene. In other embodiments, B is isoquinoline.

[0039] In some embodiments, R₁ is H. In other embodiments, R₁ is F. In other embodiments, R₁ is Cl. In other embodiments, R₁ is Br. In other embodiments, R₁ is I. In other embodiments, R₁ is CF₃. In other embodiments, R₁ is OCD₃. In other embodiments, R₁ is NO₂. In other embodiments, R₁ is NH₂. In other embodiments, R₁ is R₈-N(R₁₀)(R₁₁). In other embodiments, R₁ is CH₂-NH₂. In other embodiments, R₁ is CH₂-N(CH₃)₂. In other embodiments, R₁ is R₉-R₈-N(R₁₀)(R₁₁). In other embodiments, R₁ is C≡C-CH₂-NH₂. In other embodiments, R₁ is B(OH)₂. In other embodiments, R₁ is NHC(O)-R₁₀. In other embodiments, R₁ is NHC(O)CH₃. In other embodiments, R₁ is NHCO-N(R₁₀)(R₁₁). In other embodiments, R₁ is NHC(O)N(CH₃)₂. In other embodiments, R₁ is COOH. In other embodiments, R₁ is C(O)O-R₁₀. In other embodiments, R₁ is C(O)O-CH(CH₃)₂. In other embodiments, R₁ is C(O)O-CH₃. In other embodiments, R₁ is SO₂N(R₁₀)(R₁₁). In other embodiments, R₁ is SO₂N(CH₃)₂. In other embodiments, R₁ is SO₂NHC(O)CH₃. In other embodiments, R₁ is C₁-C₅ linear or branched, substituted or unsubstituted alkyl. In other embodiments, R₁ is methyl. In other embodiments, R₁ is 2-CH₂-C₆H₄-Cl. In other embodiments, R₁ is 3-CH₂-C₆H₄-Cl. In other embodiments, R₁ is 4-CH₂-C₆H₄-Cl. In other embodiments, R₁ is ethyl. In other embodiments, R₁ is propyl. In other embodiments, R₁ is iso-propyl. In other embodiments, R₁ is t-Bu. In other embodiments, R₁ is iso-butyl. In other embodiments, R₁ is pentyl. In other embodiments, R₁ is substituted or

unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R₁ is C₁-C₅ linear, branched or cyclic alkoxy. In other embodiments, R₁ is methoxy. In other embodiments, R₁ is ethoxy. In other embodiments, R₁ is propoxy. In other embodiments, R₁ is isopropoxy. In other embodiments, R₁ is O-CH₂-cyclopropyl. In other embodiments, R₁ is O-cyclobutyl. In other embodiments, R₁ is O-cyclopentyl. In other embodiments, R₁ is O-cyclohexyl. In other embodiments, R₁ is O-1-oxacyclobutyl. In other embodiments, R₁ is O-2-oxacyclobutyl. In other embodiments, R₁ is 1-butoxy. In other embodiments, R₁ is 2-butoxy. In other embodiments, R₁ is O-tBu. In other embodiments, R₁ is C₁-C₅ linear, branched or cyclic alkoxy wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom (O). In other embodiments, R₁ is O-1-oxacyclobutyl. In other embodiments, R₁ is O-2-oxacyclobutyl. In other embodiments, R₁ is C₁-C₅ linear or branched haloalkoxy. In other embodiments, R₁ is OCF₃. In other embodiments, R₁ is OCHF₂. In other embodiments, R₁ is substituted or unsubstituted C₃-C₈ heterocyclic ring. In other embodiments, R₁ is oxazole. In other embodiments, R₁ is methyl substituted oxazole. In other embodiments, R₁ is oxadiazole. In other embodiments, R₁ is methyl substituted oxadiazole. In other embodiments, R₁ is imidazole. In other embodiments, R₁ is methyl substituted imidazole. In other embodiments, R₁ is pyridine. In other embodiments, R₁ is 2-pyridine. In other embodiments, R₁ is 3-pyridine. In other embodiments, R₁ is 4-pyridine. In other embodiments, R₁ is tetrazole. In other embodiments, R₁ is pyrimidine. In other embodiments, R₁ is pyrazine. In other embodiments, R₁ is oxacyclobutane. In other embodiments, R₁ is 1-oxacyclobutane. In other embodiments, R₁ is 2-oxacyclobutane. In other embodiments, R₁ is indole. In other embodiments, R₁ is pyridine oxide. In other embodiments, R₁ is protonated pyridine oxide. In other embodiments, R₁ is deprotonated pyridine oxide. In other embodiments, R₁ is substituted or unsubstituted aryl. In other embodiments, R₁ is phenyl. In other embodiments, R₁ is bromophenyl. In other embodiments, R₁ is 2-bromophenyl. In other embodiments, R₁ is 3-bromophenyl. In other embodiments, R₁ is 4-bromophenyl. In other embodiments, R₁ is R₈-N(R₁₀)(R₁₁). In other embodiments, R₁ is CH₂-NH₂.

[0040] In some embodiments, R₂ is H. In other embodiments, R₂ is F. In other embodiments, R₂ is Cl. In other embodiments, R₂ is Br. In other embodiments, R₂ is I. In other embodiments, R₂ is CF₃. In other embodiments, R₂ is OCD₃. In other embodiments, R₂ is NO₂. In other embodiments, R₂ is NH₂. In other embodiments, R₂ is R₈-N(R₁₀)(R₁₁). In other embodiments, R₂ is CH₂-NH₂. In other embodiments, R₂ is CH₂-N(CH₃)₂. In other embodiments, R₂ is R₉-R₈-N(R₁₀)(R₁₁). In other embodiments, R₂ is C≡C-CH₂-NH₂. In other embodiments, R₂ is B(OH)₂. In other embodiments, R₂ is NHC(O)-R₁₀. In other embodiments, R₂ is NHC(O)CH₃. In other embodiments, R₂ is NHCO-N(R₁₀)(R₁₁). In other embodiments, R₂ is NHC(O)N(CH₃)₂. In other embodiments, R₂ is COOH. In other embodiments, R₂ is C(O)O-R₁₀. In other embodiments, R₂ is C(O)O-CH(CH₃)₂. In other embodiments, R₂ is C(O)O-CH₃. In other embodiments, R₂ is SO₂N(R₁₀)(R₁₁). In other embodiments, R₂ is SO₂N(CH₃)₂. In other embodiments, R₂ is

SO₂NHC(O)CH₃. In other embodiments, R₂ is C₁-C₅ linear or branched, substituted or unsubstituted alkyl. In other embodiments, R₂ is methyl. In other embodiments, R₂ is 2-CH₂-C₆H₄-Cl. In other embodiments, R₂ is 3-CH₂-C₆H₄-Cl. In other embodiments, R₂ is 4-CH₂-C₆H₄-Cl. In other embodiments, R₂ is ethyl. In other embodiments, R₂ is propyl. In other embodiments, R₂ is iso-propyl. In other embodiments, R₂ is t-Bu. In other embodiments, R₂ is iso-butyl. In other embodiments, R₂ is pentyl. In other embodiments, R₂ is substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R₂ is C₁-C₅ linear, branched or cyclic alkoxy. In other embodiments, R₂ is methoxy. In other embodiments, R₂ is ethoxy. In other embodiments, R₂ is propoxy. In other embodiments, R₂ is isopropoxy. In other embodiments, R₂ is O-CH₂-cyclopropyl. In other embodiments, R₂ is O-cyclobutyl. In other embodiments, R₂ is O-cyclopentyl. In other embodiments, R₂ is O-cyclohexyl. In other embodiments, R₂ is O-1-oxacyclobutyl. In other embodiments, R₂ is O-2-oxacyclobutyl. In other embodiments, R₂ is 1-butoxy. In other embodiments, R₂ is 2-butoxy. In other embodiments, R₂ is O-tBu. In other embodiments, R₂ is C₁-C₅ linear or branched haloalkoxy. In other embodiments, R₂ is OCF₃. In other embodiments, R₂ is OCHF₂. In other embodiments, R₂ is substituted or unsubstituted C₃-C₈ heterocyclic ring. In other embodiments, R₂ is oxazole or methyl substituted oxazole. In other embodiments, R₂ is oxadiazole or methyl substituted oxadiazole. In other embodiments, R₂ is imidazole or methyl substituted imidazole. In other embodiments, R₂ is pyridine. In other embodiments, R₂ is 2-pyridine. In other embodiments, R₂ is 3-pyridine. In other embodiments, R₂ is 4-pyridine. In other embodiments, R₂ is tetrazole. In other embodiments, R₂ is pyrimidine. In other embodiments, R₂ is pyrazine. In other embodiments, R₂ is oxacyclobutane. In other embodiments, R₂ is 1-oxacyclobutane. In other embodiments, R₂ is 2-oxacyclobutane. In other embodiments, R₂ is indole. In other embodiments, R₂ is pyridine oxide. In other embodiments, R₂ is protonated pyridine oxide. In other embodiments, R₂ is deprotonated pyridine oxide. In other embodiments, R₂ is substituted or unsubstituted aryl. In other embodiments, R₂ is phenyl. In other embodiments, R₂ is bromophenyl. In other embodiments, R₂ is 2-bromophenyl. In other embodiments, R₂ is 3-bromophenyl. In other embodiments, R₂ is 4-bromophenyl. In other embodiments, R₂ is R₈-N(R₁₀)(R₁₁). In other embodiments, R₂ is CH₂-NH₂.

[0041] In some embodiments, R₁ and R₂ are joined together to form a [1,3]dioxole ring. In some embodiments, R₁ and R₂ are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R₁ and R₂ are joined together to form a benzene ring. In some embodiments, R₁ and R₂ are joined together to form a pyridine ring.

[0042] In other embodiments, R₃ is C₂-C₅ linear or branched haloalkyl. In other embodiments, R₃ is CF₂CH₃. In other embodiments, R₃ is CH₂CF₃. In other embodiments, R₃ is CF₂CH₂CH₃. In other embodiments, R₃ is substituted or unsubstituted C₃-C₈ cycloalkyl. In other

embodiments, R_3 is cyclopropyl. In other embodiments, R_3 is cyclopentyl. In other embodiments, R_3 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_3 is thiophene. In other embodiments, R_3 is oxazole. In other embodiments, R_3 is isoxazole. In other embodiments, R_3 is imidazole. In other embodiments, R_3 is furane. In other embodiments, R_3 is triazole. In other embodiments, R_3 is pyridine. In other embodiments, R_3 is 2-pyridine. In other embodiments, R_3 is 3-pyridine. In other embodiments, R_3 is 4-pyridine. In other embodiments, R_3 is pyrimidine. In other embodiments, R_3 is pyrazine. In other embodiments, R_3 is oxacyclobutane. In other embodiments, R_3 is 1-oxacyclobutane. In other embodiments, R_3 is 2-oxacyclobutane. In other embodiments, R_3 is indole. In other embodiments, R_3 is substituted or unsubstituted aryl. In other embodiments, R_3 is phenyl. In other embodiments, R_3 is $CH(CF_3)(NH-R_{10})$.

[0043] In some embodiments, R_4 is H. In other embodiments, R_4 is Cl. In other embodiments, R_4 is I. In other embodiments, R_4 is F. In other embodiments, R_4 is Br. In other embodiments, R_4 is OH. In other embodiments, R_4 is CD_3 . In other embodiments, R_4 is OCD_3 . In other embodiments, R_4 is R_8-OH . In other embodiments, R_4 is CH_2-OH . In other embodiments, R_4 is $-R_8-O-R_{10}$. In other embodiments, R_4 is CH_2-O-CH_3 . In other embodiments, R_4 is CF_3 . In other embodiments, R_4 is $R_8-N(R_{10})(R_{11})$. In other embodiments, R_4 is CH_2-NH_2 . In other embodiments, R_4 is $CH_2-N(CH_3)_2$. In other embodiments, R_4 is $COOH$. In other embodiments, R_4 is $C(O)O-R_{10}$. In other embodiments, R_4 is $C(O)O-CH_2CH_3$. In other embodiments, R_4 is $R_8-C(O)-R_{10}$. In other embodiments, R_4 is $CH_2C(O)CH_3$. In other embodiments, R_4 is $C(O)-R_{10}$. In other embodiments, R_4 is $C(O)-CH_3$. In other embodiments, R_4 is $C(O)-CH_2CH_3$. In other embodiments, R_4 is $C(O)-CH_2CH_2CH_3$. In other embodiments, R_4 is C_1 - C_5 linear or branched $C(O)$ -haloalkyl. In other embodiments, R_4 is $C(O)-CF_3$. In other embodiments, R_4 is $C(O)N(R_{10})(R_{11})$. In other embodiments, R_4 is $C(O)N(CH_3)_2$. In other embodiments, R_4 is $SO_2N(R_{10})(R_{11})$. In other embodiments, R_4 is $SO_2N(CH_3)_2$. In other embodiments, R_4 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_4 is methyl. In other embodiments, R_4 is $C(OH)(CH_3)(Ph)$. In other embodiments, R_4 is ethyl. In other embodiments, R_4 is propyl. In other embodiments, R_4 is iso-propyl. In other embodiments, R_4 is t-Bu. In other embodiments, R_4 is iso-butyl. In other embodiments, R_4 is pentyl. In other embodiments, R_4 is C_1 - C_5 linear or branched haloalkyl. In other embodiments, R_4 is CF_2CH_3 . In other embodiments, R_4 is CH_2CF_3 . In other embodiments, R_4 is $CF_2CH_2CH_3$. In other embodiments, R_4 is C_1 - C_5 linear, branched or cyclic alkoxy. In other embodiments, R_4 is methoxy. In other embodiments, R_4 is isopropoxy. In other embodiments, R_4 is substituted or unsubstituted C_3 - C_8 cycloalkyl. In other embodiments, R_4 is cyclopropyl. In other embodiments, R_4 is cyclopentyl. In other embodiments, R_4 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_4 is thiophene. In other embodiments, R_4 is oxazole. In other embodiments, R_4 is isoxazole. In other embodiments, R_4 is imidazole. In other embodiments, R_4 is furane. In other embodiments, R_4 is triazole. In other embodiments, R_4 is pyridine. In

other embodiments, R_4 is 2-pyridine. In other embodiments, R_4 is 3-pyridine. In other embodiments, R_4 is 4-pyridine. In other embodiments, R_4 is pyrimidine. In other embodiments, R_4 is pyrazine. In other embodiments, R_4 is oxacyclobutane. In other embodiments, R_4 is 1-oxacyclobutane. In other embodiments, R_4 is 2-oxacyclobutane. In other embodiments, R_4 is indole. In other embodiments, R_4 is substituted or unsubstituted aryl. In other embodiments, R_4 is phenyl. In other embodiments, R_4 is $\text{CH}(\text{CF}_3)(\text{NH}-R_{10})$.

[0044] In some embodiments, R_3 and R_4 are joined together to form a [1,3]dioxole ring. In some embodiments, R_3 and R_4 are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R_3 and R_4 are joined together to form a benzene ring. In some embodiments, R_3 and R_4 are joined together to form a cyclopentene ring. In some embodiments, R_3 and R_4 are joined together to form an imidazole ring.

[0045] In some embodiments, R_5 is H. In other embodiments, R_5 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_5 is methyl. In other embodiments, R_5 is CH_2SH . In other embodiments, R_5 is ethyl. In other embodiments, R_5 is iso-propyl. In other embodiments, R_5 is C_1 - C_5 linear or branched haloalkyl. In other embodiments, R_5 is CF_3 . In other embodiments, R_5 is R_8 -aryl. In other embodiments, R_5 is $\text{CH}_2\text{-Ph}$ (i.e., benzyl). In other embodiments, R_5 is substituted or unsubstituted aryl. In other embodiments, R_5 is phenyl. In other embodiments, R_5 is substituted or unsubstituted heteroaryl. In other embodiments, R_5 is pyridine. In other embodiments, R_5 is 2-pyridine. In other embodiments, R_5 is 3-pyridine. In other embodiments, R_5 is 4-pyridine.

[0046] In some embodiments, R_6 is H. In other embodiments, R_6 is C_1 - C_5 linear or branched alkyl. In other embodiments, R_6 is methyl.

[0047] In some embodiments, R_8 is CH_2 . In other embodiments, R_8 is CH_2CH_2 . In other embodiments, R_8 is $\text{CH}_2\text{CH}_2\text{CH}_2$.

[0048] In some embodiments, p is 1. In other embodiments, p is 2. In other embodiments, p is 3.

[0049] In some embodiments, R_9 is $\text{C}\equiv\text{C}$.

[0050] In some embodiments, q is 2.

[0051] In some embodiments, R_{10} is C_1 - C_5 linear or branched alkyl. In other embodiments, R_{10} is H. In other embodiments, R_{10} is CH_3 . In other embodiments, R_{10} is CH_2CH_3 . In other embodiments, R_{10} is $\text{CH}_2\text{CH}_2\text{CH}_3$.

[0052] In some embodiments, R_{11} is C_1 - C_5 linear or branched alkyl. In other embodiments, R_{10} is H. In other embodiments, R_{11} is CH_3 .

[0053] In some embodiments, **R** is H. In other embodiments, **R** is C_1 - C_5 linear or branched alkyl. In other embodiments, **R** is methyl. In other embodiments, **R** is ethyl.

[0054] In some embodiments, **m** is 1. In other embodiments, **m** is 0.

[0055] In some embodiments, **n** is 1. In other embodiments, **n** is 0.


[0056] In some embodiments, **k** is 1. In other embodiments, **k** is 0.

[0057] In some embodiments, **1** is 1.

[0058] In some embodiments, **Q₁** is O.

[0059] In some embodiments, **Q₂** is O.

[0060] In various embodiments, the compound is represented by the structure of formula (II)



wherein

R₁ and **R₂** are each independently H, F, Cl, Br, I, OH, SH, R_8 -OH (e.g., CH_2 -OH), R_8 -SH, $-R_8$ -OR₁₀, (e.g., $-CH_2$ -O- CH_3), CF_3 , CD_3 , OCD_3 , CN, NO_2 , $-CH_2$ CN, $-R_8$ CN, NH_2 , NHR, $N(R)_2$, R_8 - $N(R_{10})(R_{11})$ (e.g., CH_2 - NH_2 , CH_2 - $N(CH_3)_2$), R_9 - R_8 - $N(R_{10})(R_{11})$ (e.g., $C\equiv C$ - CH_2 - NH_2), $B(OH)_2$, $-OC(O)CF_3$, $-OCH_2Ph$, $NHC(O)-R_{10}$ (e.g., $NHC(O)CH_3$), $NHCO-N(R_{10})(R_{11})$ (e.g., $NHC(O)N(CH_3)_2$), $COOH$, $-C(O)Ph$, $C(O)OR_{10}$ (e.g. $C(O)O-CH_3$, $C(O)O-CH(CH_3)_2$, $C(O)O-CH_2CH_3$), $R_8-C(O)-R_{10}$ (e.g., $CH_2C(O)CH_3$), $C(O)H$, $C(O)-R_{10}$ (e.g., $C(O)-CH_3$, $C(O)-CH_2CH_3$, $C(O)-CH_2CH_2CH_3$), C_1 - C_5 linear or branched $C(O)$ -haloalkyl (e.g., $C(O)-CF_3$), $-C(O)NH_2$, $C(O)NHR$, $C(O)N(R_{10})(R_{11})$ (e.g., $C(O)N(CH_3)_2$), SO_2R , $SO_2N(R_{10})(R_{11})$ (e.g., $SO_2N(CH_3)_2$, $SO_2NHC(O)CH_3$), C_1 - C_5 linear or branched, substituted or unsubstituted alkyl (e.g., methyl, 2, 3, or 4- CH_2 - C_6H_4 -Cl, ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C_1 - C_5 linear or branched haloalkyl (e.g., CF_2CH_3 , CH_2CF_3), C_1 - C_5 linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, O- CH_2 -cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, 1-butoxy, 2-butoxy, O-tBu), optionally wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom (O) (e.g., O-1-oxacyclobutyl, O-2-oxacyclobutyl), C_1 - C_5 linear or

branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy (e.g., OCF₃, OCHF₂), C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C₃-C₈ heterocyclic ring (e.g., thiophene, oxazole, oxadiazole, imidazole, furane, triazole, tetrazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole, protonated or deprotonated pyridine oxide), substituted or unsubstituted aryl (e.g., phenyl) (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl (e.g. methyl, ethyl), OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₂** and **R₁** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, pyridine);

R₃ is C₂-C₅ linear or branched haloalkyl, CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃, CH₂CH₂CF₃, CF₂CH(CH₃)₂, CF(CH₃)-CH(CH₃)₂, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

and **R₄** is H, F, Cl, Br, I, OH, SH, R₈-OH (e.g., CH₂-OH), R₈-SH, -R₈-O-R₁₀, (e.g., CH₂-O-CH₃) CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁) (e.g., CH₂-NH₂, CH₂-N(CH₃)₂), R₉-R₈-N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀ (e.g., NHC(O)CH₃), NHCO-N(R₁₀)(R₁₁) (e.g., NHC(O)N(CH₃)₂), COOH, -C(O)Ph, C(O)O-R₁₀ (e.g. C(O)O-CH₃, C(O)O-CH₂CH₃), R₈-C(O)-R₁₀ (e.g., CH₂C(O)CH₃), C(O)H, C(O)-R₁₀ (e.g., C(O)-CH₃, C(O)-CH₂CH₃, C(O)-CH₂CH₂CH₃), C₁-C₅ linear or branched C(O)-haloalkyl (e.g., C(O)-CF₃), -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁) (e.g., C(O)N(CH₃)₂), SO₂R, SO₂N(R₁₀)(R₁₁) (e.g., SO₂N(CH₃)₂), C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, C(OH)(CH₃)(Ph), ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃), C₁-C₅ linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, O-CH₂-cyclopropyl), C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C₃-C₈ heterocyclic ring (e.g., thiophene, oxazole, isoxazole, imidazole, furane, triazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane) , indole), substituted or unsubstituted aryl (e.g., phenyl), (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₃** and **R₄** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, cyclopentane, imidazole);

R₅ is H, C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, CH₂SH, ethyl, iso-propyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₃), Rs-aryl (e.g., CH₂-Ph),

substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted heteroaryl (e.g., pyridine (2, 3, and 4-pyridine), (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

R₆ is H, C₁-C₅ linear or branched alkyl (e.g., methyl);

R₈ is [CH₂]_p

wherein **p** is between 1 and 10;

R₉ is [CH]_q, [C]_q

wherein **q** is between 2 and 10;

R₁₀ and **R₁₁** are each independently H, C₁-C₅ linear or branched alkyl (e.g., methyl, ethyl), C(O)R, or S(O)₂R;

R is H, C₁-C₅ linear or branched alkyl (e.g., methyl, ethyl), C₁-C₅ linear or branched alkoxy, phenyl, aryl or heteroaryl, or two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring;

m, n and k are each independently an integer between 0 and 4;

l is an integer between 1 and 4;

Q₁ and **Q₂** are each independently S, O;

X₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈, X₉ or **X₁₀** are each independently C or N.

[0061] In some embodiments, **R₁** is H. In other embodiments, **R₁** is F. In other embodiments, **R₁** is Cl. In other embodiments, **R₁** is Br. In other embodiments, **R₁** is I. In other embodiments, **R₁** is CF₃. In other embodiments, **R₁** is OCD₃. In other embodiments, **R₁** is NO₂. In other embodiments, **R₁** is NH₂. In other embodiments, **R₁** is R₈-N(R₁₀)(R₁₁). In other embodiments, **R₁** is CH₂-NH₂. In other embodiments, **R₁** is CH₂-N(CH₃)₂. In other embodiments, **R₁** is R₉-R₈-N(R₁₀)(R₁₁). In other embodiments, **R₁** is CC-CH₂-NH₂. In other embodiments, **R₁** is B(OH)₂. In other embodiments, **R₁** is NHC(O)-R₁₀. In other embodiments, **R₁** is NHC(O)CH₃. In other embodiments, **R₁** is NHCO-N(R₁₀)(R₁₁). In other embodiments, **R₁** is NHC(O)N(CH₃)₂. In other embodiments, **R₁** is COOH. In other embodiments, **R₁** is C(O)O-R₁₀. In other embodiments, **R₁** is C(O)O-CH(CH₃)₂. In other embodiments, **R₁** is C(O)O-CH₃. In other embodiments, **R₁** is SO₂N(R₁₀)(R₁₁). In other embodiments, **R₁** is SO₂N(CH₃)₂. In other embodiments, **R₁** is SO₂NHC(O)CH₃. In other embodiments, **R₁** is C₁-C₅ linear or branched, substituted or unsubstituted alkyl. In other embodiments, **R₁** is methyl. In other embodiments, **R₁** is 2-CH₂-C₆H₄-Cl. In other embodiments, **R₁** is 3-CH₂-C₆H₄-Cl. In other embodiments, **R₁** is 4-CH₂-C₆H₄-Cl. In other embodiments, **R₁** is ethyl. In other embodiments, **R₁** is propyl. In other

embodiments, R_1 is iso-propyl. In other embodiments, R_1 is t-Bu. In other embodiments, R_1 is iso-butyl. In other embodiments, R_1 is pentyl. In other embodiments, R_1 is substituted or unsubstituted C_3 - C_8 cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R_1 is C_1 - C_5 linear, branched or cyclic alkoxy. In other embodiments, R_1 is methoxy. In other embodiments, R_1 is ethoxy. In other embodiments, R_1 is propoxy. In other embodiments, R_1 is isopropoxy. In other embodiments, R_1 is O-CH₂-cyclopropyl. In other embodiments, R_1 is O-cyclobutyl. In other embodiments, R_1 is O-cyclopentyl. In other embodiments, R_1 is O-cyclohexyl. In other embodiments, R_1 is O-1-oxacyclobutyl. In other embodiments, R_1 is O-2-oxacyclobutyl. In other embodiments, R_1 is 1-butoxy. In other embodiments, R_1 is 2-butoxy. In other embodiments, R_1 is O-tBu. In other embodiments, R_1 is C_1 - C_5 linear, branched or cyclic alkoxy wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom (O). In other embodiments, R_1 is O-1-oxacyclobutyl. In other embodiments, R_1 is O-2-oxacyclobutyl. In other embodiments, R_1 is C_1 - C_5 linear or branched haloalkoxy. In other embodiments, R_1 is OCF₃. In other embodiments, R_1 is OCHF₂. In other embodiments, R_1 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_1 is oxazole. In other embodiments, R_1 is methyl substituted oxazole. In other embodiments, R_1 is oxadiazole. In other embodiments, R_1 is methyl substituted oxadiazole. In other embodiments, R_1 is imidazole. In other embodiments, R_1 is methyl substituted imidazole. In other embodiments, R_1 is pyridine. In other embodiments, R_1 is 2-pyridine. In other embodiments, R_1 is 3-pyridine. In other embodiments, R_1 is 4-pyridine. In other embodiments, R_1 is tetrazole. In other embodiments, R_1 is pyrimidine. In other embodiments, R_1 is pyrazine. In other embodiments, R_1 is oxacyclobutane. In other embodiments, R_1 is 1-oxacyclobutane. In other embodiments, R_1 is 2-oxacyclobutane. In other embodiments, R_1 is indole. In other embodiments, R_1 is pyridine oxide. In other embodiments, R_1 is protonated pyridine oxide. In other embodiments, R_1 is deprotonated pyridine oxide. In other embodiments, R_1 is substituted or unsubstituted aryl. In other embodiments, R_1 is phenyl. In other embodiments, R_1 is bromophenyl. In other embodiments, R_1 is 2-bromophenyl. In other embodiments, R_1 is 3-bromophenyl. In other embodiments, R_1 is 4-bromophenyl. In other embodiments, R_1 is R_8 -N(R_{10})(R_{11}). In other embodiments, R_1 is CH₂-NH₂.

[0062] In some embodiments, R_2 is H. In other embodiments, R_2 is F. In other embodiments, R_2 is Cl. In other embodiments, R_2 is Br. In other embodiments, R_2 is I. In other embodiments, R_2 is CF₃. In other embodiments, R_2 is OCD₃. In other embodiments, R_2 is NO₂. In other embodiments, R_2 is NH₂. In other embodiments, R_2 is R_8 -N(R_{10})(R_{11}). In other embodiments, R_2 is CH₂-NH₂. In other embodiments, R_2 is CH₂-N(CH₃)₂. In other embodiments, R_2 is R_9 - R_8 -N(R_{10})(R_{11}). In other embodiments, R_2 is C≡C-CH₂-NH₂. In other embodiments, R_2 is B(OH)₂. In other embodiments, R_2 is NHC(O)- R_{10} . In other embodiments, R_2 is NHC(O)CH₃. In other embodiments, R_2 is NHCO-N(R_{10})(R_{11}). In other embodiments, R_2 is NHC(O)N(CH₃)₂. In other embodiments, R_2 is COOH. In other embodiments, R_2 is C(O)O- R_{10} . In other embodiments, R_2

is $\text{C}(\text{O})\text{O}-\text{CH}(\text{CH}_3)_2$. In other embodiments, R_2 is $\text{C}(\text{O})\text{O}-\text{CH}_3$. In other embodiments, R_2 is $\text{SO}_2\text{N}(\text{R}_{10})(\text{R}_{11})$. In other embodiments, R_2 is $\text{SO}_2\text{N}(\text{CH}_3)_2$. In other embodiments, R_2 is $\text{SO}_2\text{NHC}(\text{O})\text{CH}_3$. In other embodiments, R_2 is $\text{C}_1\text{-C}_5$ linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_2 is methyl. In other embodiments, R_2 is $2\text{-CH}_2\text{-C}_6\text{H}_4\text{-Cl}$. In other embodiments, R_2 is $3\text{-CH}_2\text{-C}_6\text{H}_4\text{-Cl}$. In other embodiments, R_2 is $4\text{-CH}_2\text{-C}_6\text{H}_4\text{-Cl}$. In other embodiments, R_2 is ethyl. In other embodiments, R_2 is propyl. In other embodiments, R_2 is iso-propyl. In other embodiments, R_2 is t-Bu. In other embodiments, R_2 is iso-butyl. In other embodiments, R_2 is pentyl. In other embodiments, R_2 is substituted or unsubstituted $\text{C}_3\text{-C}_8$ cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R_2 is $\text{C}_1\text{-C}_5$ linear, branched or cyclic alkoxy. In other embodiments, R_2 is methoxy. In other embodiments, R_2 is ethoxy. In other embodiments, R_2 is propoxy. In other embodiments, R_2 is isopropoxy. In other embodiments, R_2 is $\text{O}-\text{CH}_2\text{-cyclopropyl}$. In other embodiments, R_2 is O-cyclobutyl . In other embodiments, R_2 is O-cyclopentyl . In other embodiments, R_2 is O-cyclohexyl . In other embodiments, R_2 is O-1-oxacyclobutyl . In other embodiments, R_2 is O-2-oxacyclobutyl . In other embodiments, R_2 is 1-butoxy. In other embodiments, R_2 is 2-butoxy. In other embodiments, R_2 is O-tBu . In other embodiments, R_2 is $\text{C}_1\text{-C}_5$ linear or branched haloalkoxy. In other embodiments, R_2 is OCF_3 . In other embodiments, R_2 is OCHF_2 . In other embodiments, R_2 is substituted or unsubstituted $\text{C}_3\text{-C}_8$ heterocyclic ring. In other embodiments, R_2 is oxazole or methyl substituted oxazole. In other embodiments, R_2 is oxadiazole or methyl substituted oxadiazole. In other embodiments, R_2 is imidazole or methyl substituted imidazole. In other embodiments, R_2 is pyridine. In other embodiments, R_2 is 2-pyridine. In other embodiments, R_2 is 3-pyridine. In other embodiments, R_2 is 4-pyridine. In other embodiments, R_2 is tetrazole. In other embodiments, R_2 is pyrimidine. In other embodiments, R_2 is pyrazine. In other embodiments, R_2 is oxacyclobutane. In other embodiments, R_2 is 1-oxacyclobutane. In other embodiments, R_2 is 2-oxacyclobutane. In other embodiments, R_2 is indole. In other embodiments, R_2 is pyridine oxide. In other embodiments, R_2 is protonated pyridine oxide. In other embodiments, R_2 is deprotonated pyridine oxide. In other embodiments, R_2 is substituted or unsubstituted aryl. In other embodiments, R_2 is phenyl. In other embodiments, R_2 is bromophenyl. In other embodiments, R_2 is 2-bromophenyl. In other embodiments, R_2 is 3-bromophenyl. In other embodiments, R_2 is 4-bromophenyl. In other embodiments, R_2 is $\text{R}_8\text{-N}(\text{R}_{10})(\text{R}_{11})$. In other embodiments, R_2 is $\text{CH}_2\text{-NH}_2$.

[0063] In some embodiments, R_1 and R_2 are joined together to form a [1,3]dioxole ring. In some embodiments, R_1 and R_2 are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R_1 and R_2 are joined together to form a benzene ring.

[0064] In other embodiments, R_3 is $\text{C}_2\text{-C}_5$ linear or branched haloalkyl. In other embodiments, R_3 is CF_2CH_3 . In other embodiments, R_3 is CH_2CF_3 . In other embodiments, R_3 is $\text{CF}_2\text{CH}_2\text{CH}_3$.

In other embodiments, R_3 is substituted or unsubstituted C_3 - C_8 cycloalkyl. In other embodiments, R_3 is cyclopropyl. In other embodiments, R_3 is cyclopentyl. In other embodiments, R_3 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_3 is thiophene. In other embodiments, R_3 is oxazole. In other embodiments, R_3 is isoxazole. In other embodiments, R_3 is imidazole. In other embodiments, R_3 is furane. In other embodiments, R_3 is triazole. In other embodiments, R_3 is pyridine. In other embodiments, R_3 is 2-pyridine. In other embodiments, R_3 is 3-pyridine. In other embodiments, R_3 is 4-pyridine. In other embodiments, R_3 is pyrimidine. In other embodiments, R_3 is pyrazine. In other embodiments, R_3 is oxacyclobutane. In other embodiments, R_3 is 1-oxacyclobutane. In other embodiments, R_3 is 2-oxacyclobutane. In other embodiments, R_3 is indole. In other embodiments, R_3 is substituted or unsubstituted aryl. In other embodiments, R_3 is phenyl. In other embodiments, R_3 is $CH(CF_3)(NH-R_{10})$.

[0065] In some embodiments, R_4 is H. In other embodiments, R_4 is Cl. In other embodiments, R_4 is I. In other embodiments, R_4 is F. In other embodiments, R_4 is Br. In other embodiments, R_4 is OH. In other embodiments, R_4 is CD_3 . In other embodiments, R_4 is OCD_3 . In other embodiments, R_4 is R_8 -OH. In other embodiments, R_4 is CH_2 -OH. In other embodiments, R_4 is $-R_8$ -O- R_{10} . In other embodiments, R_4 is CH_2 -O- CH_3 . In other embodiments, R_4 is CF_3 . In other embodiments, R_4 is R_8 -N(R_{10})(R_{11}). In other embodiments, R_4 is CH_2 -NH₂. In other embodiments, R_4 is CH_2 -N(CH_3)₂. In other embodiments, R_4 is COOH. In other embodiments, R_4 is C(O)O- R_{10} . In other embodiments, R_4 is C(O)O- CH_2CH_3 . In other embodiments, R_4 is R_8 -C(O)- R_{10} . In other embodiments, R_4 is CH_2 C(O) CH_3 . In other embodiments, R_4 is C(O)- R_{10} . In other embodiments, R_4 is C(O)- CH_3 . In other embodiments, R_4 is C(O)- CH_2CH_3 . In other embodiments, R_4 is C(O)- $CH_2CH_2CH_3$. In other embodiments, R_4 is C_1 - C_5 linear or branched C(O)-haloalkyl. In other embodiments, R_4 is C(O)- CF_3 . In other embodiments, R_4 is C(O)N(R_{10})(R_{11}). In other embodiments, R_4 is C(O)N(CH_3)₂. In other embodiments, R_4 is SO_2 N(R_{10})(R_{11}). In other embodiments, R_4 is SO_2 N(CH_3)₂. In other embodiments, R_4 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_4 is methyl. In other embodiments, R_4 is C(OH)(CH_3)(Ph). In other embodiments, R_4 is ethyl. In other embodiments, R_4 is propyl. In other embodiments, R_4 is iso-propyl. In other embodiments, R_4 is t-Bu. In other embodiments, R_4 is iso-butyl. In other embodiments, R_4 is pentyl. In other embodiments, R_4 is C_1 - C_5 linear or branched haloalkyl. In other embodiments, R_4 is CF_2CH_3 . In other embodiments, R_4 is CH_2CF_3 . In other embodiments, R_4 is $CF_2CH_2CH_3$. In other embodiments, R_4 is C_1 - C_5 linear, branched or cyclic alkoxy. In other embodiments, R_4 is methoxy. In other embodiments, R_4 is isopropoxy. In other embodiments, R_4 is substituted or unsubstituted C_3 - C_8 cycloalkyl. In other embodiments, R_4 is cyclopropyl. In other embodiments, R_4 is cyclopentyl. In other embodiments, R_4 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_4 is thiophene. In other embodiments, R_4 is oxazole. In other

embodiments, R_4 is isoxazole. In other embodiments, R_4 is imidazole. In other embodiments, R_4 is furane. In other embodiments, R_4 is triazole. In other embodiments, R_4 is pyridine. In other embodiments, R_4 is 2-pyridine. In other embodiments, R_4 is 3-pyridine. In other embodiments, R_4 is 4-pyridine. In other embodiments, R_4 is pyrimidine. In other embodiments, R_4 is pyrazine. In other embodiments, R_4 is oxacyclobutane. In other embodiments, R_4 is 1-oxacyclobutane. In other embodiments, R_4 is 2-oxacyclobutane. In other embodiments, R_4 is indole. In other embodiments, R_4 is substituted or unsubstituted aryl. In other embodiments, R_4 is phenyl. In other embodiments, R_4 is $\text{CH}(\text{CF}_3)(\text{NH}-R_{10})$.

[0066] In some embodiments, R_3 and R_4 are joined together to form a [1,3]dioxole ring. In some embodiments, R_3 and R_4 are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R_3 and R_4 are joined together to form a benzene ring. In some embodiments, R_3 and R_4 are joined together to form a cyclopentane ring. In some embodiments, R_3 and R_4 are joined together to form an imidazole ring.

[0067] In some embodiments, R_5 is H. In other embodiments, R_5 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_5 is methyl. In other embodiments, R_5 is CH_2SH . In other embodiments, R_5 is ethyl. In other embodiments, R_5 is iso-propyl. In other embodiments, R_5 is C_1 - C_5 linear or branched haloalkyl. In other embodiments, R_5 is CF_3 . In other embodiments, R_5 is R_8 -aryl. In other embodiments, R_5 is CH_2 -Ph (i.e., benzyl). In other embodiments, R_5 is substituted or unsubstituted aryl. In other embodiments, R_5 is phenyl. In other embodiments, R_5 is substituted or unsubstituted heteroaryl. In other embodiments, R_5 is pyridine. In other embodiments, R_5 is 2-pyridine. In other embodiments, R_5 is 3-pyridine. In other embodiments, R_5 is 4-pyridine.

[0068] In some embodiments, R_6 is H. In other embodiments, R_6 is C_1 - C_5 linear or branched alkyl. In other embodiments, R_6 is methyl.

[0069] In some embodiments, R_8 is CH_2 . In other embodiments, R_8 is CH_2CH_2 . In other embodiments, R_8 is $\text{CH}_2\text{CH}_2\text{CH}_2$.

[0070] In some embodiments, p is 1. In other embodiments, p is 2. In other embodiments, p is 3.

[0071] In some embodiments, R_9 is $\text{C}\equiv\text{C}$.

[0072] In some embodiments, q is 2.

[0073] In some embodiments, R_{10} is C_1 - C_5 linear or branched alkyl. In other embodiments, R_{10} is CH_3 . In other embodiments, R_{10} is CH_2CH_3 . In other embodiments, R_{10} is $\text{CH}_2\text{CH}_2\text{CH}_3$.

[0074] In some embodiments, R_{11} is C_1 - C_5 linear or branched alkyl. In other embodiments, R_{11} is CH_3 .

[0075] In some embodiments, R is H. In other embodiments, R is C_1 - C_5 linear or branched alkyl. In other embodiments, R is methyl. In other embodiments, R is ethyl.

[0076] In some embodiments, m is 1. In other embodiments, m is 0.

[0077] In some embodiments, n is 1. In other embodiments, n is 0.

[0078] In some embodiments, k is 1. In other embodiments, k is 0.

[0079] In some embodiments, 1 is 1.

[0080] In some embodiments, Q_1 is O.

[0081] In some embodiments, Q_2 is O.

[0082] In some embodiments, X_1 is C. In other embodiments, X_1 is N.

[0083] In some embodiments, X_2 is C. In other embodiments, X_2 is N.

[0084] In some embodiments, X_3 is C. In other embodiments, X_3 is N.

[0085] In some embodiments, X_4 is C. In other embodiments, X_4 is N.

[0086] In some embodiments, X_6 is C. In other embodiments, X_6 is N.


[0087] In some embodiments, X_7 is C. In other embodiments, X_7 is N.


[0088] In some embodiments, X_8 is C. In other embodiments, X_8 is N.

[0089] In some embodiments, X_9 is C. In other embodiments, X_9 is N.

[0090] In some embodiments, X_{10} is C. In other embodiments, X_{10} is N.

[0091] In various embodiments, the compound is represented by the structure of formula (III)





(III)

wherein

R₁ and **R₂** are each independently H, F, Cl, Br, I, OH, SH, Rs-OH (e.g., CH₂-OH), R₈-SH, -Rs-OR₁₀, (e.g., -CH₂-O-CH₃), CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁) (e.g., CH₂-NH₂, CH₂-N(CH₃)₂), R₉-R₈-N(R₁₀)(R₁₁) (e.g., C≡C-CH₂-NH₂), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, NHC(O)-R₁₀ (e.g., NHC(O)CH₃), NHCO-N(R₁₀)(R₁₁) (e.g., NHC(O)N(CH₃)₂), COOH, -C(O)Ph, C(O)OR₁₀ (e.g. C(O)O-CH₃, C(O)O-CH(CH₃)₂, C(O)O-CH₂CH₃), R₈-C(O)-R₁₀ (e.g., CH₂C(O)CH₃), C(O)H, C(O)-R₁₀ (e.g., C(O)-CH₃, C(O)-CH₂CH₃, C(O)-CH₂CH₂CH₃), C₁-C₅ linear or branched C(O)-haloalkyl (e.g., C(O)-CF₃), -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁) (e.g., C(O)N(CH₃)₂), SO₂R, SO₂N(R₁₀)(R₁₁) (e.g., SO₂N(CH₃)₂, SO₂NHC(O)CH₃), C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, 2, 3, or -CH₂-C₆H₄-Cl, ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₂CH₃, CH₂CF₃), C₁-C₅ linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, O-CH₂-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, 1-butoxy, 2-butoxy, O-tBu), optionally wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom (O) (e.g., O-1-oxacyclobutyl, O-2-oxacyclobutyl), C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy (e.g., OCF₃, OCHF₂), C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C₃-C₈ heterocyclic ring (e.g., thiophene, oxazole, oxadiazole, imidazole, furane, triazole, tetrazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole, protonated or deprotonated pyridine oxide), substituted or unsubstituted aryl (e.g., phenyl) (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl (e.g. methyl, ethyl), OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₂** and **R₁** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, pyridine);

R₃ is C₂-C₅ linear or branched haloalkyl, CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃, CH₂CH₂CF₃, CF₂CH(CH₃)₂, CF(CH₃)-CH(CH₃)₂, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

and **R₄** is H, F, Cl, Br, I, OH, SH, Rs-OH (e.g., CH₂-OH), R₈-SH, -R₈-O-R₁₀, (e.g., CH₂-O-CH₃) CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁) (e.g., CH₂-NH₂, CH₂-N(CH₃)₂), R₉-R₈-N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀ (e.g., NHC(O)CH₃), NHCO-N(R₁₀)(R₁₁) (e.g., NHC(O)N(CH₃)₂), COOH, -C(O)Ph, C(O)O-R₁₀ (e.g.

C(O)O-CH₃, C(O)O-CH₂CH₃, R₈-C(O)-R₁₀ (e.g., CH₂C(O)CH₃), C(O)H, C(O)-R₁₀ (e.g., C(O)-CH₃, C(O)-CH₂CH₃, C(O)-CH₂CH₂CH₃), C₁-C₅ linear or branched C(O)-haloalkyl (e.g., C(O)-CF₃), -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁) (e.g., C(O)N(CH₃)₂), SO₂R, SO₂N(R₁₀)(R₁₁) (e.g., SO₂N(CH₃)₂), C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, C(OH)(CH₃)(Ph), ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃), C₁-C₅ linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, O-CH₂-cyclopropyl), C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C₃-C₈ heterocyclic ring (e.g., thiophene, oxazole, isoxazole, imidazole, furane, triazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole), substituted or unsubstituted aryl (e.g., phenyl), (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₃** and **R₄** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, cyclopentane, imidazole);

R₅ is H, C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, CH₂SH, ethyl, iso-propyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₃), R₈-aryl (e.g., CH₂-Ph), substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted heteroaryl (e.g., pyridine (2, 3, and 4-pyridine), (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

R₆ is H, C₁-C₅ linear or branched alkyl (e.g., methyl);

R₈ is [CH₂]_p

wherein **p** is between 1 and 10;

R₉ is [CH]_q, [C]_q

wherein **q** is between 2 and 10;

R₁₀ and **R₁₁** are each independently H, C₁-C₅ linear or branched alkyl (e.g., methyl, ethyl), C(O)R, or S(O)₂R;

R is H, C₁-C₅ linear or branched alkyl (e.g., methyl, ethyl), C₁-C₅ linear or branched alkoxy, phenyl, aryl or heteroaryl, or two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring;

Q₁ and **Q₂** are each independently S, O;

X₃ and **X₄** are each independently C or N, wherein if **X₃** is N, then **R₄** is absent;

X₆, **X₇** and **X₈** are each independently C or N, wherein if **X₈** is N, then **R₂** is absent.

[0092] In some embodiments, R_1 is H. In other embodiments, R_1 is F. In other embodiments, R_1 is Cl. In other embodiments, R_1 is Br. In other embodiments, R_1 is I. In other embodiments, R_1 is $C(O)O-R_{10}$. In other embodiments, R_1 is $C(O)O-CH_3$. In other embodiments, R_1 is CF_3 . In other embodiments, R_1 is OCD_3 . In other embodiments, R_1 is NO_2 . In other embodiments, R_1 is NH_2 . In other embodiments, R_1 is $R_8-N(R_{10})(R_{11})$. In other embodiments, R_1 is CH_2-NH_2 . In other embodiments, R_1 is $CH_2-N(CH_3)_2$. In other embodiments, R_1 is $R_9-R_8-N(R_{10})(R_{11})$. In other embodiments, R_1 is $CC-CH_2-NH_2$. In other embodiments, R_1 is $B(OH)_2$. In other embodiments, R_1 is C_1-C_5 linear or branched haloalkoxy. In other embodiments, R_1 is OCF_3 . In other embodiments, R_1 is $OCHF_2$. In other embodiments, R_1 is $COOH$. In other embodiments, R_1 is $SO_2N(R_{10})(R_{11})$. In other embodiments, R_1 is $SO_2N(CH_3)_2$. In other embodiments, R_1 is $SO_2NHC(O)CH_3$. In other embodiments, R_1 is $C(O)O-CH(CH_3)_2$. In other embodiments, R_1 is substituted or unsubstituted C_3-C_8 heterocyclic ring. In other embodiments, R_1 is pyridine. In other embodiments, R_1 is 2-pyridine. In other embodiments, R_1 is 3-pyridine. In other embodiments, R_1 is 4-pyridine. In other embodiments, R_1 is oxazole. In other embodiments, R_1 is methyl substituted oxazole. In other embodiments, R_1 is oxadiazole. In other embodiments, R_1 is methyl substituted oxadiazole. In other embodiments, R_1 is imidazole. In other embodiments, R_1 is methyl substituted imidazole. In other embodiments, R_1 is tetrazole. In other embodiments, R_1 is pyrimidine. In other embodiments, R_1 is pyrazine. In other embodiments, R_1 is oxacyclobutane. In other embodiments, R_1 is 1-oxacyclobutane. In other embodiments, R_1 is 2-oxacyclobutane. In other embodiments, R_1 is indole. In other embodiments, R_1 is pyridine oxide. In other embodiments, R_1 is protonated pyridine oxide. In other embodiments, R_1 is deprotonated pyridine oxide. In other embodiments, R_1 is substituted or unsubstituted aryl. In other embodiments, R_1 is phenyl. In other embodiments, R_1 is bromophenyl. In other embodiments, R_1 is 2-bromophenyl. In other embodiments, R_1 is 3-bromophenyl. In other embodiments, R_1 is 4-bromophenyl. In other embodiments, R_1 is C_1-C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_1 is methyl. In other embodiments, R_1 is 2- $CH_2-C_6H_4-Cl$. In other embodiments, R_1 is 3- $CH_2-C_6H_4-Cl$. In other embodiments, R_1 is 4- $CH_2-C_6H_4-Cl$. In other embodiments, R_1 is ethyl. In other embodiments, R_1 is propyl. In other embodiments, R_1 is iso-propyl. In other embodiments, R_1 is t-Bu. In other embodiments, R_1 is iso-butyl. In other embodiments, R_1 is pentyl. In other embodiments, R_1 is substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R_1 is C_1-C_5 linear, branched or cyclic alkoxy. In other embodiments, R_1 is methoxy. In other embodiments, R_1 is ethoxy. In other embodiments, R_1 is propoxy. In other embodiments, R_1 is isopropoxy. In other embodiments, R_1 is O-cyclobutyl. In other embodiments, R_1 is O-cyclopentyl. In other embodiments, R_1 is O-cyclohexyl. In other embodiments, R_1 is 1-butoxy. In other embodiments, R_1 is 2-butoxy. In other embodiments, R_1

is O-tBu. In other embodiments, R_1 is C_1 - C_5 linear, branched or cyclic alkoxy wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom (O). In other embodiments, R_1 is O-1-oxacyclobutyl. In other embodiments, R_1 is O-2-oxacyclobutyl. In other embodiments, R_1 is R_8 -N(R_{10})(R_{11}). In other embodiments, R_1 is CH_2 -NH₂.

[0093] In some embodiments, R_2 is H. In other embodiments, R_2 is F. In other embodiments, R_2 is Cl. In other embodiments, R_2 is Br. In other embodiments, R_2 is I. In other embodiments, R_2 is CF_3 . In other embodiments, R_2 is OCD_3 . In other embodiments, R_2 is C_1 - C_5 linear or branched haloalkoxy. In other embodiments, R_2 is OCF_3 . In other embodiments, R_2 is $OCHF_2$. In other embodiments, R_2 is $SO_2N(R_{10})(R_{11})$. In other embodiments, R_2 is $SO_2N(CH_3)_2$. In other embodiments, R_2 is $SO_2NHC(O)CH_3$. In other embodiments, R_2 is NO_2 . In other embodiments, R_2 is NH_2 . In other embodiments, R_2 is R_8 -N(R_{10})(R_{11}). In other embodiments, R_2 is CH_2 -NH₂. In other embodiments, R_2 is CH_2 -N(CH_3)₂. In other embodiments, R_2 is R_9 - R_8 -N(R_{10})(R_{11}). In other embodiments, R_2 is $C\equiv C$ - CH_2 -NH₂. In other embodiments, R_2 is $B(OH)_2$. In other embodiments, R_2 is $NHC(O)$ - R_{10} . In other embodiments, R_2 is $NHC(O)CH_3$. In other embodiments, R_2 is $NHCO$ -N(R_{10})(R_{11}). In other embodiments, R_2 is $NHC(O)N(CH_3)_2$. In other embodiments, R_2 is $COOH$. In other embodiments, R_2 is ethoxy. In other embodiments, R_2 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_2 is methyl. In other embodiments, R_2 is 2- CH_2 - C_6H_4 -Cl. In other embodiments, R_2 is 3- CH_2 - C_6H_4 -Cl. In other embodiments, R_2 is 4- CH_2 - C_6H_4 -Cl. In other embodiments, R_2 is ethyl. In other embodiments, R_2 is propyl. In other embodiments, R_2 is iso-propyl. In other embodiments, R_2 is t-Bu. In other embodiments, R_2 is iso-butyl. In other embodiments, R_2 is pentyl. In other embodiments, R_2 is substituted or unsubstituted C_3 - C_8 cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R_2 is C_1 - C_5 linear, branched or cyclic alkoxy. In other embodiments, R_2 is methoxy. In other embodiments, R_2 is ethoxy. In other embodiments, R_2 is propoxy. In other embodiments, R_2 is isopropoxy. In other embodiments, R_2 is O-CH₂-cyclopropyl. In other embodiments, R_2 is O-cyclobutyl. In other embodiments, R_2 is O-cyclopentyl. In other embodiments, R_2 is O-cyclohexyl. In other embodiments, R_2 is O-1-oxacyclobutyl. In other embodiments, R_2 is O-2-oxacyclobutyl. In other embodiments, R_2 is 1-butoxy. In other embodiments, R_2 is 2-butoxy. In other embodiments, R_2 is O-tBu. In other embodiments, R_2 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_2 is pyridine. In other embodiments, R_2 is 2-pyridine. In other embodiments, R_2 is 3-pyridine. In other embodiments, R_2 is 4-pyridine. In other embodiments, R_2 is oxazole or methyl substituted oxazole. In other embodiments, R_2 is oxadiazole or methyl substituted oxadiazole. In other embodiments, R_2 is imidazole or methyl substituted imidazole. In other embodiments, R_2 is tetrazole. In other embodiments, R_2 is pyrimidine. In other embodiments, R_2 is pyrazine. In other embodiments, R_2 is oxacyclobutane. In other embodiments, R_2 is 1-oxacyclobutane. In other embodiments, R_2 is 2-oxacyclobutane. In other embodiments, R_2 is indole. In other embodiments, R_2 is pyridine oxide. In other embodiments, R_2 is protonated

pyridine oxide. In other embodiments, R_2 is deprotonated pyridine oxide. In other embodiments, R_2 is substituted or unsubstituted aryl. In other embodiments, R_2 is phenyl. In other embodiments, R_2 is bromophenyl. In other embodiments, R_2 is 2-bromophenyl. In other embodiments, R_2 is 3-bromophenyl. In other embodiments, R_2 is 4-bromophenyl. In other embodiments, R_2 is $R_8-N(R_{10})(R_{11})$. In other embodiments, R_2 is CH_2-NH_2 .

[0094] In some embodiments, R_1 and R_2 are joined together to form a [1,3]dioxole ring. In some embodiments, R_1 and R_2 are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R_1 and R_2 are joined together to form a benzene ring. In some embodiments, R_1 and R_2 are joined together to form a pyridine ring.

[0095] In other embodiments, R_3 is C_2-C_5 linear or branched haloalkyl. In other embodiments, R_3 is CF_2CH_3 . In other embodiments, R_3 is substituted or unsubstituted C_3-C_8 heterocyclic ring. In other embodiments, R_3 is furane. In other embodiments, R_3 is thiophene. In other embodiments, R_3 is pyrimidine. In other embodiments, R_3 is pyrazine. In other embodiments, R_3 is imidazole. In other embodiments, R_3 is oxazole. In other embodiments, R_3 is isoxazole. In other embodiments, R_3 is triazole. In other embodiments, R_3 is oxacyclobutane. In other embodiments, R_3 is 1-oxacyclobutane. In other embodiments, R_3 is 2-oxacyclobutane. In other embodiments, R_3 is indole. In other embodiments, R_3 is substituted or unsubstituted C_3-C_8 cycloalkyl. In other embodiments, R_3 is cyclopropyl. In other embodiments, R_3 is C_2-C_5 linear or branched haloalkyl. In other embodiments, R_3 is CH_2CF_3 . In other embodiments, R_3 is $CF_2CH_2CH_3$. In other embodiments, R_3 is substituted or unsubstituted C_3-C_8 cycloalkyl. In other embodiments, R_3 is cyclopentyl. In other embodiments, R_3 is substituted or unsubstituted aryl. In other embodiments, R_3 is phenyl. In other embodiments, R_3 is pyridine. In other embodiments, R_3 is 2-pyridine. In other embodiments, R_3 is 3-pyridine. In other embodiments, R_3 is 4-pyridine. In other embodiments, R_3 is $CH(CF_3)(NH-R_{10})$.

[0096] In other embodiments, R_4 is H. In other embodiments, R_4 is $SO_2N(R_{10})(R_{11})$. In other embodiments, R_4 is $SO_2N(CH_3)_2$. In other embodiments, R_4 is methoxy. In other embodiments, R_4 is F. In other embodiments, R_4 is $C(O)-CH_3$. In other embodiments, R_4 is OH. In other embodiments, R_4 is OH. In other embodiments, R_4 is $C(O)O-R_{10}$. In other embodiments, R_4 is $C(O)O-CH_3$. In other embodiments, R_4 is CD_3 . In other embodiments, R_4 is OCD_3 . In other embodiments, R_3 is substituted or unsubstituted C_3-C_8 heterocyclic ring. In other embodiments, R_4 is imidazole. In other embodiments, R_4 is furane. In other embodiments, R_4 is oxacyclobutane. In other embodiments, R_4 is 1-oxacyclobutane. In other embodiments, R_4 is 2-oxacyclobutane. In other embodiments, R_4 is indole. In other embodiments, R_3 is C_1-C_5 linear or branched haloalkyl. In other embodiments, R_4 is CF_2CH_3 . In other embodiments, R_4 is CH_2CF_3 . In other embodiments, R_4 is $CF_2CH_2CH_3$. In other embodiments, R_4 is $Rs-OH$. In other embodiments, R_4 is CH_2-OH . In other embodiments, R_4 is C_1-C_5 linear or branched,

substituted or unsubstituted alkyl. In other embodiments, R_4 is methyl. In other embodiments, R_4 is $C(OH)(CH_3)(Ph)$. In other embodiments, R_4 is ethyl. In other embodiments, R_4 is propyl. In other embodiments, R_4 is iso-propyl. In other embodiments, R_4 is iso-butyl. In other embodiments, R_4 is t-Bu. In other embodiments, R_4 is pentyl.

[0097] In some embodiments, R_3 and R_4 are joined together to form a [1,3]dioxole ring. In some embodiments, R_3 and R_4 are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R_3 and R_4 are joined together to form a cyclopentane ring. In some embodiments, R_3 and R_4 are joined together to form an imidazole ring.

[0098] In some embodiments, R_5 is H. In other embodiments, R_5 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_5 is methyl. In other embodiments, R_5 is CH_2SH . In other embodiments, R_5 is ethyl. In other embodiments, R_5 is iso-propyl. In other embodiments, R_5 is C_1 - C_5 linear or branched haloalkyl. In other embodiments, R_5 is CF_3 . In other embodiments, R_5 is R_8 -aryl. In other embodiments, R_5 is CH_2 -Ph (i.e., benzyl). In other embodiments, R_5 is substituted or unsubstituted aryl. In other embodiments, R_5 is phenyl. In other embodiments, R_5 is substituted or unsubstituted heteroaryl. In other embodiments, R_5 is pyridine. In other embodiments, R_5 is 2-pyridine. In other embodiments, R_5 is 3-pyridine. In other embodiments, R_5 is 4-pyridine.

[0099] In some embodiments, R_6 is H. In other embodiments, R_6 is C_1 - C_5 linear or branched alkyl. In other embodiments, R_6 is methyl.

[0100] In some embodiments, R_8 is CH_2 . In other embodiments, R_8 is CH_2CH_2 . In other embodiments, R_8 is $CH_2CH_2CH_2$.

[0101] In some embodiments, p is 1. In other embodiments, p is 2. In other embodiments, p is 3.

[0102] In some embodiments, R_9 is $C\equiv C$.

[0103] In some embodiments, q is 2.

[0104] In some embodiments, R_{10} is C_1 - C_5 linear or branched alkyl. In other embodiments, R_{10} is H. In other embodiments, R_{10} is CH_3 . In other embodiments, R_{10} is CH_2CH_3 . In other embodiments, R_{10} is $CH_2CH_2CH_3$.

[0105] In some embodiments, R_{11} is C_1 - C_5 linear or branched alkyl. In other embodiments, R_{11} is H. In other embodiments, R_{11} is CH_3 .

[0106] In some embodiments, **R** is H. In other embodiments, **R** is C₁-C₅ linear or branched alkyl. In other embodiments, **R** is methyl. In other embodiments, **R** is ethyl.

[0107] In some embodiments, **Q₁** is O.

[0108] In some embodiments, **Q₂** is O.

[0109] In some embodiments, **X₃** is C. In other embodiments, **X₃** is N.


[0110] In some embodiments, **X₄** is C. In other embodiments, **X₄** is N.

[0111] In some embodiments, **X₆** is C. In other embodiments, **X₆** is N.

[0112] In some embodiments, **X₇** is C. In other embodiments, **X₇** is N.

[0113] In some embodiments, **X₈** is C. In other embodiments, **X₈** is N.

[0114] In various embodiments, the compound is represented by the structure of formula (IV)



(IV)

wherein

R₁ and **R₂** are each independently H, F, Cl, Br, I, OH, SH, Rs-OH (e.g., CH₂-OH), R₈-SH, -Rs-OR₁₀, (e.g., -CH₂-O-CH₃), CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁) (e.g., CH₂-NH₂, CH₂-N(CH₃)₂), R₉-R₈-N(R₁₀)(R₁₁) (e.g., C≡C-CH₂-NH₂), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, NHC(O)-R₁₀ (e.g., NHC(O)CH₃), NHCO-N(R₁₀)(R₁₁) (e.g., NHC(O)N(CH₃)₂), COOH, -C(O)Ph, C(O)OR₁₀ (e.g. C(O)O-CH₃, C(O)O-CH(CH₃)₂, C(O)O-CH₂CH₃), R₈-C(O)-R₁₀ (e.g., CH₂C(O)CH₃), C(O)H, C(O)-R₁₀ (e.g., C(O)-CH₃, C(O)-CH₂CH₃, C(O)-CH₂CH₂CH₃), C₁-C₅ linear or branched C(O)-haloalkyl (e.g., C(O)-CF₃), -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁) (e.g., C(O)N(CH₃)₂), SO₂R, SO₂N(R₁₀)(R₁₁) (e.g., SO₂N(CH₃)₂, SO₂NHC(O)CH₃), C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, 2, 3, or 4-CH₂-C₆H₄-Cl, ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₂CH₃, CH₂CF₃), C₁-C₅ linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, O-CH₂-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, 1-butoxy, 2-butoxy, O-tBu), optionally wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom (O) (e.g., O-1-oxacyclobutyl, O-2-oxacyclobutyl), C₁-C₅ linear or

branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy (e.g., OCF₃, OCHF₂), C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C₃-C₈ heterocyclic ring (e.g., thiophene, oxazole, oxadiazole, imidazole, furane, triazole, tetrazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole, protonated or deprotonated pyridine oxide), substituted or unsubstituted aryl (e.g., phenyl) (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl (e.g. methyl, ethyl), OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₂** and **R₁** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, pyridine);

R₃ is C₂-C₅ linear or branched haloalkyl, CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃, CH₂CH₂CF₃, CF₂CH(CH₃)₂, CF(CH₃)-CH(CH₃)₂, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

and **R₄** is H, F, Cl, Br, I, OH, SH, R₈-OH (e.g., CH₂-OH), R₈-SH, -R₈-O-R₁₀, (e.g., CH₂-O-CH₃) CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁) (e.g., CH₂-NH₂, CH₂-N(CH₃)₂), R₉-R₈-N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀ (e.g., NHC(O)CH₃), NHCO-N(R₁₀)(R₁₁) (e.g., NHC(O)N(CH₃)₂), COOH, -C(O)Ph, C(O)O-R₁₀ (e.g. C(O)O-CH₃, C(O)O-CH₂CH₃), R₈-C(O)-R₁₀ (e.g., CH₂C(O)CH₃), C(O)H, C(O)-R₁₀ (e.g., C(O)-CH₃, C(O)-CH₂CH₃, C(O)-CH₂CH₂CH₃), C₁-C₅ linear or branched C(O)-haloalkyl (e.g., C(O)-CF₃), -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁) (e.g., C(O)N(CH₃)₂), SO₂R, SO₂N(R₁₀)(R₁₁) (e.g., SO₂N(CH₃)₂), C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, C(OH)(CH₃)(Ph), ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃), C₁-C₅ linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, O-CH₂-cyclopropyl), C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C₃-C₈ heterocyclic ring (e.g., thiophene, oxazole, isoxazole, imidazole, furane, triazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole), substituted or unsubstituted aryl (e.g., phenyl), (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₃** and **R₄** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, cyclopentane, imidazole);

R₅ is H, C₁-C₅ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, CH₂SH,

ethyl, iso-propyl), C₁-C₅ linear or branched haloalkyl (e.g., CF₃), Rs-aryl (e.g., CH₂-Ph), substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted heteroaryl (e.g., pyridine (2, 3, and 4-pyridine), (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

R₈ is [CH₂]_p

wherein **p** is between 1 and 10;

R₉ is [CH]_q, [C]_q

wherein **q** is between 2 and 10;

R₁₀ and **R₁₁** are each independently H, C₁-C₅ linear or branched alkyl (e.g., methyl, ethyl), C(O)R, or S(O)₂R;

R is H, C₁-C₅ linear or branched alkyl (e.g., methyl, ethyl), C₁-C₅ linear or branched alkoxy, phenyl, aryl or heteroaryl, or two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring;

X₃ and **X₄** are each independently C or N, wherein if X₃ is N, then R₄ is absent;

X₇ and **X₈** are each independently C or N, wherein if X₈ is N, then R₂ is absent.

[0115] In some embodiments, R₁ is H. In other embodiments, R₁ is F. In other embodiments, R₁ is Cl. In other embodiments, R₁ is Br. In other embodiments, R₁ is I. In other embodiments, R₁ is C(O)O-R₁₀. In other embodiments, R₁ is C(O)O-CH₃. In other embodiments, R₁ is CF₃. In other embodiments, R₁ is OCD₃. In other embodiments, R₁ is NO₂. In other embodiments, R₁ is NH₂. In other embodiments, R₁ is R₈-N(R₁₀)(R₁₁). In other embodiments, R₁ is CH₂-NH₂. In other embodiments, R₁ is CH₂-N(CH₃)₂. In other embodiments, R₁ is R₉-R₈-N(R₁₀)(R₁₁). In other embodiments, R₁ is C≡C-CH₂-NH₂. In other embodiments, R₁ is B(OH)₂. In other embodiments, R₁ is C₁-C₅ linear or branched haloalkoxy. In other embodiments, R₁ is OCF₃. In other embodiments, R₁ is OCHF₂. In other embodiments, R₁ is COOH. In other embodiments, R₁ is SO₂N(R₁₀)(R₁₁). In other embodiments, R₁ is SO₂N(CH₃)₂. In other embodiments, R₁ is SO₂NHC(O)CH₃. In other embodiments, R₁ is C(O)O-CH(CH₃)₂. In other embodiments, R₁ is substituted or unsubstituted C₃-C₈ heterocyclic ring. In other embodiments, R₁ is pyridine. In other embodiments, R₁ is 2-pyridine. In other embodiments, R₁ is 3-pyridine. In other embodiments, R₁ is 4-pyridine. In other embodiments, R₁ is oxazole. In other embodiments, R₁ is methyl substituted oxazole. In other embodiments, R₁ is oxadiazole. In other embodiments, R₁ is methyl substituted oxadiazole. In other embodiments, R₁ is imidazole. In other embodiments, R₁ is methyl substituted imidazole. In other embodiments, R₁ is tetrazole. In other embodiments, R₁ is pyrimidine. In other embodiments, R₁ is pyrazine. In other

embodiments, R_1 is oxacyclobutane. In other embodiments, R_1 is 1-oxacyclobutane. In other embodiments, R_1 is 2-oxacyclobutane. In other embodiments, R_1 is indole. In other embodiments, R_1 is pyridine oxide. In other embodiments, R_1 is protonated pyridine oxide. In other embodiments, R_1 is deprotonated pyridine oxide. In other embodiments, R_1 is substituted or unsubstituted aryl. In other embodiments, R_1 is phenyl. In other embodiments, R_1 is bromophenyl. In other embodiments, R_1 is 2-bromophenyl. In other embodiments, R_1 is 3-bromophenyl. In other embodiments, R_1 is 4-bromophenyl. In other embodiments, R_1 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_1 is methyl. In other embodiments, R_1 is 2- CH_2 - C_6H_4 -Cl. In other embodiments, R_1 is 3- CH_2 - C_6H_4 -Cl. In other embodiments, R_1 is 4- CH_2 - C_6H_4 -Cl. In other embodiments, R_1 is ethyl. In other embodiments, R_1 is propyl. In other embodiments, R_1 is iso-propyl. In other embodiments, R_1 is t-Bu. In other embodiments, R_1 is iso-butyl. In other embodiments, R_1 is pentyl. In other embodiments, R_1 is substituted or unsubstituted C_3 - C_8 cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R_1 is C_1 - C_5 linear, branched or cyclic alkoxy. In other embodiments, R_1 is methoxy. In other embodiments, R_1 is ethoxy. In other embodiments, R_1 is propoxy. In other embodiments, R_1 is isopropoxy. In other embodiments, R_1 is O-cyclobutyl. In other embodiments, R_1 is O-cyclopentyl. In other embodiments, R_1 is O-cyclohexyl. In other embodiments, R_1 is 1-butoxy. In other embodiments, R_1 is 2-butoxy. In other embodiments, R_1 is O-tBu. In other embodiments, R_1 is C_1 - C_5 linear, branched or cyclic alkoxy wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom (O). In other embodiments, R_1 is O-1-oxacyclobutyl. In other embodiments, R_1 is O-2-oxacyclobutyl. In other embodiments, R_1 is R_8 -N(R_{10})(R_{11}). In other embodiments, R_1 is CH_2 -NH₂.

[0116] In some embodiments, R_2 is H. In other embodiments, R_2 is F. In other embodiments, R_2 is Cl. In other embodiments, R_2 is Br. In other embodiments, R_2 is I. In other embodiments, R_2 is CF_3 . In other embodiments, R_2 is OCD_3 . In other embodiments, R_2 is C_1 - C_5 linear or branched haloalkoxy. In other embodiments, R_2 is OCF_3 . In other embodiments, R_2 is $OCHF_2$. In other embodiments, R_2 is $SO_2N(R_{10})(R_{11})$. In other embodiments, R_2 is $SO_2N(CH_3)_2$. In other embodiments, R_2 is $SO_2NHC(O)CH_3$. In other embodiments, R_2 is NO_2 . In other embodiments, R_2 is NH_2 . In other embodiments, R_2 is R_8 -N(R_{10})(R_{11}). In other embodiments, R_2 is CH_2 -NH₂. In other embodiments, R_2 is CH_2 -N(CH_3)₂. In other embodiments, R_2 is R_9 - R_8 -N(R_{10})(R_{11}). In other embodiments, R_2 is $C\equiv C$ - CH_2 -NH₂. In other embodiments, R_2 is $B(OH)_2$. In other embodiments, R_2 is $NHC(O)$ - R_{10} . In other embodiments, R_2 is $NHC(O)CH_3$. In other embodiments, R_2 is $NHCO$ -N(R_{10})(R_{11}). In other embodiments, R_2 is $NHC(O)N(CH_3)_2$. In other embodiments, R_2 is $COOH$. In other embodiments, R_2 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_2 is methyl. In other embodiments, R_2 is 2- CH_2 - C_6H_4 -Cl. In other embodiments, R_2 is 3- CH_2 - C_6H_4 -Cl. In other embodiments, R_2 is 4- CH_2 - C_6H_4 -Cl. In other embodiments, R_2 is ethyl. In other embodiments, R_2 is propyl. In other embodiments, R_2 is iso-propyl. In other embodiments, R_2 is t-Bu. In other embodiments, R_2 is

iso-butyl. In other embodiments, R_2 is pentyl. In other embodiments, R_2 is substituted or unsubstituted C_3 - C_8 cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R_2 is ethoxy. In other embodiments, R_2 is C_1 - C_5 linear, branched or cyclic alkoxy. In other embodiments, R_2 is methoxy. In other embodiments, R_2 is propoxy. In other embodiments, R_2 is isopropoxy. In other embodiments, R_2 is O- CH_2 -cyclopropyl. In other embodiments, R_2 is O-cyclobutyl. In other embodiments, R_2 is O-cyclopentyl. In other embodiments, R_2 is O-cyclohexyl. In other embodiments, R_2 is 1-butoxy. In other embodiments, R_2 is 2-butoxy. In other embodiments, R_2 is O-tBu. In other embodiments, R_2 is C_1 - C_5 linear, branched or cyclic alkoxy wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom (O). In other embodiments, R_2 is O-1-oxacyclobutyl. In other embodiments, R_2 is O-2-oxacyclobutyl. In other embodiments, R_2 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_2 is pyridine. In other embodiments, R_2 is 2-pyridine. In other embodiments, R_2 is 3-pyridine. In other embodiments, R_2 is 4-pyridine. In other embodiments, R_2 is oxazole. In other embodiments, R_2 is methyl substituted oxazole. In other embodiments, R_2 is oxadiazole. In other embodiments, R_2 is methyl substituted oxadiazole. In other embodiments, R_2 is imidazole. In other embodiments, R_2 is methyl substituted imidazole. In other embodiments, R_2 is tetrazole. In other embodiments, R_2 is pyrimidine. In other embodiments, R_2 is pyrazine. In other embodiments, R_2 is oxacyclobutane. In other embodiments, R_2 is 1-oxacyclobutane. In other embodiments, R_2 is 2-oxacyclobutane. In other embodiments, R_2 is indole. In other embodiments, R_2 is pyridine oxide. In other embodiments, R_2 is protonated pyridine oxide. In other embodiments, R_2 is deprotonated pyridine oxide. In other embodiments, R_2 is substituted or unsubstituted aryl. In other embodiments, R_2 is phenyl. In other embodiments, R_2 is bromophenyl. In other embodiments, R_2 is 2-bromophenyl. In other embodiments, R_2 is 3-bromophenyl. In other embodiments, R_2 is 4-bromophenyl. In other embodiments, R_2 is R_8 -N(R_{10})(R_{11}). In other embodiments, R_2 is CH_2 - NH_2 .

[0117] In some embodiments, R_1 and R_2 are joined together to form a [1,3]dioxole ring. In some embodiments, R_1 and R_2 are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R_1 and R_2 are joined together to form a benzene ring. In some embodiments, R_1 and R_2 are joined together to form a pyridine ring.

[0118] In other embodiments, R_3 is C_2 - C_5 linear or branched haloalkyl. In other embodiments, R_3 is CF_2CH_3 . In other embodiments, R_3 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_3 is furane. In other embodiments, R_3 is thiophene. In other embodiments, R_3 is pyrimidine. In other embodiments, R_3 is pyrazine. In other embodiments, R_3 is imidazole. In other embodiments, R_3 is oxazole. In other embodiments, R_3 is isoxazole. In other embodiments, R_3 is triazole. In other embodiments, R_3 is oxacyclobutane. In other embodiments, R_3 is 1-oxacyclobutane. In other embodiments, R_3 is 2-oxacyclobutane. In other

embodiments, R_3 is indole. In other embodiments, R_3 is substituted or unsubstituted C_3 - C_8 cycloalkyl. In other embodiments, R_3 is cyclopropyl. In other embodiments, R_3 is C_2 - C_5 linear or branched haloalkyl. In other embodiments, R_3 is CH_2CF_3 . In other embodiments, R_3 is $CF_2CH_2CH_3$. In other embodiments, R_3 is substituted or unsubstituted C_3 - C_8 cycloalkyl. In other embodiments, R_3 is cyclopentyl. In other embodiments, R_3 is substituted or unsubstituted aryl. In other embodiments, R_3 is phenyl. In other embodiments, R_3 is pyridine. In other embodiments, R_3 is 2-pyridine. In other embodiments, R_3 is 3-pyridine. In other embodiments, R_3 is 4-pyridine. In other embodiments, R_3 is $CH(CF_3)(NH-R_{10})$.

[0119] In other embodiments, R_4 is H. In other embodiments, R_4 is $SO_2N(R_{10})(R_{11})$. In other embodiments, R_4 is $SO_2N(CH_3)_2$. In other embodiments, R_4 is methoxy. In other embodiments, R_4 is F. In other embodiments, R_4 is $C(O)-CH_3$. In other embodiments, R_4 is OH. In other embodiments, R_4 is OH. In other embodiments, R_4 is $C(O)O-R_{10}$. In other embodiments, R_4 is $C(O)O-CH_3$. In other embodiments, R_4 is CD_3 . In other embodiments, R_4 is OCD_3 . In other embodiments, R_4 is substituted or unsubstituted C_3 - C_8 heterocyclic ring. In other embodiments, R_4 is imidazole. In other embodiments, R_4 is oxacyclobutane. In other embodiments, R_4 is 1-oxacyclobutane. In other embodiments, R_4 is 2-oxacyclobutane. In other embodiments, R_4 is C_1 - C_5 linear or branched haloalkyl. In other embodiments, R_4 is CF_2CH_3 . In other embodiments, R_4 is CH_2CF_3 . In other embodiments, R_4 is $CF_2CH_2CH_3$. In other embodiments, R_4 is indole. In other embodiments, R_4 is R_8-OH . In other embodiments, R_4 is CH_2-OH . In other embodiments, R_4 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_4 is methyl. In other embodiments, R_4 is $C(OH)(CH_3)(Ph)$. In other embodiments, R_4 is ethyl. In other embodiments, R_4 is propyl. In other embodiments, R_4 is iso-propyl. In other embodiments, R_4 is iso-butyl. In other embodiments, R_4 is t-Bu. In other embodiments, R_4 is pentyl.

[0120] In some embodiments, R_3 and R_4 are joined together to form a [1,3]dioxole ring. In some embodiments, R_3 and R_4 are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R_3 and R_4 are joined together to form a cyclopentane ring. In some embodiments, R_3 and R_4 are joined together to form an imidazole ring.

[0121] In some embodiments, R_5 is H. In other embodiments, R_5 is C_1 - C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_5 is methyl. In other embodiments, R_5 is CH_2SH . In other embodiments, R_5 is ethyl. In other embodiments, R_5 is iso-propyl. In other embodiments, R_5 is C_1 - C_5 linear or branched haloalkyl. In other embodiments, R_5 is CF_3 . In other embodiments, R_5 is R_8 -aryl. In other embodiments, R_5 is CH_2-Ph (i.e., benzyl). In other embodiments, R_5 is substituted or unsubstituted aryl. In other embodiments, R_5 is phenyl. In other embodiments, R_5 is substituted or unsubstituted heteroaryl. In other embodiments, R_5 is pyridine. In other embodiments, R_5 is 2-pyridine. In other embodiments, R_5 is 3-pyridine. In

$N(R_{10})(R_{11})$ (e.g., $CH_2-NH_2, CH_2-N(CH_3)_2$), $R_9-R_8-N(R_{10})(R_{11})$ (e.g., $C\equiv C-CH_2-NH_2$), $B(OH)_2$, $-OC(O)CF_3$, $-OCH_2Ph$, $NHC(O)-R_{10}$ (e.g., $NHC(O)CH_3$), $NHCO-N(R_{10})(R_{11})$ (e.g., $NHC(O)N(CH_3)_2$), $COOH$, $-C(O)Ph$, $C(O)OR_{10}$ (e.g. $C(O)O-CH_3$, $C(O)O-CH(CH_3)_2$, $C(O)O-CH_2CH_3$), $R_8-C(O)-R_{10}$ (e.g., $CH_2C(O)CH_3$), $C(O)H$, $C(O)-R_{10}$ (e.g., $C(O)-CH_3$, $C(O)-CH_2CH_3$, $C(O)-CH_2CH_2CH_3$), C_1-C_5 linear or branched $C(O)$ -haloalkyl (e.g., $C(O)-CF_3$), $-C(O)NH_2$, $C(O)NHR$, $C(O)N(R_{10})(R_{11})$ (e.g., $C(O)N(CH_3)_2$), SO_2R , $SO_2N(R_{10})(R_{11})$ (e.g., $SO_2N(CH_3)_2$, $SO_2NHC(O)CH_3$), C_1-C_5 linear or branched, substituted or unsubstituted alkyl (e.g., methyl, 2, 3, or 4- $CH_2-C_6H_4-Cl$, ethyl, propyl, iso-propyl, t-Bu, iso-butyl, pentyl), C_1-C_5 linear or branched haloalkyl (e.g., CF_2CH_3 , CH_2CF_3), C_1-C_5 linear, branched or cyclic alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, $O-CH_2$ -cyclopropyl, O -cyclobutyl, O -cyclopentyl, O -cyclohexyl, 1-butoxy, 2-butoxy, O -tBu), optionally wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom (O) (e.g., O -1-oxacyclobutyl, O -2-oxacyclobutyl), C_1-C_5 linear or branched thioalkoxy, C_1-C_5 linear or branched haloalkoxy (e.g., OCF_3 , $OCHF_2$), C_1-C_5 linear or branched alkoxyalkyl, substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., thiophene, oxazole, oxadiazole, imidazole, furane, triazole, tetrazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole, protonated or deprotonated pyridine oxide), substituted or unsubstituted aryl (e.g., phenyl) (wherein substitutions include: F, Cl, Br, I, C_1-C_5 linear or branched alkyl (e.g. methyl, ethyl), OH, alkoxy, $N(R)_2$, CF_3 , CN or NO_2), $CH(CF_3)(NH-R_{10})$;

or R_2 and R_1 are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring (e.g., [1,3]dioxole, furan-2(3H)-one, benzene, pyridine);

R_3 is C_2-C_5 linear or branched haloalkyl (e.g., CF_2CH_3 , CH_2CF_3 , $CF_2CH_2CH_3$), substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl, cyclopentyl), substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., thiophene, oxazole, isoxazole, imidazole, furane, triazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole), substituted or unsubstituted aryl (e.g., phenyl), (wherein substitutions include: F, Cl, Br, I, C_1-C_5 linear or branched alkyl, OH, alkoxy, $N(R)_2$, CF_3 , CN or NO_2), $CH(CF_3)(NH-R_{10})$;

R_8 is $[CH_2]_p$

wherein p is between 1 and 10;

R_9 is $[CH]_q$, $[C]_q$

wherein q is between 2 and 10;

R_{10} and R_{11} are each independently H, C_1-C_5 linear or branched alkyl (e.g., methyl, ethyl), $C(O)R$, or $S(O)_2R$;

R is H, C_1-C_5 linear or branched alkyl (e.g., methyl, ethyl), C_1-C_5 linear or branched alkoxy,

phenyl, aryl or heteroaryl, or two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring;

X_3 and X_7 are each independently C or N.

[0134] In some embodiments, R_1 is H. In other embodiments, R_1 is F. In other embodiments, R_1 is Cl. In other embodiments, R_1 is Br. In other embodiments, R_1 is I. In other embodiments, R_1 is $C(O)O-R_{10}$. In other embodiments, R_1 is $C(O)O-CH_3$. In other embodiments, R_1 is CF_3 . In other embodiments, R_1 is OCD_3 . In other embodiments, R_1 is $R_8-N(R_{10})(R_{11})$. In other embodiments, R_1 is CH_2-NH_2 . In other embodiments, R_1 is $CH_2-N(CH_3)_2$. In other embodiments, R_1 is $R_9-R_8-N(R_{10})(R_{11})$. In other embodiments, R_1 is $C\equiv C-CH_2-NH_2$. In other embodiments, R_1 is $B(OH)_2$. In other embodiments, R_1 is C_1-C_5 linear or branched haloalkoxy. In other embodiments, R_1 is OCF_3 . In other embodiments, R_1 is $OCHF_2$. In other embodiments, R_1 is $COOH$. In other embodiments, R_1 is $SO_2N(R_{10})(R_{11})$. In other embodiments, R_1 is $SO_2N(CH_3)_2$. In other embodiments, R_1 is $SO_2NHC(O)CH_3$. In other embodiments, R_1 is $C(O)O-CH(CH_3)_2$. In other embodiments, R_1 is substituted or unsubstituted C_3-C_8 heterocyclic ring. In other embodiments, R_1 is pyridine. In other embodiments, R_1 is 2-pyridine. In other embodiments, R_1 is 3-pyridine. In other embodiments, R_1 is 4-pyridine. In other embodiments, R_1 is oxazole. In other embodiments, R_1 is methyl substituted oxazole. In other embodiments, R_1 is oxadiazole. In other embodiments, R_1 is methyl substituted oxadiazole. In other embodiments, R_1 is imidazole. In other embodiments, R_1 is methyl substituted imidazole. In other embodiments, R_1 is tetrazole. In other embodiments, R_1 is pyrimidine. In other embodiments, R_1 is pyrazine. In other embodiments, R_1 is oxacyclobutane. In other embodiments, R_1 is 1-oxacyclobutane. In other embodiments, R_1 is 2-oxacyclobutane. In other embodiments, R_1 is indole. In other embodiments, R_1 is pyridine oxide. In other embodiments, R_1 is protonated pyridine oxide. In other embodiments, R_1 is deprotonated pyridine oxide. In other embodiments, R_1 is substituted or unsubstituted aryl. In other embodiments, R_1 is phenyl. In other embodiments, R_1 is bromophenyl. In other embodiments, R_1 is 2-bromophenyl. In other embodiments, R_1 is 3-bromophenyl. In other embodiments, R_1 is 4-bromophenyl. In other embodiments, R_1 is C_1-C_5 linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_1 is methyl. In other embodiments, R_1 is 2- $CH_2-C_6H_4-Cl$. In other embodiments, R_1 is 3- $CH_2-C_6H_4-Cl$. In other embodiments, R_1 is 4- $CH_2-C_6H_4-Cl$. In other embodiments, R_1 is ethyl. In other embodiments, R_1 is propyl. In other embodiments, R_1 is iso-propyl. In other embodiments, R_1 is t-Bu. In other embodiments, R_1 is iso-butyl. In other embodiments, R_1 is pentyl. In other embodiments, R_1 is substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R_1 is C_1-C_5 linear, branched or cyclic alkoxy. In other embodiments, R_1 is methoxy. In other embodiments, R_1 is ethoxy. In other embodiments, R_1 is propoxy. In other embodiments, R_1 is

isopropoxy. In other embodiments, R_1 is O-cyclobutyl. In other embodiments, R_1 is O-cyclopentyl. In other embodiments, R_1 is O-cyclohexyl. In other embodiments, R_1 is 1-butoxy. In other embodiments, R_1 is 2-butoxy. In other embodiments, R_1 is O-tBu. In other embodiments, R_1 is C₁-C₅ linear, branched or cyclic alkoxy wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom (O). In other embodiments, R_1 is O-1-oxacyclobutyl. In other embodiments, R_1 is O-2-oxacyclobutyl. In other embodiments, R_1 is R₈-N(R₁₀)(R₁₁). In other embodiments, R_1 is CH₂-NH₂.

[0135] In some embodiments, R_2 is H. In other embodiments, R_2 is F. In other embodiments, R_2 is Cl. In other embodiments, R_2 is Br. In other embodiments, R_2 is I. In other embodiments, R_2 is CF₃. In other embodiments, R_2 is OCD₃. In other embodiments, R_2 is R₈-N(R₁₀)(R₁₁). In other embodiments, R_2 is CH₂-NH₂. In other embodiments, R_2 is CH₂-N(CH₃)₂. In other embodiments, R_2 is R₉-R₈-N(R₁₀)(R₁₁). In other embodiments, R_2 is C≡C-CH₂-NH₂. In other embodiments, R_2 is B(OH)₂. In other embodiments, R_2 is C₁-C₅ linear or branched haloalkoxy. In other embodiments, R_2 is OCF₃. In other embodiments, R_2 is OCHF₂. In other embodiments, R_2 is SO₂N(R₁₀)(R₁₁). In other embodiments, R_2 is SO₂N(CH₃)₂. In other embodiments, R_2 is SO₂NHC(O)CH₃. In other embodiments, R_2 is NO₂. In other embodiments, R_2 is NH₂. In other embodiments, R_2 is NHC(O)-R₁₀. In other embodiments, R_2 is NHC(O)CH₃. In other embodiments, R_2 is NHCO-N(R₁₀)(R₁₁). In other embodiments, R_2 is NHC(O)N(CH₃)₂. In other embodiments, R_2 is COOH. In other embodiments, R_2 is C₁-C₅ linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_2 is methyl. In other embodiments, R_2 is 2-CH₂-C₆H₄-Cl. In other embodiments, R_2 is 3-CH₂-C₆H₄-Cl. In other embodiments, R_2 is 4-CH₂-C₆H₄-Cl. In other embodiments, R_2 is ethyl. In other embodiments, R_2 is propyl. In other embodiments, R_2 is iso-propyl. In other embodiments, R_2 is t-Bu. In other embodiments, R_2 is iso-butyl. In other embodiments, R_2 is pentyl. In other embodiments, R_2 is substituted or unsubstituted C₃-C₈ cycloalkyl (e.g., cyclopropyl, cyclopentyl). In other embodiments, R_2 is ethoxy. In other embodiments, R_2 is C₁-C₅ linear, branched or cyclic alkoxy. In other embodiments, R_2 is methoxy. In other embodiments, R_2 is propoxy. In other embodiments, R_2 is isopropoxy. In other embodiments, R_2 is O-CH₂-cyclopropyl. In other embodiments, R_2 is O-cyclobutyl. In other embodiments, R_2 is O-cyclopentyl. In other embodiments, R_2 is O-cyclohexyl. In other embodiments, R_2 is 1-butoxy. In other embodiments, R_2 is 2-butoxy. In other embodiments, R_2 is O-tBu. In other embodiments, R_2 is C₁-C₅ linear, branched or cyclic alkoxy wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom (O). In other embodiments, R_2 is O-1-oxacyclobutyl. In other embodiments, R_2 is O-2-oxacyclobutyl. In other embodiments, R_2 is substituted or unsubstituted C₃-C₈ heterocyclic ring. In other embodiments, R_2 is pyridine. In other embodiments, R_2 is 2-pyridine. In other embodiments, R_2 is 3-pyridine. In other embodiments, R_2 is 4-pyridine. In other embodiments, R_2 is oxazole. In other embodiments, R_2 is methyl substituted oxazole. In other embodiments, R_2 is oxadiazole. In other embodiments, R_2 is methyl substituted oxadiazole. In other

embodiments, R_2 is imidazole. In other embodiments, R_2 is methyl substituted imidazole. In other embodiments, R_2 is tetrazole. In other embodiments, R_2 is pyrimidine. In other embodiments, R_2 is pyrazine. In other embodiments, R_2 is oxacyclobutane. In other embodiments, R_2 is 1-oxacyclobutane. In other embodiments, R_2 is 2-oxacyclobutane. In other embodiments, R_2 is indole. In other embodiments, R_2 is pyridine oxide. In other embodiments, R_2 is protonated pyridine oxide. In other embodiments, R_2 is deprotonated pyridine oxide. In other embodiments, R_2 is substituted or unsubstituted aryl. In other embodiments, R_2 is phenyl. In other embodiments, R_2 is bromophenyl. In other embodiments, R_2 is 2-bromophenyl. In other embodiments, R_2 is 3-bromophenyl. In other embodiments, R_2 is 4-bromophenyl. In other embodiments, R_2 is $R_8-N(R_{10})(R_{11})$. In other embodiments, R_2 is CH_2-NH_2 .

[0136] In some embodiments, R_1 and R_2 are joined together to form a [1,3]dioxole ring. In some embodiments, R_1 and R_2 are joined together to form a furanone ring (e.g., furan-2(3H)-one). In some embodiments, R_1 and R_2 are joined together to form a benzene ring. In some embodiments, R_1 and R_2 are joined together to form a pyridine ring.

[0137] In other embodiments, R_3 is C_2-C_5 linear or branched haloalkyl. In other embodiments, R_3 is CF_2CH_3 . In other embodiments, R_3 is substituted or unsubstituted C_3-C_8 heterocyclic ring. In other embodiments, R_3 is furane. In other embodiments, R_3 is thiophene. In other embodiments, R_3 is pyrimidine. In other embodiments, R_3 is pyrazine. In other embodiments, R_3 is imidazole. In other embodiments, R_3 is oxazole. In other embodiments, R_3 is isoxazole. In other embodiments, R_3 is triazole. In other embodiments, R_3 is oxacyclobutane. In other embodiments, R_3 is 1-oxacyclobutane. In other embodiments, R_3 is 2-oxacyclobutane. In other embodiments, R_3 is indole. In other embodiments, R_3 is substituted or unsubstituted C_3-C_8 cycloalkyl. In other embodiments, R_3 is cyclopropyl. In other embodiments, R_3 is $Ci-C_5$ linear or branched, substituted or unsubstituted alkyl. In other embodiments, R_3 is C_2-C_5 linear or branched haloalkyl. In other embodiments, R_3 is CH_2CF_3 . In other embodiments, R_3 is $CF_2CH_2CH_3$. In other embodiments, R_3 is substituted or unsubstituted C_3-C_8 cycloalkyl. In other embodiments, R_3 is cyclopentyl. In other embodiments, R_3 is substituted or unsubstituted aryl. In other embodiments, R_3 is phenyl. In other embodiments, R_3 is pyridine. In other embodiments, R_3 is 2-pyridine. In other embodiments, R_3 is 3-pyridine. In other embodiments, R_3 is 4-pyridine. In other embodiments, R_3 is $CH(CF_3)(NH-R_{10})$.

[0138] In some embodiments, R_8 is CH_2 . In other embodiments, R_8 is CH_2CH_2 . In other embodiments, R_8 is $CH_2CH_2CH_2$.

[0139] In some embodiments, p is 1. In other embodiments, p is 2. In other embodiments, p is 3.

[0140] In some embodiments, R_9 is $C\equiv C$.

[0141] In some embodiments, q is 2.

[0142] In some embodiments, R_{10} is C_1 - C_5 linear or branched alkyl. In other embodiments, R_{10} is H. In other embodiments, R_{10} is CH_3 . In other embodiments, R_{10} is CH_2CH_3 . In other embodiments, R_{10} is $CH_2CH_2CH_3$.

[0143] In some embodiments, R_{11} is C_1 - C_5 linear or branched alkyl. In other embodiments, R_{11} is H. In other embodiments, R_{11} is CH_3 .




[0144] In some embodiments, R is H. In other embodiments, R is C_1 - C_5 linear or branched alkyl. In other embodiments, R is methyl. In other embodiments, R is ethyl.









[0145] In some embodiments, X_3 is C. In other embodiments, X_3 is N.










[0146] In some embodiments, X_7 is C. In other embodiments, X_7 is N.









[0147] In various embodiments, the compounds presented in Table 1a are selected from the compound (I) or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, N -oxide, isotopic variants (e.g., deuterated analog), PROTAC, pharmaceutical product or any combination thereof:









Table 1a:









Compound name	Structure
101	
104	
107	









Compound name	Structure
	 <chem>C1=CN=CN=C1</chem>
109	 <chem>CC1=C(C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3N1C(=O)c4c(C)nn(c4)C5=CC=CC=C5)C6=CC=C(C=C6)N7=CC=CC=C7</chem>
119	 <chem>CC1=C(C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3N1C(=O)c4c(C)nn(c4)C5=CC=CC=C5)C6=CC=C(C=C6)N7CC7</chem>
122	 <chem>CC1=C(C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3N1C(=O)c4c(C)nn(c4)C5=CC=CC=C5)C6=CC=C(C=C6)N7COC7</chem>
124	 <chem>CC1=C(C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3N1C(=O)c4c(C)nn(c4)C5=CC=CC=C5)C6=CC=C(C=C6)N7COC7</chem>
132	 <chem>CC1=C(C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3N1C(=O)c4c(C)nn(c4)C5=CC=CC=C5)C6=CC=C(C=C6)N7=CC=CC=C7</chem>
141	 <chem>CC1=C(C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3N1C(=O)c4c(C)nn(c4)C5=CC=CC=C5)C6=CC=C(C=C6)N7C(F)(F)F7</chem>
146	 <chem>CC1=C(C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3N1C(=O)c4c(C)nn(c4)C5=CC=CC=C5)C6=CC=C(C=C6)N7CCCCC7</chem>
148	










Compound name	Structure
	
149	
150	
159	
160	
161	
162	
164	
165	









Compound name	Structure
166	
167	
169	
170	
171	
172	
173	
174	










Compound name	Structure
	
176	
185	
209	
219	
226	
227	
228	








Compound name	Structure
	
229	
230	
231	
232	
233	
234	
235	
236	







Compound name	Structure
	
237	
238	
239	
240	
241	
242	
243	
244	






Compound name	Structure
	
245	
246	
247	
248	
249	
250	
251	
252	








Compound name	Structure
	
253	
254	
255	
256	
257	
258	
259	
261	








Compound name	Structure
	
262	
263	
264	
265	
266	
269	
270	
271	







Compound name	Structure
	 <chem>CC1=CN(C(=O)Nc2ccc(C(F)(F)F)cc2)C(=O)N1c3ccccc3</chem>
272	 <chem>Cc1nc2c(c(=O)n2Nc3ccc(cc3N4C=CC=CC=C4S(=O)(=O)N(C)C)C(=O)N1c5ccc(cc5)C6=CC=CC=C6N=C6)C(=O)N1c7ccc(cc7)N=C8C=CC=CC=C8N1</chem>
273	 <chem>Cc1nc2c(c(=O)n2Nc3ccc(cc3N4C=CC=CC=C4C(=O)O)C(=O)N1c5ccc(cc5)C6=CC=CC=C6N=C6)C(=O)N1c7ccc(cc7)N=C8C=CC=CC=C8N1</chem>
274	 <chem>Cc1nc2c(c(=O)n2Nc3ccc(cc3N4C=CC=CC=C4C(=O)O)C(=O)N1c5ccc(cc5)C6=CC=CC=C6N=C6)C(=O)N1c7ccc(cc7)N=C8C=CC=CC=C8N1</chem>
275	 <chem>Cc1nc2c(c(=O)n2Nc3ccc(cc3N4C=CC=CC=C4C(=O)OC)C(=O)N1c5ccc(cc5)C6=CC=CC=C6N=C6)C(=O)N1c7ccc(cc7)N=C8C=CC=CC=C8N1</chem>
276	 <chem>Cc1nc2c(c(=O)n2Nc3ccc(cc3N4C=CC=CC=C4C(=O)OC)C(=O)N1c5ccc(cc5)C6=CC=CC=C6N=C6)C(=O)N1c7ccc(cc7)N=C8C=CC=CC=C8N1</chem>
277	 <chem>Cc1nc2c(c(=O)n2Nc3ccc(cc3N4C=CC=CC=C4S(=O)(=O)N(C)C)C(=O)N1c5ccc(cc5)C6=CC=CC=C6N=C6)C(=O)N1c7ccc(cc7)N=C8C=CC=CC=C8N1</chem>
278	 <chem>C=CCN</chem>







Compound name	Structure
	 <chem>Cc1nn(C(=O)NCC2=CN=CC=C2)c(=O)n1-c3ccccc3</chem>
279	 <chem>Cc1nn(C(=O)NCC2=CN=CC=C2)c(=O)n1-c3ccc(cc3-c4ccoc4)C5=CC=CC=C5</chem>
280	 <chem>Cc1nn(C(=O)NCC2=CC=C(C=C2)C(F)(F)F)c(=O)n1-c3ccc(cc3-c4cc5nnco5)C6=CC=CC=C6</chem>
281	 <chem>Cc1nn(C(=O)NCC2=CC=C(C=C2)C(F)(F)F)c(=O)n1-c3ccc(cc3-c4cc(OC)c(O)cc4)C5=CC=CC=C5</chem>
282	 <chem>Cc1nn(C(=O)NCC2=CC=C(C=C2)C(F)(F)F)c(=O)n1-c3ccc(cc3-c4cc5nnco5)C6=CC=CC=C6</chem>
286	 <chem>Cc1nn(C(=O)NCC2=CC=C(C=C2)C(F)(F)F)c(=O)n1-c3ccc(cc3-OC(F)(F)F)C4=CC=CC=C4</chem>







Compound name	Structure
287	
289	
291	
292	
293	
294	








Compound name	Structure
	
295	
296	
297	
298	
299	
300	









Compound name	Structure
	 <chem>COc1ccc(N2C(=O)C(=N2)C(=O)NC3=CC=C(C(F)(F)F)C3)cc1</chem>
301	 <chem>COc1cc(N2C(=O)C(=N2)C(=O)NC3=CC=C(C(F)(F)F)C3)cc(C4=CC=CC=O4)c1</chem>
302	 <chem>COc1cc(N2C(=O)C(=N2)C(=O)NC3=CC=C(C(F)(F)F)C3)cc(C)c1</chem>
303	 <chem>COc1cc(N2C(=O)C(=N2)C(=O)NC3=CC=C(C(F)(F)F)C3)cc(C)c1</chem>
304	 <chem>COc1cc(N2C(=O)C(=N2)C(=O)NC3=CC=C(C(F)(F)F)C3)ccn1</chem>
305	 <chem>COc1cc(N2C(=O)C(=N2)C(=O)NC3=CC=C(C(F)(F)F)C3)cc(C(C)(C)C)c1</chem>
306	 <chem>COc1cc(N2C(=O)C(=N2)C(=O)NC3=CC=C(C(F)(F)F)C3)cc(C(F)F)c1</chem>










Compound name	Structure
	
308	
309	
310	
311	
312	
313	









Compound name	Structure
	 <chem>COc1ccc(cc1)N2C(=O)C(=CN2)C(=O)Nc3ccc(cc3)C(F)(F)F</chem>
314	 <chem>COc1ccc(cc1)N2C(=O)C(=CN2)C(=O)Nc3ccc(cc3)C(F)(F)F</chem>
315	 <chem>COc1ccc(cc1N2C(=O)C(=CN2)C(=O)Nc3ccc(cc3)C(F)(F)F)C(F)F</chem>
316	 <chem>COc1ccc(cc1N2C(=O)C(=CN2)C(=O)Nc3ccc(cc3)C(F)(F)F)C(F)F</chem>
317	 <chem>CCOC1=CC=C(C=C1)N2C(=O)C(=CN2)C(=O)Nc3ccc(cc3)C(F)(F)F</chem>
318	 <chem>CC(C)OC1=CC=C(C=C1)N2C(=O)C(=CN2)C(=O)Nc3ccc(cc3)C(F)(F)F</chem>
319	




Compound name	Structure
	
320	
321	
322	
323	
324	
325	

Compound name	Structure
	
326	
327	
328	
329	
330	
331	

Compound name	Structure
	
332	
333	
334	
335	
336	
338	
339	





Compound name	Structure
	
340	
341	
342	
343	
344	
345	
346	
347	










Compound name	Structure
	
348	
349	
350	
351	
352	
353	
354	
355	









Compound name	Structure
	
356	 HCl
357	










[0148] The present invention also provides a compound represented by any of the following structures presented in Table 1b:










Table 1b:









Compound name	Structure
100	
102	
103	
105	
106	










Compound name	Structure
	
108	
110	
111	
112	
113	
114	
115	
116	
117	











Compound name	Structure
	
118	
120	
121	
123	
125	
126	
127	
128	
129	










Compound name	Structure
	
130	
131	
133	
134	
135	
136	
137	
138	









Compound name	Structure
	
139	
140	
142	
143	
144	
145	
147	
152	
153	






Compound name	Structure
	
154	
155	
156	
157	
158	
168	
176	
183	

Compound name	Structure
184	
186	
187	
190	
191	
192	
193	
194	
195	

Compound name	Structure
	
196	
198	
201	
202	
203	
204	
206	
207	
209	

Compound name	Structure
	
213	
214	
215	
216	
217	
218	
220	
221	

Compound name	Structure
	 <chem>O=C(NC(=O)c1ccccc1)C(=O)N1CCCC1c2ccccc2</chem>
222	 <chem>Cc1nc2ccccc2n1C(=O)Nc3ccc(O)cc3</chem>
223	 <chem>Cc1nc2ccccc2n1C(=O)Nc3ccc(CN)cc3</chem>
224	 <chem>Cc1nc2ccccc2n1C(=O)Nc3ccc(OC)cc3C(=O)Nc4ccc(CC)cc4</chem>
260	 <chem>CC(C)C=Cc1ccc(NC(=O)c2nc3ccccc3n2C(=O)Nc4ccc(C)cc4)cc1</chem>
267	 <chem>CC(C)C=Cc1ccc(NC(=O)c2nc3cc4ccncc4n3n2C(=O)Nc5ccc(C)cc5)cc1</chem>
268	 <chem>Cc1nc2ccccc2n1C(=O)Nc3ccc(C)cc3C(=O)Nc4cnc(C)n4</chem>
283	 <chem>Cc1nc2ccccc2n1C(=O)Nc3cc(C)sc3C(=O)Nc4cc(C)sc4</chem>
284	 <chem>Cc1nc2ccccc2n1C(=O)Nc3cc(C)sc3C(=O)Nc4cnc(C)n4</chem>

Compound name	Structure
	 <chem>CCc1cc(s1)C(=O)Cl</chem>
285	 <chem>CCc1cc(s1)NC(=O)C2=C(C)N(C3=CC=CC=C3)C(=O)N2C(=O)N</chem>
288	 <chem>CCc1cc(s1)NC(=O)C2=C(C)N(C3=CC=CC=C3)C(=O)N2C(=O)N</chem>
290	 <chem>CCc1cc(s1)NC(=O)C2=C(C)N(C3=CC=CC=C3)C(=O)N2C(=O)N</chem>
307	 <chem>CC1=C(C)N(C2=CC=CC=C2OC(F)F)C(=O)N1C(=O)N(C(=O)N[C@@H]3CC[C@H](O)[C@H](O)C3)C(=O)N</chem>
337	 <chem>CC1=C(C)N(C2=CC=CC=C2OC(F)F)C(=O)N1C(=O)N(C(=O)N[C@@H](C3=CC=CC=C3)C(C4=CC=CC=C4)O)C(=O)N</chem>

[0149] It is well understood that in structures presented in this invention wherein the nitrogen atom has less than 3 bonds, H atoms are present to complete the valence of the nitrogen.

[0150] In some embodiments, this invention is directed to the compounds listed hereinabove, pharmaceutical compositions and/or uses thereof, wherein the compound is pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, *N*-oxide, isotopic variant (deuterated

analog), PROTAC, pharmaceutical product or any combination thereof. In some embodiments, the compounds are Acyl-CoA Synthetase Short-Chain Family Member 2 (ACSS2) inhibitors.

[0151] In various embodiments, the **A** ring of formula I is phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, 1-methylimidazole, isoquinoline, pyrazolyl, pyrrolyl, furanyl, thiophene-yl, isoquinolinyl, indolyl, 1H-indole, isoindolyl, naphthyl, anthracenyl, benzimidazolyl, indazolyl, 2H-indazole, triazolyl, 4,5,6,7-tetrahydro-2H-indazole, 3H-indol-3-one, purinyl, benzoxazolyl, 1,3-benzoxazolyl, benzisoxazolyl, benzothiazolyl, 1,3-benzothiazole, 4,5,6,7-tetrahydro-1,3-benzothiazole, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinolinyl, isoquinolinyl, 2,3-dihydroindenyl, indenyl, tetrahydronaphthyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepine, benzo[d][1,3]dioxole, acridinyl, benzofuranyl, 1-benzofuran, isobenzofuranyl, benzofuran-2(3H)-one, benzothiophenyl, benzoxadiazole, benzo[c][1,2,5]oxadiazolyl, benzo[c]thiophenyl, benzodioxolyl, benzo[d][1,3]dioxole, thiadiazolyl, [1,3]oxazolo[4,5-b]pyridine, oxadiazolyl, imidazo[2,1-b][1,3]thiazole, 4H,5H,6H-cyclopenta[d][1,3]thiazole, 5H,6H,7H,8H-imidazo[1,2-a]pyridine, 7-oxo-6H,7H-[1,3]thiazolo[4,5-d]pyrimidine, [1,3]thiazolo[5,4-b]pyridine, 2H,3H-imidazo[2,1-b][1,3]thiazole, thieno[3,2-d]pyrimidin-4(3H)-one, 4-oxo-4H-thieno[3,2-d][1,3]thiazin, imidazo[1,2-a]pyridine, 1H-imidazo[4,5-b]pyridine, 1H-imidazo[4,5-c]pyridine, 3H-imidazo[4,5-c]pyridine, pyrazolo[1,5-a]pyridine, imidazo[1,2-a]pyrazine, imidazo[1,2-a]pyrimidine, 1H-pyrrolo[2,3-b]pyridine, pyrido[2,3-b]pyrazine, pyrido[2,3-b]pyrazin-3(4H)-one, 4H-thieno[3,2-b]pyrrole, quinoxalin-2(1H)-one, 1H-pyrrolo[3,2-b]pyridine, 7H-pyrrolo[2,3-d]pyrimidine, oxazolo[5,4-b]pyridine, thiazolo[5,4-b]pyridine, thieno[3,2-c]pyridine; or **A** is C₃-C₈ cycloalkyl (e.g. cyclohexyl) or C₃-C₈ heterocyclic ring including: tetrahydropyran, piperidine, 1-methylpiperidine, tetrahydrothiophene 1,1-dioxide, 1-(piperidin-1-yl)ethanone or morpholine.

[0152] In various embodiments, the **A** ring of formula I is phenyl. In some embodiments, the **A** ring is naphthyl. In some embodiments, the **A** ring is pyridinyl. In some embodiments, the **A** ring is pyrimidinyl. In some embodiments, the **A** ring is pyridazinyl. In some embodiments, **A** is pyrazinyl. In some embodiments, the **A** ring is triazinyl. In some embodiments, the **A** ring is tetrazinyl. In some embodiments, the **A** ring is thiazolyl. In some embodiments, the **A** ring is isothiazolyl. In some embodiments, the **A** ring is oxazolyl. In some embodiments, the **A** ring is isoxazolyl. In some embodiments, the **A** ring is imidazolyl. In some embodiments, the **A** ring is 1-methylimidazole. In some embodiments, the **A** ring is pyrazolyl. In some embodiments, the **A** ring is pyrrolyl. In some embodiments, the **A** ring is furanyl. In some embodiments, the **A** ring is thiophene-yl. In some embodiments, the **A** ring is indolyl. In some embodiments, the **A** ring is indenyl. In some embodiments, the **A** ring is 2,3-dihydroindenyl. In some embodiments, the **A** ring is tetrahydronaphthyl. In some embodiments, the **A** ring is isoindolyl. In some embodiments, the **A** ring is naphthyl. In some embodiments, the **A** ring is anthracenyl. In some embodiments, the **A** ring is benzimidazolyl. In some embodiments, the **A** ring is indazolyl. In some embodiments, the **A** ring is purinyl. In some embodiments, the **A** ring is benzoxazolyl. In some embodiments, the **A** ring is benzisoxazolyl. In some embodiments, the **A** ring is benzothiazolyl. In some embodiments, the **A** ring is quinazolinyl. In some embodiments, the **A** ring is quinoxalinyl. In some embodiments, the **A** ring is cinnolinyl. In some embodiments, the **A** ring is phthalazinyl. In some embodiments, the **A** ring is quinolinyl. In some embodiments,

the **A** ring is isoquinolinyl. In some embodiments, the **A** ring is 3,4-dihydro-2H-benzo[b][1,4]dioxepine. In some embodiments, the **A** ring is benzo[d][1,3]dioxole. In some embodiments, the **A** ring is benzofuran-2(3H)-one. In some embodiments, the **A** ring is benzodioxolyl. In some embodiments, the **A** ring is acridinyl. In some embodiments, the **A** ring is benzofuranyl. In some embodiments, the **A** ring is isobenzofuranyl. In some embodiments, the **A** ring is benzothiophenyl. In some embodiments, the **A** ring is benzo[c]thiophenyl. In some embodiments, the **A** ring is benzodioxolyl. In some embodiments, the **A** ring is thiadiazolyl. In some embodiments, the **A** ring is oxadiazolyl. In some embodiments, the **A** ring is 7-oxo-6H,7H-[1,3]thiazolo[4,5-d]pyrimidine. In some embodiments, the **A** ring is [1,3]thiazolo[5,4-b]pyridine. In some embodiments, the **A** ring is thieno[3,2-d]pyrimidin-4(3H)-one. In some embodiments, the **A** ring is 4-oxo-4H-thieno[3,2-d][1,3]thiazin. In some embodiments, the **A** ring is pyrido[2,3-b]pyrazin or pyrido[2,3-b]pyrazin-3(4H)-one. In some embodiments, the **A** ring is quinoxalin-2(1H)-one. In some embodiments, the **A** ring is 1H-indole. In some embodiments, the **A** ring is 2H-indazole. In some embodiments, the **A** ring is 4,5,6,7-tetrahydro-2H-indazole. In some embodiments, the **A** ring is 3H-indol-3-one. In some embodiments, the **A** ring is 1,3-benzoxazolyl. In some embodiments, the **A** ring is 1,3-benzothiazole. In some embodiments, the **A** ring is 4,5,6,7-tetrahydro-1,3-benzothiazole. In some embodiments, the **A** ring is 1-benzofuran. In some embodiments, the **A** ring is [1,3]oxazolo[4,5-b]pyridine. In some embodiments, the **A** ring is imidazo[2,1-b][1,3]thiazole. In some embodiments, the **A** ring is 4H,5H,6H-cyclopenta[d][1,3]thiazole. In some embodiments, the **A** ring is 5H,6H,7H,8H-imidazo[1,2-a]pyridine. In some embodiments, the **A** ring is 2H,3H-imidazo[2,1-b][1,3]thiazole. In some embodiments, the **A** ring is imidazo[1,2-a]pyridine. In some embodiments, the **A** ring is pyrazolo[1,5-a]pyridine. In some embodiments, the **A** ring is imidazo[1,2-a]pyrazine. In some embodiments, the **A** ring is imidazo[1,2-a]pyrimidine. In some embodiments, the **A** ring is 4H-thieno[3,2-b]pyrrole. In some embodiments, the **A** ring is 1H-pyrrolo[2,3-b]pyridine. In some embodiments, the **A** ring is 1H-pyrrolo[3,2-b]pyridine. In some embodiments, the **A** ring is 7H-pyrrolo[2,3-d]pyrimidine. In some embodiments, the **A** ring is oxazolo[5,4-b]pyridine. In some embodiments, the **A** ring is thiazolo[5,4-b]pyridine. In some embodiments, the **A** ring is triazolyl. In some embodiments, the **A** ring is benzoxadiazole. In some embodiments, the **A** ring is benzo[c][1,2,5]oxadiazolyl. In some embodiments, the **A** ring is 1H-imidazo[4,5-b]pyridine. In some embodiments, the **A** ring is 3H-imidazo[4,5-c]pyridine. In some embodiments, the **A** ring is a C₃-C₈ cycloalkyl. In some embodiments, the **A** ring is C₃-C₈ heterocyclic ring. In some embodiments, the **A** ring is tetrahydropyran. In some embodiments, the **A** ring is piperidine. In some embodiments, the **A** ring is 1-(piperidin-1-yl)ethanone. In some embodiments, the **A** ring is morpholine. In some embodiments, the **A** ring is thieno[3,2-c]pyridine. In some embodiments, the **A** ring is 1-methylpiperidine. In some embodiments, the **A** ring is tetrahydrothiophene 1,1-dioxide. In some embodiments, the **A** ring is cyclohexyl.

[0153] In various embodiments, the **B** ring of formula I is phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, 1-methylimidazole, isoquinoline, pyrazolyl, pyrrolyl, furanyl, thiophene-yl, isoquinolinyl, indolyl, 1H-indole, isoindolyl, naphthyl, anthracenyl, benzimidazolyl, 2,3-dihydro-1H-benzo[d]imidazolyl, tetrahydronaphthyl 3,4-dihydro-2H-benzo[b][1,4]dioxepine, benzofuran-2(3H)-one, benzo[d][1,3]dioxole, indazolyl, 2H-indazole, triazolyl, 4,5,6,7-tetrahydro-2H-

indazole, 3H-indol-3-one, purinyl, benzoxazolyl, 1,3-benzoxazolyl, benzisoxazolyl, benzothiazolyl, 1,3-benzothiazole, 4,5,6,7-tetrahydro-1,3-benzothiazole, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinolinyl, isoquinolinyl, acridinyl, benzofuranyl, 1-benzofuran, isobenzofuranyl, benzothiophenyl, benzoxadiazole, benzo[c][1,2,5]oxadiazolyl, benzo[c]thiophenyl, benzodioxolyl, thiadiazolyl, [1,3]oxazolo[4,5-b]pyridine, oxadiazolyl, imidazo[2,1-b][1,3]thiazole, 4H,5H,6H-cyclopenta[d][1,3]thiazole, 5H,6H,7H,8H-imidazo[1,2-a]pyridine, 7-oxo-6H,7H-[1,3]thiazolo[4,5-d]pyrimidine, [1,3]thiazolo[5,4-b]pyridine, 2H,3H-imidazo[2,1-b][1,3]thiazole, thieno[3,2-d]pyrimidin-4(3H)-one, 4-oxo-4H-thieno[3,2-d][1,3]thiazin, imidazo[1,2-a]pyridine, 1H-imidazo[4,5-b]pyridine, 3H-imidazo[4,5-b]pyridine, 3H-imidazo[4,5-c]pyridine, pyrazolo[1,5-a]pyridine, imidazo[1,2-a]pyrazine, imidazo[1,2-a]pyrimidine, pyrido[2,3-b]pyrazin or pyrido[2,3-b]pyrazin-3(4H)-one, 4H-thieno[3,2-b]pyrrole, quinoxalin-2(1H)-one, 1,2,3,4-tetrahydroquinoxaline, 1-(pyridin-1(2H)-yl)ethanone, 1H-pyrrolo[2,3-b]pyridine, 1H-pyrrolo[3,2-b]pyridine, 7H-pyrrolo[2,3-d]pyrimidine, oxazolo[5,4-b]pyridine, thiazolo[5,4-b]pyridine, thieno[3,2-c]pyridine, C₃-C₈ cycloalkyl, or C₃-C₈ heterocyclic ring including: tetrahydropyran, piperidine, 1-methylpiperidine, tetrahydrothiophene 1,1-dioxide, 1-(piperidin-1-yl)ethanone or morpholine.

[0154] In various embodiments, the **B** ring of formula I is phenyl. In some embodiments, the **B** ring is naphthyl. In some embodiments, the **B** ring is pyridinyl. In some embodiments, the **B** ring is pyrimidinyl. In some embodiments, the **B** ring is pyridazinyl. In some embodiments, the **B** ring is pyrazinyl. In some embodiments, the **B** ring is triazinyl. In some embodiments, the **B** ring is tetrazinyl. In some embodiments, the **B** ring is thiazolyl. In some embodiments, the **B** ring is isothiazolyl. In some embodiments, the **B** ring is oxazolyl. In some embodiments, the **B** ring is isoxazolyl. In some embodiments, the **B** ring is imidazolyl. In some embodiments, the **B** ring is 1-methylimidazole. In some embodiments, the **B** ring is pyrazolyl. In some embodiments, the **B** ring is pyrrolyl. In some embodiments, the **B** ring is furanyl. In some embodiments, the **B** ring is thiophene-yl. In some embodiments, the **B** ring is isoquinolinyl. In some embodiments, the **B** ring is indolyl. In some embodiments, the **B** ring is isoindolyl. In some embodiments, the **B** ring is naphthyl. In some embodiments, the **B** ring is anthracenyl. In some embodiments, the **B** ring is benzimidazolyl. In some embodiments, the **B** ring is 2,3-dihydro-1H-benzo[d]imidazole. In some embodiments, the **B** ring is indazolyl. In some embodiments, the **B** ring is purinyl. In some embodiments, the **B** ring is benzoxazolyl. In some embodiments, the **B** ring is benzisoxazolyl. In some embodiments, the **B** ring is benzothiazolyl. In some embodiments, the **B** ring is quinazolinyl. In some embodiments, the **B** ring is quinoxalinyl. In some embodiments, the **B** ring is 1,2,3,4-tetrahydroquinoxaline. In other embodiments, **B** is 1-(pyridin-1(2H)-yl)ethanone. In some embodiments, the **B** ring is benzo[d][1,3]dioxole. In some embodiments, the **B** ring is benzofuran-2(3H)-one. In some embodiments, the **B** ring is benzodioxolyl. In some embodiments, the **B** ring is tetrahydronaphthyl. In some embodiments, the **B** ring is cinnolinyl. In some embodiments, the **B** ring is phthalazinyl. In some embodiments, the **B** ring is quinolinyl. In some embodiments, the **B** ring is isoquinolinyl. In some embodiments, the **B** ring is acridinyl. In some embodiments, the **B** ring is benzofuranyl. In some embodiments, the **B** ring is isobenzofuranyl. In some embodiments, the **B** ring is benzothiophenyl. In some embodiments, the **B** ring is benzo[c]thiophenyl. In some embodiments, the **B** ring is benzodioxolyl. In some embodiments,

the **B** ring is thiadiazolyl. In some embodiments, the **B** ring is oxadiazolyl. In some embodiments, the **B** ring is 7-oxo-6H,7H-[1,3]thiazolo[4,5-d]pyrimidine. In some embodiments, the **B** ring is [1,3]thiazolo[5,4-b]pyridine. In some embodiments, the **C** ring is thieno[3,2-d]pyrimidin-4(3H)-one. In some embodiments, the **B** ring is 4-oxo-4H-thieno[3,2-d][1,3]thiazin. In some embodiments, the **B** ring is pyrido[2,3-b]pyrazin or pyrido[2,3-b]pyrazin-3(4H)-one. In some embodiments, the **B** ring is quinoxalin-2(1H)-one. In some embodiments, the **B** ring is 1H-indole. In some embodiments, the **B** ring is 2H-indazole. In some embodiments, the **B** ring is 4,5,6,7-tetrahydro-2H-indazole. In some embodiments, the **B** ring is 3H-indol-3-one. In some embodiments, the **B** ring is 1,3-benzoxazolyl. In some embodiments, the **B** ring is 1,3-benzothiazole. In some embodiments, the **B** ring is 4,5,6,7-tetrahydro-1,3-benzothiazole. In some embodiments, the **B** ring is 1-benzofuran. In some embodiments, the **C** ring is [1,3]oxazolo[4,5-b]pyridine. In some embodiments, the **B** ring is imidazo[2,1-b][1,3]thiazole. In some embodiments, the **B** ring is 4H,5H,6H-cyclopenta[d][1,3]thiazole. In some embodiments, the **C** ring is 5H,6H,7H,8H-imidazo[1,2-a]pyridine. In some embodiments, the **B** ring is 2H,3H-imidazo[2,1-b][1,3]thiazole. In some embodiments, the **B** ring is imidazo[1,2-a]pyridine. In some embodiments, the **B** ring is pyrazolo[1,5-a]pyridine. In some embodiments, the **B** ring is imidazo[1,2-a]pyrazine. In some embodiments, the **B** ring is imidazo[1,2-a]pyrimidine. In some embodiments, the **B** ring is 4H-thieno[3,2-b]pyrrole. In some embodiments, the **B** ring is 1H-pyrrolo[2,3-b]pyridine. In some embodiments, the **B** ring is 1H-pyrrolo[3,2-b]pyridine. In some embodiments, the **B** ring is 7H-pyrrolo[2,3-d]pyrimidine. In some embodiments, the **B** ring is oxazolo[5,4-b]pyridine. In some embodiments, the **B** ring is thiazolo[5,4-b]pyridine. In some embodiments, the **B** ring is triazolyl. In some embodiments, the **B** ring is benzoxadiazole. In some embodiments, the **B** ring is benzo[c][1,2,5]oxadiazolyl. In some embodiments, the **B** ring is 1H-imidazo[4,5-b]pyridine. In some embodiments, the **B** ring is 3H-imidazo[4,5-c]pyridine. In some embodiments, the **B** ring is a C₃-C₈ cycloalkyl. In some embodiments, the **B** ring is C₃-C₈ heterocyclic ring. In some embodiments, the **B** ring is tetrahydropyran. In some embodiments, the **B** ring is piperidine. In some embodiments, the **B** ring is 1-(piperidin-1-yl)ethanone. In some embodiments, the **B** ring is morpholine. In some embodiments, the **B** ring is thieno[3,2-c]pyridine. In some embodiments, the **B** ring is 1-methylpiperidine. In some embodiments, the **B** ring is tetrahydrothiophene 1,1-dioxide.

[0155] In various embodiments, compound of formula I is substituted by R₁ and R₂. Single substituents can be present at the *ortho*, *meta*, or *para* positions.

[0156] In various embodiments, R₁ of formula I-V is H. In some embodiments, R₁ is F. In some embodiments, R₁ is Cl. In some embodiments, R₁ is Br. In some embodiments, R₁ is I. In some embodiments, R₁ is OH. In some embodiments, R₁ is SH. In some embodiments, R₁ is R₈-OH. In some embodiments, R₁ is CH₂-OH. In some embodiments, R₁ is R₈-SH. In some embodiments, R₁ is -R₈-O-R₁₀. In some embodiments, R₁ is -CH₂-O-CH₃. In some embodiments, R₁ is CF₃. In other embodiments, R₁ is CD₃. In other embodiments, R₁ is OCD₃. In some embodiments, R₁ is CN. In some embodiments, R₁ is NO₂. In some embodiments, R₁ is -CH₂CN. In some embodiments, R₁ is -R₈CN. In some embodiments, R₁ is NH₂. In some embodiments, R₁ is NHR. In some embodiments, R₁ is N(R)₂. In some embodiments, R₁ is R₈-

$N(R_{10})(R_{11})$. In other embodiments, R_1 is CH_2-NH_2 . In some embodiments, R_1 is $CH_2-N(CH_3)_2$. In other embodiments, R_1 is $R_9-R_8-N(R_{10})(R_{11})$. In other embodiments, R_1 is $C\equiv C-CH_2-NH_2$. In other embodiments, R_1 is $B(OH)_2$. In some embodiments, R_1 is $-OC(O)CF_3$. In some embodiments, R_1 is $-OCH_2Ph$. In some embodiments, R_1 is $NHC(O)-R_{10}$. In some embodiments, R_1 is $NHC(O)CH_3$. In some embodiments, R_1 is $NHCO-N(R_{10})(R_{11})$. In some embodiments, R_1 is $NHC(O)N(CH_3)_2$. In some embodiments, R_1 is $COOH$. In some embodiments, R_1 is $-C(O)Ph$. In some embodiments, R_1 is $C(O)OR_{10}$. In some embodiments, R_1 is $C(O)O-CH_3$. In some embodiments, R_1 is $C(O)O-CH(CH_3)_2$. In some embodiments, R_1 is $C(O)O-CH_2CH_3$. In some embodiments, R_1 is $R_8-C(O)-R_{10}$. In some embodiments, R_1 is $CH_2C(O)CH_3$. In some embodiments, R_1 is $C(O)H$. In some embodiments, R_1 is $C(O)-R_{10}$. In some embodiments, R_1 is $C(O)-CH_3$. In some embodiments, R_1 is $C(O)-CH_2CH_3$. In some embodiments, R_1 is $C(O)-CH_2CH_2CH_3$. In some embodiments, R_1 is C_1-C_5 linear or branched $C(O)$ -haloalkyl. In some embodiments, R_1 is $C(O)-CF_3$. In some embodiments, R_1 is $-C(O)NH_2$. In some embodiments, R_1 is $C(O)NHR$. In some embodiments, R_1 is $C(O)N(R_{10})(R_{11})$. In some embodiments, R_1 is $C(O)N(CH_3)_2$. In some embodiments, R_1 is SO_2R . In some embodiments, R_1 is $SO_2N(R_{10})(R_{11})$. In some embodiments, R_1 is $SO_2N(CH_3)_2$. In some embodiments, R_1 is C_1-C_5 linear or branched, substituted or unsubstituted alkyl. In some embodiments, R_1 is methyl, 2,3, or 4- $CH_2-C_6H_4-Cl$, ethyl, propyl, iso-propyl, t-Bu, iso-butyl or pentyl. In some embodiments, R_1 is C_1-C_5 linear or branched haloalkyl. In some embodiments, R_1 is CF_2CH_3 . In some embodiments, R_1 is CH_2CF_3 . In some embodiments, R_1 is C_1-C_5 linear, branched or cyclic alkoxy. In some embodiments, R_1 is methoxy, ethoxy, propoxy, isopropoxy or O- CH_2 -cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, 1-butoxy, 2-butoxy, O-tBu. In other embodiments, R_1 is C_1-C_5 linear, branched or cyclic alkoxy wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom (O). In some embodiments, R_1 is O-1-oxacyclobutyl, O-2-oxacyclobutyl. In some embodiments, R_1 is C_1-C_5 linear or branched thioalkoxy. In some embodiments, R_1 is C_1-C_5 linear or branched haloalkoxy. In some embodiments, R_1 is OCF_3 . In some embodiments, R_1 is $OCHF_2$. In some embodiments, R_1 is C_1-C_5 linear or branched alkoxyalkyl. In some embodiments, R_1 is substituted or unsubstituted C_3-C_8 cycloalkyl. In some embodiments, R_1 is cyclopropyl. In some embodiments, R_1 is cyclopentyl. In some embodiments, R_1 is substituted or unsubstituted C_3-C_8 heterocyclic ring. In some embodiments, R_1 is thiophene, oxazole, oxadiazole, imidazole, furane, triazole, tetrazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, 1 or 2-oxacyclobutane, indole, protonated or deprotonated pyridine oxide. In some embodiments, R_1 is methyl substituted oxazole. In some embodiments, R_1 is methyl substituted oxadiazole. In some embodiments, R_1 is methyl substituted imidazole. In other embodiments, R_1 is tetrazole. In some embodiments, R_1 is substituted aryl. In some embodiments, R_1 is phenyl. In some embodiments, substitutions include: F, Cl, Br, I, C_1-C_5 linear or branched alkyl (e.g. methyl, ethyl), OH, alkoxy, $N(R)_2$, CF_3 , CN or NO_2 . In some embodiments, R_1 is $CH(CF_3)(NH-R_{10})$. In some embodiments, R_1 is 2,3, or 4 bromophenyl.

[0157] In some embodiments, R_1 and R_2 are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring. In some embodiments, R_1 and R_2 are joined together to form a 5 or 6 membered heterocyclic ring. In some embodiments, R_1 and R_2 are joined together to form a [1,3]dioxole ring. In some embodiments, R_1 and R_2 are joined together to form a furan-2(3H)-one ring. In some embodiments, R_1 and R_2 are joined together to form a benzene ring. In some embodiments, R_1 and R_2 are joined together to form a pyridine ring. In some embodiments, R_1 and R_2 are joined together to form a morpholine ring. In some embodiments, R_1 and R_2 are joined together to form a piperazine ring. In some embodiments, R_1 and R_2 are joined together to form an imidazole ring. In some embodiments, R_1 and R_2 are joined together to form a pyrrole ring. In some embodiments, R_1 and R_2 are joined together to form a cyclohexene ring. In some embodiments, R_1 and R_2 are joined together to form a pyrazine ring.

[0158] In various embodiments, R_2 of formula I-V is H. In some embodiments, R_2 is F. In some embodiments, R_2 is Cl. In some embodiments, R_2 is Br. In some embodiments, R_2 is I. In some embodiments, R_2 is OH. In some embodiments, R_2 is SH. In some embodiments, R_2 is R_8 -OH. In some embodiments, R_2 is CH_2 -OH. In some embodiments, R_2 is R_8 -SH. In some embodiments, R_1 is $-R_8$ -O- R_{10} . In some embodiments, R_2 is $-CH_2$ -O- CH_3 . In some embodiments, R_2 is CF_3 . In other embodiments, R_2 is CD_3 . In other embodiments, R_2 is OCD_3 . In some embodiments, R_2 is CN. In some embodiments, R_2 is NO_2 . In some embodiments, R_2 is $-CH_2CN$. In some embodiments, R_2 is $-R_8CN$. In some embodiments, R_2 is NH_2 . In some embodiments, R_2 is NHR. In some embodiments, R_2 is $N(R)_2$. In some embodiments, R_2 is R_8 - $N(R_{10})(R_{11})$. In other embodiments, R_2 is CH_2 - NH_2 . In some embodiments, R_2 is CH_2 - $N(CH_3)_2$. In other embodiments, R_2 is R_9 - R_8 - $N(R_{10})(R_{11})$. In other embodiments, R_2 is $C\equiv C$ - CH_2 - NH_2 . In other embodiments, R_2 is $B(OH)_2$. In some embodiments, R_2 is $-OC(O)CF_3$. In some embodiments, R_2 is $-OCH_2Ph$. In some embodiments, R_2 is $NHC(O)-R_{10}$. In some embodiments, R_2 is $NHC(O)CH_3$. In some embodiments, R_2 is $NHCO-N(R_{10})(R_{11})$. In some embodiments, R_2 is $NHC(O)N(CH_3)_2$. In some embodiments, R_2 is $COOH$. In some embodiments, R_2 is $-C(O)Ph$. In some embodiments, R_2 is $C(O)OR_{10}$. In some embodiments, R_2 is $C(O)O-CH(CH_3)_2$. In some embodiments, R_2 is $C(O)O-CH_3$. In some embodiments, R_2 is $C(O)O-CH_2CH_3$. In some embodiments, R_2 is $R_8-C(O)-R_{10}$. In some embodiments, R_2 is $CH_2C(O)CH_3$. In some embodiments, R_2 is $C(O)H$. In some embodiments, R_2 is $C(O)-R_{10}$. In some embodiments, R_2 is $C(O)-CH_3$. In some embodiments, R_2 is $C(O)-CH_2CH_3$. In some embodiments, R_2 is $C(O)-CH_2CH_2CH_3$. In some embodiments, R_2 is C_1 - C_5 linear or branched $C(O)$ -haloalkyl. In some embodiments, R_2 is $C(O)-CF_3$. In some embodiments, R_2 is $-C(O)NH_2$. In some embodiments, R_2 is $C(O)NHR$. In some embodiments, R_2 is $C(O)N(R_{10})(R_{11})$. In some embodiments, R_2 is $C(O)N(CH_3)_2$. In some embodiments, R_2 is SO_2R . In some embodiments, R_2 is $SO_2N(R_{10})(R_{11})$. In some embodiments, R_2 is $SO_2N(CH_3)_2$. In some embodiments, R_2 is

C₁-C₅ linear or branched, substituted or unsubstituted alkyl. In some embodiments, R₂ is methyl, 2, 3, or 4-CH₂-C₆H₄-Cl, ethyl, propyl, iso-propyl, t-Bu, iso-butyl or pentyl. In some embodiments, R₂ is C₁-C₅ linear or branched haloalkyl. In some embodiments, R₂ is CF₂CH₃. In some embodiments, R₂ is CH₂CF₃. In some embodiments, R₂ is C₁-C₅ linear, branched or cyclic alkoxy. In some embodiments, R₂ is methoxy, ethoxy, propoxy, isopropoxy or O-CH₂-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-1-oxacyclobutyl, O-2-oxacyclobutyl, 1-butoxy, 2-butoxy, O-tBu. In other embodiments, R₂ is C₁-C₅ linear, branched or cyclic alkoxy wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom (O). In some embodiments, R₂ is O-1-oxacyclobutyl or O-2-oxacyclobutyl. In some embodiments, R₂ is C₁-C₅ linear or branched thioalkoxy. In some embodiments, R₂ is C₁-C₅ linear or branched haloalkoxy. In some embodiments, R₂ is OCF₃. In some embodiments, R₂ is OCHF₂. In some embodiments, R₂ is C₁-C₅ linear or branched alkoxyalkyl. In some embodiments, R₂ is substituted or unsubstituted C₃-C₈ cycloalkyl. In some embodiments, R₂ is cyclopropyl. In some embodiments, R₂ is cyclopentyl. In some embodiments, R₂ is substituted or unsubstituted C₃-C₈ heterocyclic ring. In some embodiments, R₂ is thiophene, oxazole, oxadiazole, imidazole, furane, triazole, tetrazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, 1 or 2-oxacyclobutane, indole, protonated or deprotonated pyridine oxide. In some embodiments, R₂ is methyl substituted oxazole. In some embodiments, R₂ is methyl substituted oxadiazole. In some embodiments, R₂ is methyl substituted imidazole. In other embodiments, R₂ is tetrazole. In some embodiments, R₂ is substituted aryl. In some embodiments, R₂ is phenyl. In some embodiments, substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl (e.g. methyl, ethyl), OH, alkoxy, N(R)₂, CF₃, CN or NO₂. In some embodiments, R₂ is CH(CF₃)(NH-R₁₀). In some embodiments, R₂ is 2, 3, or 4 bromophenyl.

[0159] In various embodiments, compound of formula I-V is substituted by R₃ and R₄. Single substituents can be present at the *ortho*, *meta*, or *para* positions.

[0160] In various embodiments, R₃ of formula I-V is In some embodiments, R₃ is C₂-C₅ linear or branched haloalkyl. In some embodiments, R₃ is CF₂CH₃. In some embodiments, R₃ is CH₂CF₃. In other embodiments, R₃ is CF₂CH₂CH₃. In some embodiments, R₃ is C₂-C₅ linear or branched haloalkoxy. In some embodiments, R₃ is substituted or unsubstituted C₃-C₈ cycloalkyl. In some embodiments, R₃ is cyclopropyl. In some embodiments, R₃ is cyclopentyl. In some embodiments, R₃ is substituted or unsubstituted C₃-C₈ heterocyclic ring. In some embodiments, R₃ is thiophene, oxazole, isoxazole, imidazole, furane, triazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole. In some embodiments, R₃ is substituted or unsubstituted aryl. In some embodiments, R₃ is phenyl. In some embodiments, substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂. In some embodiments, R₃ is CH(CF₃)(NH-R₁₀).

[0161] In some embodiments, **R₃** and **R₄** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring. In some embodiments, **R₃** and **R₄** are joined together to form a 5 or 6 membered carbocyclic ring. In some embodiments, **R₃** and **R₄** are joined together to form a 5 or 6 membered heterocyclic ring. In some embodiments, **R₃** and **R₄** are joined together to form a dioxole ring. [1,3]dioxole ring. In some embodiments, **R₃** and **R₄** are joined together to form a dihydrofuran-2(3H)-one ring. In some embodiments, **R₃** and **R₄** are joined together to form a furan-2(3H)-one ring. In some embodiments, **R₃** and **R₄** are joined together to form a benzene ring. In some embodiments, **R₃** and **R₄** are joined together to form an imidazole ring. In some embodiments, **R₃** and **R₄** are joined together to form a pyridine ring. In some embodiments, **R₃** and **R₄** are joined together to form a pyrrole ring. In some embodiments, **R₃** and **R₄** are joined together to form a cyclohexene ring. In some embodiments, **R₃** and **R₄** are joined together to form a cyclopentene ring. In some embodiments, **R₄** and **R₃** are joined together to form a dioxepine ring.

[0162] In various embodiments, **R₄** of formula I-IV is H. In some embodiments, **R₄** is F. In some embodiments, **R₄** is Cl. In some embodiments, **R₄** is Br. In some embodiments, **R₄** is I. In some embodiments, **R₄** is OH. In some embodiments, **R₄** is SH. In some embodiments, **R₄** is R₈-OH. In some embodiments, **R₄** is CH₂-OH. In some embodiments, **R₄** is R₈-SH. In some embodiments, **R₄** is -R₈-O-R₁₀. In some embodiments, **R₄** is CH₂-O-CH₃. In some embodiments, **R₄** is CF₃. In other embodiments, **R₄** is CD₃. In other embodiments, **R₄** is OCD₃. In some embodiments, **R₄** is CN. In some embodiments, **R₄** is NO₂. In some embodiments, **R₄** is -CH₂CN. In some embodiments, **R₄** is -R₈CN. In some embodiments, **R₄** is NH₂. In some embodiments, **R₄** is NHR. In some embodiments, **R₄** is N(R)₂. In some embodiments, **R₄** is R₈-N(R₁₀)(R₁₁). In other embodiments, **R₄** is CH₂-NH₂. In some embodiments, **R₄** is CH₂-N(CH₃)₂. In other embodiments, **R₄** is R₉-R₈-N(R₁₀)(R₁₁). In other embodiments, **R₄** is C≡C-CH₂-NH₂. In other embodiments, **R₄** is B(OH)₂. In some embodiments, **R₄** is -OC(O)CF₃. In some embodiments, **R₄** is -OCH₂Ph. In some embodiments, **R₄** is -NHCO-R₁₀. In some embodiments, **R₄** is NHC(O)CH₃. In some embodiments, **R₄** is NHCO-N(R₁₀)(R₁₁). In some embodiments, **R₄** is NHC(O)N(CH₃)₂. In some embodiments, **R₄** is COOH. In some embodiments, **R₄** is -C(O)Ph. In some embodiments, **R₄** is C(O)O-R₁₀. In some embodiments, **R₄** is C(O)O-CH₃. In some embodiments, **R₄** is C(O)O-CH₂CH₃. In some embodiments, **R₄** is R₈-C(O)-R₁₀. In some embodiments, **R₄** is CH₂C(O)CH₃. In some embodiments, **R₄** is C(O)H. In some embodiments, **R₄** is C₁-C₅ linear or branched C(O)-R₁₀. In some embodiments, **R₄** is C(O)-CH₃. In some embodiments, **R₄** is C(O)-CH₂CH₃. In some embodiments, **R₄** is C(O)-CH₂CH₂CH₃. In some embodiments, **R₄** is C₁-C₅ linear or branched C(O)-haloalkyl. In some embodiments, **R₄** is C(O)-CF₃. In some embodiments, **R₄** is -C(O)NH₂. In some embodiments, **R₄** is C(O)NHR. In some embodiments, **R₄** is C(O)N(R₁₀)(R₁₁). In some embodiments, **R₄** is C(O)N(CH₃)₂. In some embodiments, **R₄** is SO₂R. In some embodiments, **R₄** is SO₂N(R₁₀)

(R₁₁). In some embodiments, R₄ is SO₂N(CH₃)₂. In some embodiments, R₄ is C₁-C₅ linear or branched, substituted or unsubstituted alkyl. In some embodiments, R₄ is methyl, C(OH)(CH₃) (Ph), ethyl, propyl, iso-propyl, t-Bu, iso-butyl, or pentyl. In some embodiments, R₄ is C₁-C₅ linear or branched haloalkyl. In some embodiments, R₄ is CF₂CH₃. In some embodiments, R₄ is CH₂CF₃. In other embodiments, R₄ is CF₂CH₂CH₃. In some embodiments, R₄ is C₁-C₅ linear, branched or cyclic alkoxy. In some embodiments, R₄ is methoxy, ethoxy, propoxy, isopropoxy, O-CH₂-cyclopropyl. In some embodiments, R₄ is C₁-C₅ linear or branched thioalkoxy. In some embodiments, R₄ is C₁-C₅ linear or branched haloalkoxy. In some embodiments, R₄ is C₁-C₅ linear or branched alkoxyalkyl. In some embodiments, R₄ is substituted or unsubstituted C₃-C₈ cycloalkyl. In some embodiments, R₄ is cyclopropyl. In some embodiments, R₄ is cyclopentyl. In some embodiments, R₄ is substituted or unsubstituted C₃-C₈ heterocyclic ring. In some embodiments, R₄ is thiophene, oxazole, isoxazole, imidazole, furane, triazole, pyridine (2, 3, or 4-pyridine), pyrimidine, pyrazine, oxacyclobutane (1 or 2-oxacyclobutane), indole. In some embodiments, R₄ is substituted or unsubstituted aryl. In some embodiments, R₄ is phenyl. In some embodiments, substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂. In some embodiments, R₄ is CH(CF₃)(NH-R₁₀).

[0163] In various embodiments, R₅ of compound of formula I-IV is H. In some embodiments, R₅ is C₁-C₅ linear or branched, substituted or unsubstituted alkyl. In some embodiments, R₅ is methyl, CH₂SH, ethyl, iso-propyl. In some embodiments, R₅ is C₁-C₅ linear or branched haloalkyl. In some embodiments, R₅ is CF₃. In some embodiments, R₅ is R₈-aryl. In some embodiments, R₅ is CH₂-Ph. In some embodiments, R₅ is substituted or unsubstituted aryl. In some embodiments, R₅ is phenyl. In some embodiments, R₅ is substituted or unsubstituted heteroaryl. In some embodiments, R₅ is pyridine. In some embodiments, R₅ is 2-pyridine. In some embodiments, R₅ is 3-pyridine. In some embodiments, R₅ is 4-pyridine. In some embodiments, substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂.

[0164] In various embodiments, n of compound of formula I-II is 0. In some embodiments, n is 0 or 1. In some embodiments, n is between 1 and 3. In some embodiments, n is between 1 and 4. In some embodiments, n is between 0 and 2. In some embodiments, n is between 0 and 3. In some embodiments, n is between 0 and 4. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.

[0165] In various embodiments, m of compound of formula I-II is 0. In some embodiments, m is 0 or 1. In some embodiments, m is between 1 and 3. In some embodiments, m is between 1 and 4. In some embodiments, m is between 0 and 2. In some embodiments, m is between 0 and 3. In some embodiments, m is between 0 and 4. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.

[0166] In some embodiments, **l** is 1. In some embodiments, **l** is between 1 and 3. In some embodiments, **l** is between 1 and 4. In some embodiments, **l** is between 1 and 2. In some embodiments, **l** is between 1 and 3. In some embodiments, **l** is 2. In some embodiments, **l** is 3. In some embodiments, **l** is 4.

[0167] In various embodiments, **k** of compound of formula I-II is 0. In some embodiments, **k** is 0 or 1. In some embodiments, **k** is between 1 and 3. In some embodiments, **k** is between 1 and 4. In some embodiments, **k** is between 0 and 2. In some embodiments, **k** is between 0 and 3. In some embodiments, **k** is between 0 and 4. In some embodiments, **k** is 1. In some embodiments, **k** is 2. In some embodiments, **k** is 3. In some embodiments, **k** is 4.

[0168] It is understood that for heterocyclic rings, **n**, **m**, **l** and/or **k** are limited to the number of available positions for substitution, i.e. to the number of CH or NH groups minus one. Accordingly, if A and/or B rings are, for example, furanyl, thiophenyl or pyrrolyl, **n**, **m**, **l** and **k** are between 0 and 2; and if A and/or B rings are, for example, oxazolyl, imidazolyl or thiazolyl, **n**, **m**, **l** and **k** are either 0 or 1; and if A and/or B rings are, for example, oxadiazolyl or thiadiazolyl, **n**, **m**, **l** and **k** are 0.

[0169] In various embodiments, **R₆** of compound of formula I-III is H. In some embodiments, **R₆** is C₁-C₅ linear or branched alkyl. In some embodiments, **R₆** is methyl. In some embodiments, **R₆** is ethyl.

[0170] In various embodiments, **R₈** of compound of formula I-V is CH₂. In some embodiments, **R₈** is CH₂CH₂. In some embodiments, **R₈** is CH₂CH₂CH₂. In some embodiments, **R₈** is CH₂CH₂CH₂CH₂.

[0171] In various embodiments, **p** is 1. In some embodiments, **p** is 2. In some embodiments, **p** is 3. In some embodiments, **p** is 4. In some embodiments, **p** is 5. In some embodiments, **p** is between 1 and 3. In some embodiments, **p** is between 1 and 5. In some embodiments, **p** is between 1 and 10.

[0172] In some embodiments, **R₉** of compound of formula I-V is C=C. In some embodiments, **R₉** is C=C-C=C. In some embodiments, **R₉** is CH=CH. In some embodiments, **R₉** is CH=CH-CH=CH.

[0173] In some embodiments, **q** of compound of formula I-V is 2. In some embodiments, **q** is 4. In some embodiments, **q** is 6. In some embodiments, **q** is 8. In some embodiments, **q** is between 2 and 6.

[0174] In various embodiments, **R₁₀** of compound of formula I-V is H. In some embodiments, **R₁₀** is C₁-C₅ linear or branched alkyl. In some embodiments, **R₁₀** is methyl. In some embodiments, **R₁₀** is ethyl. In some embodiments, **R₁₀** is propyl. In some embodiments, **R₁₀** is

isopropyl. In some embodiments, R_{10} is butyl. In some embodiments, R_{10} is isobutyl. In some embodiments, R_{10} is t-butyl. In some embodiments, R_{10} is cyclopropyl. In some embodiments, R_{10} is pentyl. In some embodiments, R_{10} is isopentyl. In some embodiments, R_{10} is neopentyl. In some embodiments, R_{10} is benzyl. In some embodiments, R_{10} is $C(O)R$. In some embodiments, R_{10} is $S(O)_2R$.

[0175] In various embodiments, R_{11} of compound of formula I-V is H. In some embodiments, R_{11} is C_1 - C_5 linear or branched alkyl. In some embodiments, R_n is methyl. In some embodiments, R_{11} is ethyl. In some embodiments, R_{10} is propyl. In some embodiments, R_{11} is isopropyl. In some embodiments, R_{11} is butyl. In some embodiments, R_{11} is isobutyl. In some embodiments, R_{11} is t-butyl. In some embodiments, R_{11} is cyclopropyl. In some embodiments, R_{11} is pentyl. In some embodiments, R_{11} is isopentyl. In some embodiments, R_{11} is neopentyl. In some embodiments, R_{11} is benzyl. In some embodiments, R_{11} is $C(O)R$. In some embodiments, R_{11} is $S(O)_2R$.

[0176] In various embodiments, R of compound of formula I-V is H. In other embodiments, R is C_1 - C_5 linear or branched alkyl. In other embodiments, R is methyl. In other embodiments, R is ethyl. In other embodiments, R is C_1 - C_5 linear or branched alkoxy. In other embodiments, R is phenyl. In other embodiments, R is aryl. In other embodiments, R is heteroaryl. In other embodiments, two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring.

[0177] In various embodiments, Q_1 of compound of formula I-III is O. In other embodiments, Q_1 is S.

[0178] In various embodiments, Q_2 of compound of formula I-III is O. In other embodiments, Q_2 is S.

[0179] In various embodiments, X_1 of compound of formula II is C. In other embodiments, X_1 is N.

[0180] In various embodiments, X_2 of compound of formula II is C. In other embodiments, X_2 is N.

[0181] In various embodiments, X_3 of compound of formula II-V is C. In other embodiments, X_3 is N.

[0182] In various embodiments, X_4 of compound of formula II-IV is C. In other embodiments, X_4 is N.

[0183] In various embodiments, X_5 of compound of formula II is C. In other embodiments, X_s

is N.

[0184] In various embodiments, **X₆** of compound of formula II-III is C. In other embodiments, **X₆** is N.

[0185] In various embodiments, **X₇** of compound of formula II-V is C. In other embodiments, **X₇** is N.

[0186] In various embodiments, **X₈** of compound of formula II-IV is C. In other embodiments, **X₈** is N.

[0187] In various embodiments, **X₉** of compound of formula II is C. In other embodiments, **X₉** is N.

[0188] In various embodiments, **X₁₀** of compound of formula II is C. In other embodiments, **X₁₀** is N.

[0189] As used herein, "single or fused aromatic or heteroaromatic ring systems" can be any such ring, including phenyl, naphthyl, pyridinyl, (2-, 3-, and 4-pyridinyl), quinolinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, 1-methylimidazole, pyrazolyl, pyrrolyl, furanyl, thiophene-yl, quinolinyl, isoquinolinyl, 2,3-dihydroindenyl, indenyl, tetrahydronaphthyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepine, benzodioxolyl, benzo[d][1,3]dioxole, tetrahydronaphthyl, indolyl, 1H-indole, isoindolyl, anthracenyl, benzimidazolyl, 2,3-dihydro-1H-benzo[d]imidazolyl, indazolyl, 2H-indazole, triazolyl, 4,5,6,7-tetrahydro-2H-indazole, 3H-indol-3-one, purinyl, benzoxazolyl, 1,3-benzoxazolyl, benzisoxazolyl, benzothiazolyl, 1,3-benzothiazole, 4,5,6,7-tetrahydro-1,3-benzothiazole, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxaline, 1-(pyridin-1(2H)-yl)ethanone, cinnolinyl, phthalazinyl, quinolinyl, isoquinolinyl, acridinyl, benzofuranyl, 1-benzofuran, isobenzofuranyl, benzofuran-2(3H)-one, benzothiophenyl, benzoxadiazole, benzo[c][1,2,5]oxadiazolyl, benzo[c]thiophenyl, benzodioxolyl, thiadiazolyl, [1,3]oxazolo[4,5-b]pyridine, oxadiazolyl, imidazo[2,1-b][1,3]thiazole, 4H,5H,6H-cyclopenta[d][1,3]thiazole, 5H,6H,7H,8H-imidazo[1,2-a]pyridine, 7-oxo-6H,7H-[1,3]thiazolo[4,5-d]pyrimidine, [1,3]thiazolo[5,4-b]pyridine, 2H,3H-imidazo[2,1-b][1,3]thiazole, thieno[3,2-d]pyrimidin-4(3H)-one, 4-oxo-4H-thieno[3,2-d][1,3]thiazin, imidazo[1,2-a]pyridine, 1H-imidazo[4,5-b]pyridine, 1H-imidazo[4,5-c]pyridine, 3H-imidazo[4,5-c]pyridine, pyrazolo[1,5-a]pyridine, imidazo[1,2-a]pyrazine, imidazo[1,2-a]pyrimidine, 1H-pyrrolo[2,3-b]pyridine, pyrido[2,3-b]pyrazine, pyrido[2,3-b]pyrazin-3(4H)-one, 4H-thieno[3,2-b]pyrrole, quinoxalin-2(1H)-one, 1H-pyrrolo[3,2-b]pyridine, 7H-pyrrolo[2,3-d]pyrimidine, oxazolo[5,4-b]pyridine, thiazolo[5,4-b]pyridine, thieno[3,2-c]pyridine, etc.

[0190] As used herein, the term "alkyl" can be any straight- or branched-chain alkyl group containing up to about 30 carbons unless otherwise specified. In various embodiments, an alkyl includes C₁-C₅ carbons. In some embodiments, an alkyl includes C₁-C₆ carbons. In some

embodiments, an alkyl includes Ci-Cs carbons. In some embodiments, an alkyl includes C₁-C₁₀ carbons. In some embodiments, an alkyl is a C₁-C₁₂ carbons. In some embodiments, an alkyl is a C₁-C₂₀ carbons. In some embodiments, branched alkyl is an alkyl substituted by alkyl side chains of 1 to 5 carbons. In various embodiments, the alkyl group may be unsubstituted. In some embodiments, the alkyl group may be substituted by a halogen, haloalkyl, hydroxyl, alkoxy, carbonyl, amido, alkylamido, dialkylamido, cyano, nitro, CO₂H, amino, alkylamino, dialkylamino, carboxyl, thio and/or thioalkyl.

[0191] The alkyl group can be a sole substituent or it can be a component of a larger substituent, such as in an alkoxy, alkoxyalkyl, haloalkyl, arylalkyl, alkylamino, dialkylamino, alkylamido, alkylurea, etc. Preferred alkyl groups are methyl, ethyl, and propyl, and thus halomethyl, dihalomethyl, trihalomethyl, haloethyl, dihaloethyl, trihaloethyl, halopropyl, dihalopropyl, trihalopropyl, methoxy, ethoxy, propoxy, arylmethyl, arylethyl, arylpropyl, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, methylamido, acetamido, propylamido, halomethylamido, haloethylamido, halopropylamido, methyl-urea, ethyl-urea, propyl-urea, 2, 3, or 4-CH₂-C₆H₄-Cl, C(OH)(CH₃)(Ph), etc.

[0192] As used herein, the term "aryl" refers to any aromatic ring that is directly bonded to another group and can be either substituted or unsubstituted. The aryl group can be a sole substituent, or the aryl group can be a component of a larger substituent, such as in an arylalkyl, arylamino, arylamido, etc. Exemplary aryl groups include phenyl, tolyl, xylyl, furanyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, thiazolyl, oxazolyl, isooxazolyl, pyrazolyl, imidazolyl, thiophene-yl, pyrrolyl, phenylmethyl, phenylethyl, phenylamino, phenylamido, etc. Substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₅ linear or branched alkoxy, C₁-C₅ linear or branched haloalkoxy, CF₃, CN, NO₂, -CH₂CN, NH₂, NH-alkyl, N(alkyl)₂, hydroxyl, -OC(O)CF₃, -OCH₂Ph, -NHCO-alkyl, COOH, -C(O)Ph, C(O)O-alkyl, C(O)H, or -C(O)NH₂.

[0193] As used herein, the term "alkoxy" refers to an ether group substituted by an alkyl group as defined above. Alkoxy refers both to linear and to branched alkoxy groups. Examples of alkoxy groups are methoxy, ethoxy, propoxy, *iso*-propoxy, *tert*-butoxy.

[0194] As used herein, the term "aminoalkyl" refers to an amine group substituted by an alkyl group as defined above. Aminoalkyl refers to monoalkylamine, dialkylamine or trialkylamine. Examples of aminoalkyl groups are -N(Me)₂, -NHMe, -NH₃.

[0195] A "haloalkyl" group refers, In some embodiments, to an alkyl group as defined above, which is substituted by one or more halogen atoms, e.g. by F, Cl, Br or I. The term "haloalkyl" include fluoroalkyl, i.e., to an alkyl group bearing at least one fluorine atom. Examples of haloalkyl groups are CF₃, CF₂CF₃, CF₂CH₃, CH₂CF₃.

[0196] An "alkoxyalkyl" group refers, In some embodiments, to an alkyl group as defined

above, which is substituted by alkoxy group as defined above, e.g. by methoxy, ethoxy, propoxy, i-propoxy, t-butoxy etc. Examples of alkoxyalkyl groups are $-\text{CH}_2\text{-O-CH}_3$, $-\text{CH}_2\text{-O-CH(CH}_3)_2$, $-\text{CH}_2\text{-O-C(CH}_3)_3$, $-\text{CH}_2\text{-CH}_2\text{-O-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-O-CH(CH}_3)_2$, $-\text{CH}_2\text{-CH}_2\text{-O-C(CH}_3)_3$.

[0197] A "cycloalkyl" or "carbocyclic" group refers, in various embodiments, to a ring structure comprising carbon atoms as ring atoms, which may be either saturated or unsaturated, substituted or unsubstituted, single or fused. In some embodiments the cycloalkyl is a 3-10 membered ring. In some embodiments the cycloalkyl is a 3-12 membered ring. In some embodiments the cycloalkyl is a 6 membered ring. In some embodiments the cycloalkyl is a 5-7 membered ring. In some embodiments the cycloalkyl is a 3-8 membered ring. In some embodiments, the cycloalkyl group may be unsubstituted or substituted by a halogen, alkyl, haloalkyl, hydroxyl, alkoxy, carbonyl, amido, alkylamido, dialkylamido, cyano, nitro, CO_2H , amino, alkylamino, dialkylamino, carboxyl, thio and/or thioalkyl. In some embodiments, the cycloalkyl ring may be fused to another saturated or unsaturated cycloalkyl or heterocyclic 3-8 membered ring. In some embodiments, the cycloalkyl ring is a saturated ring. In some embodiments, the cycloalkyl ring is an unsaturated ring. Examples of a cycloalkyl group comprise cyclohexyl, cyclohexenyl, cyclopropyl, cyclopropenyl, cyclopentyl, cyclopentenyl, cyclobutyl, cyclobutenyl, cycloctyl, cycloctadienyl (COD), cycloctaene (COE) etc.

[0198] A "heterocycle" or "heterocyclic" group refers, in various embodiments, to a ring structure comprising in addition to carbon atoms, sulfur, oxygen, nitrogen or any combination thereof, as part of the ring. A "heteroaromatic ring" refers in various embodiments, to an aromatic ring structure comprising in addition to carbon atoms, sulfur, oxygen, nitrogen or any combination thereof, as part of the ring. In some embodiments the heterocycle or heteroaromatic ring is a 3-10 membered ring. In some embodiments the heterocycle or heteroaromatic ring is a 3-12 membered ring. In some embodiments the heterocycle or heteroaromatic ring is a 6 membered ring. In some embodiments the heterocycle or heteroaromatic ring is a 5-7 membered ring. In some embodiments the heterocycle or heteroaromatic ring is a 3-8 membered ring. In some embodiments, the heterocycle group or heteroaromatic ring may be unsubstituted or substituted by a halogen, alkyl, haloalkyl, hydroxyl, alkoxy, carbonyl, amido, alkylamido, dialkylamido, cyano, nitro, CO_2H , amino, alkylamino, dialkylamino, carboxyl, thio and/or thioalkyl. In some embodiments, the heterocycle ring or heteroaromatic ring may be fused to another saturated or unsaturated cycloalkyl or heterocyclic 3-8 membered ring. In some embodiments, the heterocyclic ring is a saturated ring. In some embodiments, the heterocyclic ring is an unsaturated ring. Examples of a heterocyclic ring or heteroaromatic ring systems comprise pyridine, piperidine, morpholine, piperazine, thiophene, pyrrole, benzodioxole, benzofuran-2(3H)-one, benzo[d][1,3]dioxole or indole.

[0199] In various embodiments, this invention provides a compound of this invention or its isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, *N*-oxide, isotopic variant (deuterated analog), PROTAC, or combinations thereof. In various embodiments, this invention provides an isomer of the compound of this invention. In some

embodiments, this invention provides a pharmaceutically acceptable salt of the compound of this invention. In some embodiments, this invention provides a pharmaceutical product of the compound of this invention. In some embodiments, this invention provides a tautomer of the compound of this invention. In some embodiments, this invention provides a hydrate of the compound of this invention. In some embodiments, this invention provides an *N*-oxide of the compound of this invention.. In some embodiments, this invention provides an isotopic variant (including deuterated analog) of the compound of this invention. In some embodiments, this invention provides a PROTAC (Proteolysis targeting chimera) of the compound of this invention. In some embodiments, this invention provides composition comprising a compound of this invention, as described herein, or, in some embodiments, a combination of an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, *N*-oxide, isotopic variant (deuterated analog), PROTAC of this invention.

[0200] In various embodiments, the term "isomer" includes optical isomers and analogs, structural isomers and analogs, conformational isomers and analogs, and the like. In some embodiments, the isomer is an optical isomer.

[0201] In various embodiments, this invention encompasses the use of various optical isomers of the compounds of the invention. It will be appreciated by those skilled in the art that the compounds of the present invention may contain at least one chiral center. Accordingly, the compounds used in the present invention may exist in, and be isolated in, optically-active or racemic forms. Accordingly, the compounds according to this invention may exist as optically-active isomers (enantiomers or diastereomers, including: the (*R*), (*S*), (*R*)(*R*), (*R*)(*S*), (*S*)(*S*), (*S*)(*R*), (*R*)(*R*)(*R*), (*R*)(*R*)(*S*), (*R*)(*S*)(*R*), (*S*)(*R*)(*R*), (*R*)(*S*)(*S*), (*S*)(*R*)(*S*), (*S*)(*S*)(*R*) or (*S*)(*S*)(*S*) isomers); as racemic mixtures, or as enantiomerically enriched mixtures. Some compounds may also exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, which form possesses properties useful in the treatment of the various conditions described herein.


[0202] It is well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).

[0203] The compounds of the present invention can also be present in the form of a racemic mixture, containing substantially equivalent amounts of stereoisomers. In some embodiments, the compounds of the present invention can be prepared or otherwise isolated, using known procedures, to obtain a stereoisomer substantially free of its corresponding stereoisomer (i.e., substantially pure). By substantially pure, it is intended that a stereoisomer is at least about 95% pure, more preferably at least about 98% pure, most preferably at least about 99% pure.


[0204] Compounds of the present invention can also be in the form of a hydrate, which means that the compound further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

[0205] Compounds of the present invention may exist in the form of one or more of the possible tautomers and depending on the particular conditions it may be possible to separate some or all of the tautomers into individual and distinct entities. It is to be understood that all of the possible tautomers, including all additional enol and keto tautomers and/or isomers are hereby covered. For example the following tautomers are included:

Tautomerization of the imidazole ring



Tautomerization of the pyrazolone ring:



[0206] The invention includes "pharmaceutically acceptable salts" of the compounds of this invention, which may be produced, by reaction of a compound of this invention with an acid or base. Certain compounds, particularly those possessing acid or basic groups, can also be in the form of a salt, preferably a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" refers to those salts that retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine and the like. Other salts are known to those of skill in the art and can readily be adapted for use in accordance with the present invention.

[0207] Suitable pharmaceutically-acceptable salts of amines of compounds the compounds of this invention may be prepared from an inorganic acid or from an organic acid. In various embodiments, examples of inorganic salts of amines are bisulfates, borates, bromides, chlorides, hemisulfates, hydrobromates, hydrochlorates, 2-hydroxyethylsulfonates (hydroxyethanesulfonates), iodates, iodides, isothionates, nitrates, persulfates, phosphate, sulfates, sulfamates, sulfanilates, sulfonic acids (alkylsulfonates, arylsulfonates, halogen substituted alkylsulfonates, halogen substituted arylsulfonates), sulfonates and thiocyanates.

[0208] In various embodiments, examples of organic salts of amines may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are acetates, arginines, aspartates, ascorbates, adipates, anthranilates, algenates, alkane carboxylates, substituted alkane carboxylates, alginates, benzenesulfonates, benzoates, bisulfates, butyrates, bicarbonates, bitartrates, citrates, camphorates, camphorsulfonates, cyclohexylsulfamates, cyclopentanepropionates, calcium edetates, camsylates, carbonates, clavulanates, cinnamates, dicarboxylates, digluconates,

dodecylsulfonates, dihydrochlorides, decanoates, enanthuates, ethanesulfonates, edetates, edisylates, estolates, esylates, fumarates, formates, fluorides, galacturonates gluconates, glutamates, glycolates, gluconate, glucoheptanoates, glycerophosphates, gluceptates, glycolylarsanilates, glutarates, glutamate, heptanoates, hexanoates, hydroxymaleates, hydroxycarboxylic acids, hexylresorcinates, hydroxybenzoates, hydroxynaphthoates, hydrofluorates, lactates, lactobionates, laurates, malates, maleates, methylenebis(beta-oxynaphthoate), malonates, mandelates, mesylates, methane sulfonates, methylbromides, methylnitrates, methylsulfonates, monopotassium maleates, mucates, monocarboxylates, naphthalenesulfonates, 2-naphthalenesulfonates, nicotines, nitrates, napsylates, N-methylglucamines, oxalates, octanoates, oleates, pamoates, phenylacetates, picrates, phenylbenzoates, pivalates, propionates, phthalates, phenylacetate, pectinates, phenylpropionates, palmitates, pantothenates, polygalacturates, pyruvates, quinate, salicylates, succinates, stearates, sulfanilate, subacetates, tartrates, theophyllineacetates, p-toluenesulfonates (tosylates), trifluoroacetates, terephthalates, tannates, teoclates, trihaloacetates, triethiodide, tricarboxylates, undecanoates and valerates.

[0209] In various embodiments, examples of inorganic salts of carboxylic acids or hydroxyls may be selected from ammonium, alkali metals to include lithium, sodium, potassium, cesium; alkaline earth metals to include calcium, magnesium, aluminium; zinc, barium, cholines, quaternary ammoniums.

[0210] In some embodiments, examples of organic salts of carboxylic acids or hydroxyl may be selected from arginine, organic amines to include aliphatic organic amines, alicyclic organic amines, aromatic organic amines, benzathines, *t*-butylamines, benethamines (*N*-benzylphenethylamine), dicyclohexylamines, dimethylamines, diethanolamines, ethanolamines, ethylenediamines, hydrabamines, imidazoles, lysines, methylamines, meglamines, *N*-methyl-*D*-glucamines, *N,N'*-dibenzylethylenediamines, nicotinamides, organic amines, ornithines, pyridines, picolines, piperazines, procain, tris(hydroxymethyl)methylamines, triethylamines, triethanolamines, trimethylamines, tromethamines and ureas.

[0211] In various embodiments, the salts may be formed by conventional means, such as by reacting the free base or free acid form of the product with one or more equivalents of the appropriate acid or base in a solvent or medium in which the salt is insoluble or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the ions of a existing salt for another ion or suitable ionexchange resin.

Pharmaceutical composition

[0212] The present invention provides a pharmaceutical composition including a pharmaceutically acceptable carrier and a compound according to the present invention. The pharmaceutical composition can contain one or more of the above-identified compounds of the present invention. Typically, the pharmaceutical composition of the present invention will include a compound of the present invention or its pharmaceutically acceptable salt, as well as

a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to any suitable adjuvants, carriers, excipients, or stabilizers, and can be in solid or liquid form such as, tablets, capsules, powders, solutions, suspensions, or emulsions.

[0213] Typically, the composition will contain from about 0.01 to 99 percent, preferably from about 20 to 75 percent of active compound(s), together with the adjuvants, carriers and/or excipients. While individual needs may vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise about 0.01 to about 100 mg/kg body wt. The preferred dosages comprise about 0.1 to about 100 mg/kg body wt. The most preferred dosages comprise about 1 to about 100 mg/kg body wt. Treatment regimen for the administration of the compounds of the present invention can also be determined readily by those with ordinary skill in art. That is, the frequency of administration and size of the dose can be established by routine optimization, preferably while minimizing any side effects.

[0214] The solid unit dosage forms can be of the conventional type. The solid form can be a capsule and the like, such as an ordinary gelatin type containing the compounds of the present invention and a carrier, for example, lubricants and inert fillers such as, lactose, sucrose, or cornstarch. In some embodiments, these compounds are tabulated with conventional tablet bases such as lactose, sucrose, or cornstarch in combination with binders like acacia, cornstarch, or gelatin, disintegrating agents, such as cornstarch, potato starch, or alginic acid, and a lubricant, like stearic acid or magnesium stearate.

[0215] The tablets, capsules, and the like can also contain a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin. When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

[0216] Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets can be coated with shellac, sugar, or both. A syrup can contain, in addition to active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye, and flavoring such as cherry or orange flavor.

[0217] For oral therapeutic administration, these active compounds can be incorporated with excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compound in these compositions can, of course, be varied and can conveniently be between about 2% to about 60% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions according to the present invention are prepared so that an oral dosage unit contains between about 1 mg and 800 mg of active compound.

[0218] The active compounds of the present invention may be orally administered, for example, with an inert diluent, or with an assimilable edible carrier, or they can be enclosed in hard or soft shell capsules, or they can be compressed into tablets, or they can be incorporated directly with the food of the diet.

[0219] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form should be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0220] The compounds or pharmaceutical compositions of the present invention may also be administered in injectable dosages by solution or suspension of these materials in a physiologically acceptable diluent with a pharmaceutical adjuvant, carrier or excipient. Such adjuvants, carriers and/or excipients include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable components. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.

[0221] These active compounds may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols such as, propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0222] For use as aerosols, the compounds of the present invention in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.

[0223] In various embodiments, the compounds of this invention are administered in combination with an anti-cancer agent. In various embodiments, the anti-cancer agent is a monoclonal antibody. In some embodiments, the monoclonal antibodies are used for diagnosis, monitoring, or treatment of cancer. In various embodiments, monoclonal antibodies


react against specific antigens on cancer cells. In various embodiments, the monoclonal antibody acts as a cancer cell receptor antagonist. In various embodiments, monoclonal antibodies enhance the patient's immune response. In various embodiments, monoclonal antibodies act against cell growth factors, thus blocking cancer cell growth. In various embodiments, anticancer monoclonal antibodies are conjugated or linked to anti-cancer drugs, radioisotopes, other biologic response modifiers, other toxins, or a combination thereof. In various embodiments, anti-cancer monoclonal antibodies are conjugated or linked to a compound of this invention as described hereinabove.

[0224] In various embodiments, the compounds of this invention are administered in combination with an agent treating Alzheimer's disease.

[0225] In various embodiments, the compounds of this invention are administered in combination with an anti-viral agent.

[0226] In various embodiments, the compounds of this invention are administered in combination with at least one of the following: chemotherapy, molecularly-targeted therapies, DNA damaging agents, hypoxia-inducing agents, or immunotherapy.

[0227] The present invention provides a compound represented by the structure of formula (I)



wherein

A and B rings are each independently a single or fused aromatic or heteroaromatic ring system, or a single or fused C₃-C₁₀ cycloalkyl or a single or fused C₃-C₁₀ heterocyclic ring;

R₁ and R₂ are each independently H, F, Cl, Br, I, OH, SH, R_g-OH, R_g-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁) B(OH)₂, -OC(O)CF₃, -OCH₂Ph, NHC(O)-R₁₀ NHCO-N(R₁₀)(R₁₁) COOH, -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ linear or branched C(O)-haloalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁), C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₅ linear, branched or cyclic alkoxy optionally wherein at least one methylene group (CH₂) in the alkoxy is replaced with an oxygen atom, C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring, substituted or unsubstituted aryl (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₂** and **R₁** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring;

R₃ and **R₄** are each independently H, F, Cl, Br, I, OH, SH, R₈-OH, R_s-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀, NHCO-N(R₁₀)(R₁₁), COOH, -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ linear or branched C(O)-haloalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁), C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₅ linear, branched or cyclic alkoxy, C₁-C₅ linear or branched thioalkoxy, C₁-C₅ linear or branched haloalkoxy, C₁-C₅ linear or branched alkoxyalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted C₃-C₈ heterocyclic ring, substituted or unsubstituted aryl, (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂), CH(CF₃)(NH-R₁₀);

or **R₃** and **R₄** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring;

R₅ is H, C₁-C₅ linear or branched, substituted or unsubstituted alkyl, C₁-C₅ linear or branched haloalkyl, R₈-aryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl (wherein substitutions include: F, Cl, Br, I, C₁-C₅ linear or branched alkyl, OH, alkoxy, N(R)₂, CF₃, CN or NO₂);

R₆ is H, C₁-C₅ linear or branched alkyl;

R₈ is [CH₂]_p

wherein **p** is between 1 and 10;

R₉ is [CH]_q, [C]_q

wherein **q** is between 2 and 10;

R₁₀ and **R₁₁** are each independently H, C₁-C₅ linear or branched alkyl, C(O)R, or S(O)₂R;

R is H, C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched alkoxy, phenyl, aryl or heteroaryl, or two gem R substituents are joined together to form a 5 or 6 membered heterocyclic ring;

m, **n**, **l** and **k** are each independently an integer between 0 and 4;

Q₁ and **Q₂** are each independently S or O;

or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, *N*-oxide, isotopic variant, PROTAC, pharmaceutical product or any combination thereof, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting cancer in a

subject.

[0228] When administering the compounds of the present invention, they can be administered systemically or, alternatively, they can be administered directly to a specific site where cancer cells or precancerous cells are present. Thus, administering can be accomplished in any manner effective for delivering the compounds or the pharmaceutical compositions to the cancer cells or precancerous cells. Exemplary modes of administration include, administering the compounds or compositions orally, topically, transdermally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes.

Biological Activity

[0229] In various embodiments, a compound or a composition comprising the compound for use according to this invention will have utility in inhibiting, suppressing, enhancing or stimulating a desired response in a subject, as will be understood by one skilled in the art. In some embodiments, the compositions may further comprise additional active ingredients, whose activity is useful for the particular application for which the compound of this invention is being administered.

[0230] Acetate is an important source of acetyl-CoA in hypoxia. Inhibition of acetate metabolism may impair tumor growth. The nucleocytosolic acetyl-CoA synthetase enzyme, ACSS2, supplies a key source of acetyl-CoA for tumors by capturing acetate as a carbon source. Despite exhibiting no gross deficits in growth or development, adult mice lacking ACSS2 exhibit a significant reduction in tumor burden in two different models of hepatocellular carcinoma. ACSS2 is expressed in a large proportion of human tumors, and its activity is responsible for the majority of cellular acetate uptake into both lipids and histones. Further, ACSS2 was identified in an unbiased functional genomic screen as a critical enzyme for the growth and survival of breast and prostate cancer cells cultured in hypoxia and low serum. Indeed, high expression of ACSS2 is frequently found in invasive ductal carcinomas of the breast, triple-negative breast cancer, glioblastoma, ovarian cancer, pancreatic cancer and lung cancer, and often directly correlates with higher-grade tumors and poorer survival compared with tumors that have low ACSS2 expression. These observations may qualify ACSS2 as a targetable metabolic vulnerability of a wide spectrum of tumors.

[0231] Therefore, in various embodiments, this invention is directed to a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting cancer in a subject suffering from cancer. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the cancer is early cancer. In some embodiments, the cancer is advanced cancer. In some embodiments, the cancer is invasive cancer. In some embodiments, the cancer is metastatic cancer. In some embodiments, the cancer is drug resistant cancer. In some embodiments, the cancer is

selected from the list presented below:

Cancer, bladder (urothelial carcinoma)
Myelodysplasia
Cancer, breast (inflammatory)
Cancer, cervix
Cancer, endometrium
Cancer, esophagus
Cancer, head and neck (squamous cell carcinoma)
Cancer, kidney (renal cell carcinoma)
Cancer, kidney (renal cell carcinoma, clear cell)
Cancer, liver (hepatocellular carcinoma)
Cancer, lung (non-small cell) (NSCLC)
Cancer, metastatic (to brain)
Cancer, nasopharynx
Cancer, solid tumor
Cancer, stomach
Carcinoma, adrenocortical
Glioblastoma multiforme
Leukemia, acute myeloid
Leukemia, chronic lymphocytic
Lymphoma, Hodgkin's (classical)
Lymphoma, diffuse large B-cell
Lymphoma, primary central nervous system
Melanoma, malignant
Melanoma, uveal
Meningioma
Multiple myeloma
Cancer, breast
Cancer
Cancer, anus
Cancer, anus (squamous cell)
Cancer, biliary
Cancer, bladder, muscle invasive urothelial carcinoma
Cancer, breast metastatic
Cancer, colorectal
Cancer, colorectal metastatic

Cancer, fallopian tube
Cancer, gastroesophageal junction
Cancer, gastroesophageal junction (adenocarcinoma)
Cancer, larynx (squamous cell)
Cancer, lung (non-small cell) (NSCLC) (squamous cell carcinoma)
Cancer, lung (non-small cell) (NSCLC) metastatic
Cancer, lung (small cell) (SCLC)
Cancer, lung (small cell) (SCLC) (extensive)
Cancer, merkel cell
Cancer, mouth
Cancer, ovary
Cancer, ovary (epithelial)
Cancer, pancreas
Cancer, pancreas (adenocarcinoma)
Cancer, pancreas metastatic
Cancer, penis
Cancer, penis (squamous cell carcinoma)
Cancer, peritoneum
Cancer, prostate (castration-resistant)
Cancer, prostate (castration-resistant), metastatic
Cancer, rectum
Cancer, skin (basal cell carcinoma)
Cancer, skin (squamous cell carcinoma)
Cancer, small intestine (adenocarcinoma)
Cancer, testis
Cancer, thymus
Cancer, thyroid, anaplastic
Cholangiocarcinoma
Chordoma
Cutaneous T-cell lymphoma
Digestive-gastrointestinal cancer
Familial pheochromocytoma-paraganglioma
Glioma
HTLV-1-associated adult T-cell leukemia-lymphoma
Hematologic-blood cancer

Hepatitis C (HCV)
Infection, papillomaviral respiratory
Leiomyosarcoma, uterine
Leukemia, acute lymphocytic
Leukemia, chronic myeloid
Lymphoma, T-cell
Lymphoma, follicular
Lymphoma, primary mediastinal large B-cell
Lymphoma, testicular, diffuse large B-cell
Melanoma
Mesothelioma, malignant
Mesothelioma, pleural
Mycosis fungoides
Neuroendocrine cancer
Oral epithelial dysplasia
Sarcoma
Sepsis, severe
Sezary syndrome
Smoldering myeloma
Soft tissue sarcoma
T-cell lymphoma, nasal natural killer (NK) cell
T-cell lymphoma, peripheral

[0232] In some embodiments, the cancer is selected from the list of: hepatocellular carcinoma, melanoma (e.g., BRAF mutant melanoma), glioblastoma, breast cancer, prostate cancer, liver cancer, brain cancer, Lewis lung carcinoma (LLC), colon carcinoma, pancreatic cancer, renal cell carcinoma, and mammary carcinoma. In some embodiments, the cancer is selected from the list of: melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, Hodgkin lymphoma, Merkel cell skin cancer (Merkel cell carcinoma), esophagus cancer; gastroesophageal junction cancer; liver cancer, (hepatocellular carcinoma); lung cancer, (small cell) (SCLC); stomach cancer; upper urinary tract cancer, (urothelial carcinoma); multiforme Glioblastoma; Multiple myeloma; anus cancer, (squamous cell); cervix cancer; endometrium cancer; nasopharynx cancer; ovary cancer; metastatic pancreas cancer; solid tumor cancer; adrenocortical Carcinoma; HTLV-1-associated adult T-cell leukemia-lymphoma; uterine Leiomyosarcoma; acute myeloid Leukemia; chronic lymphocytic Leukemia; diffuse large B-cell Lymphoma; follicular Lymphoma; uveal Melanoma; Meningioma; pleural Mesothelioma; Myelodysplasia; Soft tissue sarcoma; breast cancer; colon cancer; Cutaneous T-cell lymphoma; and peripheral T-cell lymphoma. In some embodiments, the cancer is

selected from the list of: glioblastoma, melanoma, lymphoma, breast cancer, ovarian cancer, glioma, digestive system cancer, central nervous system cancer, hepatocellular cancer, hematological cancer, colon cancer or any combination thereof. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0233] It has been shown that glucose-independent acetate metabolism promotes melanoma cell survival and tumor growth. Glucose-starved melanoma cells are highly dependent on acetate to sustain ATP levels, cell viability and proliferation. Conversely, depletion of ACSS1 or ACSS2 reduced melanoma tumor growth in mice. Collectively, this data demonstrates acetate metabolism as a liability in melanoma.

[0234] Accordingly, in various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting melanoma in a subject suffering from melanoma. In some embodiments, the melanoma is early melanoma. In some embodiments, the melanoma is advanced melanoma. In some embodiments, the melanoma is invasive melanoma. In some embodiments, the melanoma is metastatic melanoma. In some embodiments, the melanoma is drug resistant melanoma. In some embodiments, the melanoma is BRAF mutant melanoma. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0235] Acetyl-CoA synthetases that catalyse the conversion of acetate to acetyl-CoA have now been implicated in the growth of hepatocellular carcinoma, glioblastoma, breast cancer and prostate cancer.

[0236] Hepatocellular carcinoma (HCC) is a deadly form of liver cancer, and it is currently the second leading cause of cancer-related deaths worldwide (European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer, 2012). Despite a number of available treatment strategies, the survival rate for HCC patients is low. Considering its rising prevalence, more targeted and effective treatment strategies are highly desirable for HCC.

[0237] In various embodiments, the present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting hepatocellular carcinoma (HCC) in a subject suffering from hepatocellular carcinoma (HCC). In some embodiments, the hepatocellular carcinoma (HCC) is early hepatocellular carcinoma (HCC). In some embodiments, the hepatocellular carcinoma (HCC) is advanced hepatocellular carcinoma (HCC). In some embodiments, the hepatocellular carcinoma (HCC) is invasive hepatocellular carcinoma (HCC). In some embodiments, the hepatocellular carcinoma (HCC) is metastatic hepatocellular carcinoma (HCC). In some embodiments, the hepatocellular carcinoma (HCC) is drug resistant hepatocellular carcinoma (HCC). In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0238] ACSS2-mediated acetate metabolism contributes to lipid synthesis and aggressive growth in glioblastoma and breast cancer.

[0239] Nuclear ACSS2 is shown to activate HIF-2alpha by acetylation and thus accelerate growth and metastasis of HIF2alpha-driven cancers such as certain Renal Cell Carcinoma and Glioblastomas (Chen, R. et al. Coordinate regulation of stress signaling and epigenetic events by Acss2 and HIF-2 in cancer cells, Plos One, 12 (12) 1-31, 2017).

[0240] Therefore, and in various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting glioblastoma in a subject suffering from glioblastoma. In some embodiments, the glioblastoma is early glioblastoma. In some embodiments, the glioblastoma is advanced glioblastoma. In some embodiments, the glioblastoma is invasive glioblastoma. In some embodiments, the glioblastoma is metastatic glioblastoma. In some embodiments, the glioblastoma is drug resistant glioblastoma. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0241] Therefore, and in various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting Renal Cell Carcinoma in a subject suffering from Renal Cell Carcinoma. In some embodiments, the Renal Cell Carcinoma is early Renal Cell Carcinoma. In some embodiments, the Renal Cell Carcinoma is advanced Renal Cell Carcinoma. In some embodiments, the Renal Cell Carcinoma is invasive Renal Cell Carcinoma. In some embodiments, the Renal Cell Carcinoma is metastatic Renal Cell Carcinoma. In some embodiments, the Renal Cell Carcinoma is drug resistant Renal Cell Carcinoma. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0242] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting breast cancer in a subject suffering from breast cancer. In some embodiments, the breast cancer is early breast cancer. In some embodiments, the breast cancer is advanced breast cancer. In some embodiments, the breast cancer is invasive breast cancer. In some embodiments, the breast cancer is metastatic breast cancer. In some embodiments, the breast cancer is drug resistant breast cancer. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0243] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting prostate cancer in a subject suffering from prostate cancer. In some embodiments, the prostate cancer is early prostate cancer. In some embodiments, the prostate cancer is advanced prostate cancer. In some embodiments, the prostate cancer is

invasive prostate cancer. In some embodiments, the prostate cancer is metastatic prostate cancer. In some embodiments, the prostate cancer is drug resistant prostate cancer. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0244] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting liver cancer in a subject suffering from liver cancer. In some embodiments, the liver cancer is early liver cancer. In some embodiments, the liver cancer is advanced liver cancer. In some embodiments, the liver cancer is invasive liver cancer. In some embodiments, the liver cancer is metastatic liver cancer. In some embodiments, the liver cancer is drug resistant liver cancer. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0245] Nuclear ACSS2 is also shown to promote lysosomal biogenesis, autophagy and to promote brain tumorigenesis by affecting Histone H3 acetylation (Li, X et al.: Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis and Autophagy, Molecular Cell 66, 1-14, 2017).

[0246] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting brain cancer in a subject suffering from brain cancer. In some embodiments, the brain cancer is early brain cancer. In some embodiments, the brain cancer is advanced brain cancer. In some embodiments, the brain cancer is invasive brain cancer. In some embodiments, the brain cancer is metastatic brain cancer. In some embodiments, the brain cancer is drug resistant brain cancer. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0247] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting pancreatic cancer in a subject suffering from pancreatic cancer. In some embodiments, the pancreatic cancer is early pancreatic cancer. In some embodiments, the pancreatic cancer is advanced pancreatic cancer. In some embodiments, the pancreatic cancer is invasive pancreatic cancer. In some embodiments, the pancreatic cancer is metastatic pancreatic cancer. In some embodiments, the pancreatic cancer is drug resistant pancreatic cancer. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0248] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting Lewis lung carcinoma (LLC) in to a subject suffering from Lewis lung carcinoma (LLC). In some embodiments, the Lewis lung carcinoma (LLC) is early Lewis lung

carcinoma (LLC). In some embodiments, the Lewis lung carcinoma (LLC) is advanced Lewis lung carcinoma (LLC). In some embodiments, the Lewis lung carcinoma (LLC) is invasive Lewis lung carcinoma (LLC). In some embodiments, the Lewis lung carcinoma (LLC) is metastatic Lewis lung carcinoma (LLC). In some embodiments, the Lewis lung carcinoma (LLC) is drug resistant Lewis lung carcinoma (LLC). In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0249] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting colon carcinoma in a subject suffering from colon carcinoma. In some embodiments, the colon carcinoma is early colon carcinoma. In some embodiments, the colon carcinoma is advanced colon carcinoma. In some embodiments, the colon carcinoma is invasive colon carcinoma. In some embodiments, the colon carcinoma is metastatic colon carcinoma. In some embodiments, the colon carcinoma is drug resistant colon carcinoma. In some embodiments, the compound is a 'program cell death receptor 1' (PD-1) modulator. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0250] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting mammary carcinoma in a subject suffering from mammary carcinoma. In some embodiments, the mammary carcinoma is early mammary carcinoma. In some embodiments, the mammary carcinoma is advanced mammary carcinoma. In some embodiments, the mammary carcinoma is invasive mammary carcinoma. In some embodiments, the mammary carcinoma is metastatic mammary carcinoma. In some embodiments, the mammary carcinoma is drug resistant mammary carcinoma. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0251] In various embodiments, this invention provides a compound represented by the structure of formula (I) for use in suppressing, reducing or inhibiting tumor growth in a subject suffering from a proliferative disorder (e.g., cancer). In some embodiments, the tumor growth is enhanced by increased acetate uptake by cancer cells. In some embodiments, the increase in acetate uptake is mediated by ACSS2. In some embodiments, the cancer cells are under hypoxic stress. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the tumor growth is suppressed due to suppression of lipid synthesis (e.g., fatty acid) induced by ACSS2 mediated acetate metabolism to acetyl-CoA. In some embodiments, the tumor growth is suppressed due to suppression of the regulation of histones acetylation and function induced by ACSS2 mediated acetate metabolism to acetyl-CoA. In some embodiments, the synthesis is suppressed under hypoxia (hypoxic stress). In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0252] In various embodiments, this invention is directed to an in vitro method of suppressing,

reducing or inhibiting lipid synthesis and/or regulating histones acetylation and function in a cell, comprising contacting a compound of this invention represented by the structure of formula (I) with a cell under conditions effective to suppress, reduce or inhibit lipid synthesis and/or regulating histones acetylation and function in said cell. In various embodiments, the lipid synthesis is induced by ACSS2 mediated acetate metabolism to acetyl-CoA. In various embodiments, regulating histones acetylation and function is induced by ACSS2 mediated acetate metabolism to acetyl-CoA. In various embodiments, the cell is cancer cell. In various embodiments, the lipid is fatty acid. In various embodiments, the acetate metabolism to acetyl-CoA is carried out under hypoxia (i.e., hypoxic stress). In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0253] In various embodiments, the present invention provides a compound represented by the structure of formula (I) for use in suppressing, reducing or inhibiting fatty-acid accumulation in the liver of a subject in need thereof. In various embodiments, the fatty-acid accumulation is induced by ACSS2 mediated acetate metabolism to acetyl-CoA. In various embodiments, the subject suffers from a fatty liver condition. In various embodiments, the acetate metabolism to acetyl-CoA in the liver is carried out under hypoxia (i.e., hypoxic stress). In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0254] In various embodiments, this invention is directed to an in vitro method of binding an ACSS2 inhibitor compound to an ACSS2 enzyme, comprising the step of contacting an ACSS2 enzyme with an ACSS2 inhibitor compound of this invention represented by the structure of formula (I), in an amount effective to bind the ACSS2 inhibitor compound to the ACSS2 enzyme. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0255] In various embodiments, this invention is directed to an in vitro method of suppressing, reducing or inhibiting acetyl-CoA synthesis from acetate in a cell, comprising contacting a compound according to this invention represented by the structure of formula (I) with a cell, under conditions effective to suppress, reduce or inhibit acetyl-CoA synthesis from acetate in said cell. In some embodiments, the cell is a cancer cell. In some embodiments, the synthesis is mediated by ACSS2. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the cell is under hypoxic stress. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0256] The present invention provides an in vitro method of suppressing, reducing or inhibiting acetate metabolism in a cancer cell, comprising contacting a compound according to this invention represented by the structure of formula (I) with a cancer cell, under conditions effective to suppress, reduce or inhibit acetate metabolism in said cell. In some embodiments, the acetate metabolism is mediated by ACSS2. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the cancer cell is under hypoxic stress. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0257] In various embodiments, the present invention provides a compound represented by the structure of formula (I) a compound of this invention or an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, *N*-oxide, isotopic variant (e.g., deuterated analog), PROTAC, of said compound, or any combination thereof, for use in treating, suppressing, reducing the severity, reducing the risk, or inhibiting metastatic cancer in a subject. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is hepatocellular carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is liver cancer. In some embodiments, the cancer is brain cancer. In some embodiments, the cancer is Lewis lung carcinoma. In some embodiments, the cancer is colon carcinoma. In some embodiments, the cancer is mammary carcinoma. In some embodiments, the cancer is pancreatic cancer.

[0258] In various embodiments, the present invention provides a compound represented by the structure of formula (I) or an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, *N*-oxide, isotopic variant (e.g., deuterated analog), PROTAC, of said compound, or any combination thereof, for use in increasing the survival of a subject suffering from metastatic cancer. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is hepatocellular carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is liver cancer. In some embodiments, the cancer is brain cancer. In some embodiments, the cancer is Lewis lung carcinoma. In some embodiments, the cancer is colon carcinoma. In some embodiments, the cancer is mammary carcinoma. In some embodiments, the cancer is pancreatic cancer.

[0259] In various embodiments, this invention provides a compound represented by the structure of formula (I) or an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, *N*-oxide, isotopic variant (e.g., deuterated analog), PROTAC of said compound, or any combination thereof, for use in treating, suppressing, reducing the severity, reducing the risk, or inhibiting advanced cancer in a subject. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is hepatocellular carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is liver cancer. In some embodiments, the cancer is brain cancer. In some embodiments, the cancer is Lewis lung carcinoma. In some embodiments, the cancer is colon carcinoma. In some embodiments, the cancer is mammary carcinoma. In some embodiments, the cancer is pancreatic cancer.

[0260] In various embodiments, this invention provides a compound represented by the structure of formula (I) or an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, *N*-oxide, isotopic variant (e.g., deuterated analog), PROTAC, of said

compound, or any combination thereof, for use in increasing the survival of a subject suffering from advanced cancer. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is hepatocellular carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is liver cancer. In some embodiments, the cancer is brain cancer. In some embodiments, the cancer is Lewis lung carcinoma. In some embodiments, the cancer is colon carcinoma. In some embodiments, the cancer is mammary carcinoma. In some embodiments, the cancer is pancreatic cancer.

[0261] The compounds of the present invention may be useful in the treatment, reducing the severity, reducing the risk, or inhibition of cancer, metastatic cancer, advanced cancer, drug resistant cancer, and various forms of cancer. In a preferred embodiment the cancer is hepatocellular carcinoma, melanoma (e.g., BRAF mutant melanoma), glioblastoma, breast cancer, prostate cancer, liver cancer, brain cancer, pancreatic cancer, Lewis lung carcinoma (LLC), colon carcinoma, renal cell carcinoma, and/or mammary carcinoma. Based upon their believed mode of action, it is believed that other forms of cancer will likewise be treatable or preventable upon administration of the compounds or compositions of the present invention to a patient. Preferred compounds of the present invention are selectively disruptive to cancer cells, causing ablation of cancer cells but preferably not normal cells. Significantly, harm to normal cells is minimized because the cancer cells are susceptible to disruption at much lower concentrations of the compounds of the present invention.

[0262] In various embodiments, other types of cancers that may be treatable with the ACSS2 inhibitors represented by the structure of formula (I) include: adrenocortical carcinoma, anal cancer, bladder cancer, brain tumor, brain stem tumor, breast cancer, glioma, cerebellar astrocytoma, cerebral astrocytoma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal, pineal tumors, hypothalamic glioma, carcinoid tumor, carcinoma, cervical cancer, colon cancer, central nervous system (CNS) cancer, endometrial cancer, esophageal cancer, extrahepatic bile duct cancer, Ewing's family of tumors (Pnet), extracranial germ cell tumor, eye cancer, intraocular melanoma, gallbladder cancer, gastric cancer, germ cell tumor, extragonadal, gestational trophoblastic tumor, head and neck cancer, hypopharyngeal cancer, islet cell carcinoma, laryngeal cancer, leukemia, acute lymphoblastic, leukemia, oral cavity cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell, lymphoma, AIDS-related lymphoma, central nervous system (primary), lymphoma, cutaneous T-cell, lymphoma, Hodgkin's disease, non-Hodgkin's disease, malignant mesothelioma, melanoma, Merkel cell carcinoma, metastatic squamous carcinoma, multiple myeloma, plasma cell neoplasms, mycosis fungoides, myelodysplastic syndrome, myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma, oropharyngeal cancer, osteosarcoma, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, exocrine, pancreatic cancer, islet cell carcinoma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pheochromocytoma cancer, pituitary cancer, plasma cell neoplasm, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cancer, renal cell cancer, salivary gland cancer, Sezary syndrome, skin cancer, cutaneous T-cell lymphoma, skin

cancer, Kaposi's sarcoma, skin cancer, melanoma, small intestine cancer, soft tissue sarcoma, soft tissue sarcoma, testicular cancer, thymoma, malignant, thyroid cancer, urethral cancer, uterine cancer, sarcoma, unusual cancer of childhood, vaginal cancer, vulvar cancer, Wilms' tumor, hepatocellular cancer, hematological cancer or any combination thereof. In some embodiments the cancer is invasive. In some embodiments the cancer is metastatic cancer. In some embodiments the cancer is advanced cancer. In some embodiments the cancer is drug resistant cancer.

[0263] In various embodiments "metastatic cancer" refers to a cancer that spread (metastasized) from its original site to another area of the body. Virtually all cancers have the potential to spread. Whether metastases develop depends on the complex interaction of many tumor cell factors, including the type of cancer, the degree of maturity (differentiation) of the tumor cells, the location and how long the cancer has been present, as well as other incompletely understood factors. Metastases spread in three ways - by local extension from the tumor to the surrounding tissues, through the bloodstream to distant sites or through the lymphatic system to neighboring or distant lymph nodes. Each kind of cancer may have a typical route of spread. The tumor is called by the primary site (ex. breast cancer that has spread to the brain is called metastatic breast cancer to the brain).

[0264] In various embodiments "drug-resistant cancer" refers to cancer cells that acquire resistance to chemotherapy. Cancer cells can acquire resistance to chemotherapy by a range of mechanisms, including the mutation or overexpression of the drug target, inactivation of the drug, or elimination of the drug from the cell. Tumors that recur after an initial response to chemotherapy may be resistant to multiple drugs (they are multidrug resistant). In the conventional view of drug resistance, one or several cells in the tumor population acquire genetic changes that confer drug resistance. Accordingly, the reasons for drug resistance, *inter alia*, are: a) some of the cells that are not killed by the chemotherapy mutate (change) and become resistant to the drug. Once they multiply, there may be more resistant cells than cells that are sensitive to the chemotherapy; b) Gene amplification. A cancer cell may produce hundreds of copies of a particular gene. This gene triggers an overproduction of protein that renders the anticancer drug ineffective; c) cancer cells may pump the drug out of the cell as fast as it is going in using a molecule called p-glycoprotein; d) cancer cells may stop taking in the drugs because the protein that transports the drug across the cell wall stops working; e) the cancer cells may learn how to repair the DNA breaks caused by some anti-cancer drugs; f) cancer cells may develop a mechanism that inactivates the drug. One major contributor to multidrug resistance is overexpression of P-glycoprotein (P-gp). This protein is a clinically important transporter protein belonging to the ATP-binding cassette family of cell membrane transporters. It can pump substrates including anticancer drugs out of tumor cells through an ATP-dependent mechanism; g) Cells and tumors with activating RAS mutations are relatively resistant to most anti-cancer agents. Thus, the resistance to anticancer agents used in chemotherapy is the main cause of treatment failure in malignant disorders, provoking tumors to become resistant. Drug resistance is the major cause of cancer chemotherapy failure.

[0265] In various embodiments "resistant cancer" refers to drug-resistant cancer as described

herein above. In some embodiments "resistant cancer" refers to cancer cells that acquire resistance to any treatment such as chemotherapy, radiotherapy or biological therapy.

[0266] In various embodiments, this invention is directed to a compound of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk, or inhibiting cancer in a subject, wherein the subject has been previously treated with chemotherapy, radiotherapy or biological therapy.

[0267] In various embodiments "Chemotherapy" refers to chemical treatment for cancer such as drugs that kill cancer cells directly. Such drugs are referred as "anti-cancer" drugs or "antineoplastics." Today's therapy uses more than 100 drugs to treat cancer. \Chemotherapy is used to control tumor growth when cure is not possible; to shrink tumors before surgery or radiation therapy; to relieve symptoms (such as pain); and to destroy microscopic cancer cells that may be present after the known tumor is removed by surgery (called adjuvant therapy). Adjuvant therapy is given to prevent a possible cancer reoccurrence.

[0268] In various embodiments, "Radiotherapy" (also referred herein as "Radiation therapy") refers to high energy x-rays and similar rays (such as electrons) to treat disease. Many people with cancer will have radiotherapy as part of their treatment. This can be given either as external radiotherapy from outside the body using x-rays or from within the body as internal radiotherapy. Radiotherapy works by destroying the cancer cells in the treated area. Although normal cells can also be damaged by the radiotherapy, they can usually repair themselves. Radiotherapy treatment can cure some cancers and can also reduce the chance of a cancer coming back after surgery. It may be used to reduce cancer symptoms.

[0269] In various embodiments "Biological therapy" refers to substances that occur naturally in the body to destroy cancer cells. There are several types of treatment including: monoclonal antibodies, cancer growth inhibitors, vaccines and gene therapy. Biological therapy is also known as immunotherapy.

[0270] When the compounds or pharmaceutical compositions of the present invention are administered to treat, suppress, reduce the severity, reduce the risk, or inhibit a cancerous condition, the pharmaceutical composition can also contain, or can be administered in conjunction with, other therapeutic agents or treatment regimen presently known or hereafter developed for the treatment of various types of cancer. Examples of other therapeutic agents or treatment regimen include radiation therapy, immunotherapy, chemotherapy, surgical intervention, and combinations thereof.

[0271] It is this kind of metabolic plasticity - the ability to exploit and survive on a variety of nutritional sources - that confers resistance to many of the current cancer metabolism drugs as monotherapies. Interestingly, ACSS2 is highly expressed in many cancer tissues, and its upregulation by hypoxia and low nutrient availability indicates that it is an important enzyme for coping with the typical stresses within the tumor microenvironment and, as such, a potential Achilles heel. Moreover, highly stressed regions of tumors have been shown to select for

apoptotic resistance and promote aggressive behavior, treatment resistance and relapse. In this way, the combination of ACSS2 inhibitors with a therapy that specifically targets well-oxygenated regions of tumors (for example, radiotherapy) could prove to be an effective regimen.

[0272] Accordingly, and in various embodiments, the compound according to this invention, may be administered in combination with an anti-cancer therapy. Examples of such therapies include: chemotherapy, immunotherapy, radiotherapy, biological therapy, surgical intervention, and combinations thereof. In some embodiments, the compound according to this invention is administered in combination with a therapy that specifically targets well-oxygenated regions of tumors. In some embodiments, the compound according to this invention is administered in combination with radiotherapy.

[0273] In various embodiments, the compound is administered in combination with an anti-cancer agent by administering the compounds as herein described, alone or in combination with other agents.

[0274] In various embodiments, the composition for use in cancer treatment according to the present invention can be used together with existing chemotherapy drugs or be made as a mixture with them. Such a chemotherapy drug includes, for example, alkylating agents, nitrosourea agents, antimetabolites, antitumor antibiotics, alkaloids derived from plant, topoisomerase inhibitors, hormone therapy medicines, hormone antagonists, aromatase inhibitors, P-glycoprotein inhibitors, platinum complex derivatives, other immunotherapeutic drugs, and other anticancer agents. Further, they can be used together with hypoleukocytosis (neutrophil) medicines that are cancer treatment adjuvant, thrombopenia medicines, antiemetic drugs, and cancer pain medicines for patient's QOL recovery or be made as a mixture with them.

[0275] In various embodiments, this invention is directed to a compound represented by the structure of formula (I) for use in destroying a cancerous cell by contacting the cancerous cell with the compound under conditions effective to destroy the contacted cancerous cell in vivo. In another embodiment, the invention is directed to an in vitro method of destroying a cancerous cell comprising: providing a compound represented by the structure of formula (I), and contacting the cancerous cell with the compound under conditions effective to destroy the contacted cancerous cell.

[0276] In some embodiments, the cancer is selected from the group consisting of melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, Hodgkin lymphoma, glioblastoma, renal cell carcinoma, Merkel cell skin cancer (Merkel cell carcinoma), and combinations thereof. In some embodiments, the cancer is selected from the group consisting of: melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, Hodgkin lymphoma, glioblastoma, Merkel cell skin cancer (Merkel cell carcinoma), esophagus cancer; gastroesophageal junction cancer; liver cancer, (hepatocellular carcinoma); lung cancer, (small cell) (SCLC); stomach cancer; upper urinary tract cancer,

(urothelial carcinoma); multiforme Glioblastoma; Multiple myeloma; anus cancer, (squamous cell); cervix cancer; endometrium cancer; nasopharynx cancer; ovary cancer; metastatic pancreas cancer; solid tumor cancer; adrenocortical Carcinoma; HTLV-1-associated adult T-cell leukemia-lymphoma; uterine Leiomyosarcoma; acute myeloid Leukemia; chronic lymphocytic Leukemia; diffuse large B-cell Lymphoma; follicular Lymphoma; uveal Melanoma; Meningioma; pleural Mesothelioma; Myelodysplasia; Soft tissue sarcoma; breast cancer; colon cancer; pancreatic cancer, Cutaneous T-cell lymphoma; peripheral T-cell lymphoma or any combination thereof.

[0277] A still further aspect of the present invention relates to a compound represented by the structure of formula (I) for use in treating or preventing a cancerous condition by administering an effective amount of the compound to a patient in a manner effective to treat or prevent a cancerous condition.

[0278] According to one embodiment, the patient to be treated is characterized by the presence of a precancerous condition, and the administering of the compound is effective to prevent development of the precancerous condition into the cancerous condition. This can occur by destroying the precancerous cell prior to or concurrent with its further development into a cancerous state.

[0279] According to other embodiments, the patient to be treated is characterized by the presence of a cancerous condition, and the administering of the compound is effective either to cause regression of the cancerous condition or to inhibit growth of the cancerous condition, i.e., stopping its growth altogether or reducing its rate of growth. This preferably occurs by destroying cancer cells, regardless of their location in the patient body. That is, whether the cancer cells are located at a primary tumor site or whether the cancer cells have metastasized and created secondary tumors within the patient body.

[0280] ACSS2 gene has recently been suggested to be associated with human alcoholism and ethanol intake. Accordingly, the present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting alcoholism in a human subject. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0281] Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar pathogenesis and histopathology but a different etiology and epidemiology. NASH and ASH are advanced stages of non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD). NAFLD is characterized by excessive fat accumulation in the liver (steatosis), without any other evident causes of chronic liver diseases (viral, autoimmune, genetic, etc.), and with an alcohol consumption ≤ 20 -30 g/day. On the contrary, AFLD is defined as the presence of steatosis and alcohol consumption > 20 -30 g/day.

[0282] It has been shown that synthesis of metabolically available acetyl-CoA from acetate is

critical to the increased acetylation of proinflammatory gene histones and consequent enhancement of the inflammatory response in ethanol-exposed macrophages. This mechanism is a potential therapeutic target in acute alcoholic hepatitis.

[0283] Accordingly, the present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting alcoholic steatohepatitis (ASH) in a subject suffering from alcoholic steatohepatitis (ASH). In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0284] Accordingly, the present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting non alcoholic fatty liver disease (NAFLD) in a subject suffering from non alcoholic fatty liver disease (NAFLD). In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0285] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting non-alcoholic steatohepatitis (NASH) in a suffering from non-alcoholic steatohepatitis (NASH). In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0286] ACSS2-mediated acetyl-CoA synthesis from acetate has also been shown to be necessary for human cytomegalovirus infection. It has been shown that glucose carbon can be converted to acetate and used to make cytosolic acetyl-CoA by acetyl-CoA synthetase short-chain family member 2 (ACSS2) for lipid synthesis, which is important for HCMV-induced lipogenesis and the viral growth. Accordingly, ACSS2 inhibitors are expected to be useful as an antiviral therapy, and in the treatment of HCMV infection.

[0287] Therefore, the present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting a viral infection in a subject. In some embodiments, the viral infection is HCMV. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0288] It was found that mice lacking ACSS2 showed reduced body weight and hepatic steatosis in a dietinduced obesity model (Z. Huang et al., "ACSS2 promotes systemic fat storage and utilization through selective regulation of genes involved in lipid metabolism" PNAS 115, (40), E9499-E9506, 2018).

[0289] Accordingly, the present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting a metabolic disorder in a subject suffering from a metabolic disorder. In

some embodiments, the metabolic disorder is obesity. In other embodiments, the metabolic disorder is weight gain. In other embodiments, the metabolic disorder is hepatic steatosis. In other embodiments, the metabolic disorder is fatty liver disease. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0290] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting obesity in a subject. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0291] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting weight gain in a subject. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0292] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting hepatic steatosis in a subject suffering from hepatic steatosis. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0293] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting fatty liver disease in a subject suffering from fatty liver disease. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0294] ACSS2 is also shown to enter the nucleus under certain condition (hypoxia, high fat etc.) and to affect histone acetylation and crotonylation by making available acetyl-CoA and crotonyl-CoA and thereby regulate gene expression. For example, ACSS2 decrease is shown to lower levels of nuclear acetyl-CoA and histone acetylation in neurons affecting the expression of many neuronal genes. In the hippocampus such reductions in ACSS2 lead to effects on memory and neuronal plasticity (Mews P, et al., Nature, Vol 546, 381, 2017). Such epigenetic modifications are implicated in neuropsychiatric diseases such as anxiety, PTSD, depression etc. (Graff, J et al. Histone acetylation: molecular mnemonics on chromatin. Nat Rev. Neurosci. 14, 97-111 (2013)). Thus, an inhibitor of ACSS2 may find useful application in these conditions.

[0295] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting a neuropsychiatric disease or disorder in a subject suffering from a neuropsychiatric disease or disorder. In some embodiments, the neuropsychiatric disease or disorder is

selected from: anxiety, depression, schizophrenia, autism and/or or post-traumatic stress disorder. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0296] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting anxiety in a subject suffering from anxiety. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0297] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting depression in a subject suffering from depression. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0298] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting post-traumatic stress disorder in a subject suffering from post-traumatic stress disorder. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0299] The present invention provides a compound represented by the structure of formula (I) for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting an autoimmune disease or disorder in a subject suffering from an autoimmune disease or disorder. In some embodiments, the compound is an ACSS2 inhibitor. In some embodiments, the compound is any one of the compounds listed in Table 1a or Table 1b.

[0300] As used herein, subject or patient refers to any mammalian patient, including humans and other primates, dogs, cats, horses, cows, sheep, pigs, rats, mice, and other rodents. In various embodiments, the subject is male. In some embodiments, the subject is female. In some embodiments, the compounds as described herein may be useful for treating either males or females.

[0301] When administering the compounds of the present invention, they can be administered systemically or, alternatively, they can be administered directly to a specific site where cancer cells or precancerous cells are present. Thus, administering can be accomplished in any manner effective for delivering the compounds or the pharmaceutical compositions to the cancer cells or precancerous cells. Exemplary modes of administration include administering the compounds or compositions orally, topically, transdermally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes.

[0302] The following examples are presented in order to more fully illustrate the preferred embodiments of the invention.

EXAMPLES


EXAMPLE 1

Synthetic Details for Compounds of the Invention (Figures 1-3)

Experimental Procedure:

General synthesis of compound 3


[0303]



[0304] A solution of compound 1 (1.00 eq), compound 2 (1.0 eq) in AcOH (0.5 ~ 10 mL) was stirred at 90 °C for 3 ~ 10 hours under N₂. The mixture was concentrated in vacuo. The residue was purified by trituration (in Ethyl acetate or EtOH) to give compound 3.

General preparation of compound 5

[0305]




[0306] To a solution of compound 3 (1.00 eq) in DCM (5 ~ 10 mL) Et₃N (2.00 eq) was added .

After stirring at 25 °C for 30 minutes, compound **4** (1.00 eq) was added, and then the mixture was stirred at 25°C for 2.5 hours under N₂. It was concentrated in vacuum to give the crude compound **5**, which was used in the next step as is.

General preparation of final compounds 100-277


[0307]

Method 1



[0308] To a solution of compound **5** (1.50 eq) in MeCN (10 mL), HOBT (2.00 eq), compound **7** (1.00 eq) and DIEA (3.00 eq) were added. The mixture was stirred at 70 °C for 2 hours. It was concentrated in vacuum. The residue was purified by prep-HPLC to afford the final compounds **100-277**.

Method 2





[0309] To a solution of compound **3** (1.00 eq) in DCM (1 ~ 10 mL) Et₃N (2.00 eq) was added. After stirring for 0.5 hours at 20 °C, Compound **6** (1.00 eq) was added into it, following by stirring of the mixture at 20 °C for 10 hours. The mixture was concentrated in vacuum, and the residue was purified by prep-HPLC to give compounds **100-277**.

Analytical data

3-methyl-5-oxo-N,1-diphenyl-4,5-dihydro-1H-pyrazole-4-carboxamide Compound ID: 182

[0310]






LCMS: m/z 294.2 $[M+H]^+$;

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.39 (s, 1 H), 10.68 (s, 1 H), 7.75 (d, $J = 8.4$ Hz, 2 H), 7.62 (dd, $J = 7.6, 1.2$ Hz, 2 H), 7.52 (t, $J = 8.0$ Hz, 2 H), 7.34 - 7.29 (m, 3 H), 7.03 (t, $J = 8.0$ Hz, 1 H), 2.57 (s, 3 H).

***N*-(3-acetylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide**

[0311] Compound ID: 183 Batch2




LCMS: m/z 336.2 $[M+H]^+$;

^1H NMR (400MHz, $\text{DMSO}-d_6$) δ 10.84 (s, 1 H), 8.24 (s, 1 H), 7.84 (d, $J = 8.0$ Hz, 1 H), 7.74 (d, $J = 7.6$ Hz, 2 H), 7.64 (d, $J = 8.0$ Hz, 1 H), 7.55 (t, $J = 8.0$ Hz, 2 H), 7.48 (t, $J = 8.0$ Hz, 1 H), 7.38 - 7.31 (m, 1 H), 2.60 (s, 3 H), 2.58 (s, 3 H)

***N*-(3-ethylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide**


[0312] Compound ID: 184




LCMS: m/z 322.2 $[M+H]^+$;

^1H NMR (400MHz, $\text{DMSO}-d_6$) δ 10.65 (s, 1 H), 7.71 (dd, $J = 1.0, 8.4$ Hz, 2 H), 7.57 - 7.50 (m, 2 H), 7.47 (s, 1 H), 7.44 (d, $J = 8.0$ Hz, 1 H), 7.37 - 7.29 (m, 1 H), 7.22 (t, $J = 7.6$ Hz, 1 H), 6.89 (d, $J = 7.6$ Hz, 1 H), 2.62 - 2.57 (m, 2 H), 2.56 (s, 3 H), 1.18 (t, $J = 7.6$ Hz, 3 H).


^1H NMR (400 MHz, $\text{CHLOROFORM}-d$) δ 8.02 (s, 1 H), 7.95 (d, $J = 8.0$ Hz, 1 H), 7.86 (br s, 1 H), 7.69 (d, $J = 7.6$ Hz, 1 H), 7.43 (t, $J = 8.0$ Hz, 1 H), 2.61 (s, 3 H), 2.22 (s, 3 H).

3-methyl-*N*-(naphthalen-1-yl)-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0313] Compound ID: 185****LCMS:** *m/z* 344.2 [M+H]⁺;

¹H NMR (400 MHz, MeOH) δ 8.28 - 8.30 (d, *J* = 8.0 Hz, 2H), 7.86 - 7.88 (d, *J* = 8.0 Hz, 1 H), 7.72 - 7.74 (d, *J* = 8.0 Hz, 2 H), 7.63 - 7.65 (d, *J* = 8.0 Hz, 1 H), 7.45 - 7.57 (m, 5 H), 7.36 (t, *J* = 8.0 Hz, 1 H), 3.31 (s, 1 H).

N*-benzyl-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0314] Compound ID: 186****LCMS:** *m/z* 308.0 [M+H]⁺;


¹H NMR (400 MHz, DMSO-*d*₆) δ 8.8 (s, 1 H), 7.68 - 7.71 (m, 2 H), 7.49 (t, *J* = 8.8, 2 H), 7.23 - 7.32 (m, 6 H), 4.54 (s, 2 H), 2.54 - 2.56 (m, 3 H).

1-isopropyl-3-methyl-5-oxo-*N*-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0315] Compound ID: 187****LCMS:** *m/z* 260.1 [M+H]⁺;

^1H NMR (400 MHz, DMSO- d_6) δ 10.84 (s, 1 H), 7.56 (d, J = 7.6, 2 H), 7.29 (t, J = 8.0, 2 H), 7.00 (t, J = 7.2, 1 H), 4.50 - 4.57 (m, 1 H), 2.45 (s, 3 H), 1.28 (d, J = 6.8 Hz, 6 H).

***N*-(4-methoxyphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0316] Compound ID: 188




LCMS: m/z 324.1 $[\text{M}+\text{H}]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 13.24 (s, 1 H), 10.52 (s, 1 H), 7.72 (d, J = 7.6 Hz, 2 H), 7.55 - 7.50 (m, 4 H), 7.35 - 7.32 (m, 1 H), 6.90 (d, J = 7.2 Hz, 2 H), 3.73 (s, 3 H), 2.55 (s, 3 H)

***N*-(4-fluorophenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0317] Compound ID: 189




LCMS: m/z 312.0 $[\text{M}+\text{H}]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ = 13.18 (s, 1 H), 10.68 (s, 1 H), 7.73 - 7.72 (m, 2 H), 7.71 - 7.64 (m, 2 H), 7.64 - 7.52 (m, 2 H), 7.40 - 7.30 (m, 1 H), 7.18 - 7.15 (m, 2 H), 2.55 (s, 3 H)

1,5-dimethyl-3-oxo-*N*,2-diphenyl-2,3-dihydro-1*H*-pyrazole-4-carboxamide

[0318] Compound ID: 190






LCMS: m/z 308.3 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ = 10.60 (s, 1 H), 7.59 (d, J = 8.0 Hz, 2 H), 7.48 (t, J = 7.6 Hz, 2 H), 7.38 (t, J = 7.6 Hz, 1 H), 7.29 (d, J = 7.6 Hz, 2 H), 7.23 (t, J = 7.6 Hz, 2 H), 6.98 (t, J = 7.2 Hz, 1 H), 3.27 (s, 3 H), 2.72 (s, 3 H).

3-methyl-5-oxo-1-phenyl-*N*-(pyridin-3-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0319] Compound ID: 191




LCMS: m/z 295.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ = 11.32 (s, 1 H), 8.83 (s, 1 H), 8.13 - 8.09 (m, 2 H), 8.01 (d, J = 8.0 Hz, 2 H), 7.35 (t, J = 8.0 Hz, 3 H), 7.07 (t, J = 7.6 Hz, 1 H), 2.34 (s, 3 H).

5-hydroxy-3-methyl-*N*-phenyl-1-(pyridin-2-yl)-1*H*-pyrazole-4-carboxamide


[0320] Compound ID: 192



LCMS: m/z 295.0 $[M+H]^+$;


^1H NMR (400MHz, DMSO- d_6) δ = 10.53 (s, 1 H) ,8.49 (d, J = 8.0 Hz, 1 H), 8.40 (d, J = 8.0 Hz, 1 H), 8.02 (d, J = 8.0 Hz, 1 H), 7.61 (d, J = 8.0 Hz, 2 H), 7.29-7.35 (m, 3 H), 7.03 (d, J = 8.0 Hz, 1 H), 2.52 (s, 3 H).

3-methyl-5-oxo-*N*-phenyl-1-(pyridin-4-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0321] Compound ID: 193


LCMS: m/z 295.2 $[M+H]^+$;

1H NMR (400MHz, DMSO- d_6) δ = 10.51 (s, 1 H), 8.65 - 8.41 (m, 4 H), 7.57 (d, J = 7.6 Hz, 2 H), 7.25 (t, J = 7.2 Hz, 2 H), 6.93 (t, J = 7.2 Hz, 1 H), 2.32 (s, 3 H).

1-benzyl-5-oxo-3-methyl-*N*-phenyl-1*H*-pyrazole-4-carboxamide**[0322] Compound ID: 194**


LCMS: m/z 308.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.80 (s, 1 H), 7.59 (d, J = 7.6 Hz, 2 H), 7.37 (t, J = 7.6 Hz, 2 H), 7.30 (t, J = 8.0 Hz, 3 H), 7.23 (d, J = 7.2 Hz, 2 H), 7.01 (t, J = 8.0 Hz, 1 H), 4.98 (s, 2 H), 2.41 (s, 3 H).


3-methyl-5-oxo-*N*-phenyl-1-(pyridin-3-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0323] Compound ID: 195**

LCMS: m/z 295.1 $[M+H]^+$;

1H NMR (400MHz, DMSO- d_6) δ 10.60 (s, 1 H), 9.38 (s, 1 H), 8.71 (d, J = 8.0 Hz, 1 H), 8.52 (dd, J = 1.2, 5.2 Hz, 1 H), 7.86 (dd, J = 5.2, 8.4 Hz, 1 H), 7.60 (d, J = 7.6 Hz, 2 H), 7.28 (t, J = 8.0 Hz, 2 H), 7.06 - 6.88 (m, 1 H), 2.42 (s, 3 H).


1,3-dimethyl-5-oxo-*N*-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0324] Compound ID: 196****LCMS:** m/z 232.2 $[M+H]^+$;

1H NMR (400MHz, DMSO- d_6) δ 10.80 (s, 1 H), 7.59 (d, J = 7.6 Hz, 2 H), 7.28-7.32 (m, 2 H), 6.99-7.03 (m, 1 H), 3.35 (s, 3 H), 2.43 (s, 3 H).

1-(4-methoxyphenyl)-3-methyl-5-oxo-*N*-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0325] Compound ID: 197****LCMS:** m/z 324.1 $[M+H]^+$;

1H NMR (400MHz, DMSO- d_6) δ 10.76 (s, 1 H), 7.59 - 7.61 (m, 4 H), 7.29 (t, J = 8.0 Hz, 2 H), 7.06 - 7.07 (m, 2 H), 7.00 - 7.05 (m, 1 H), 3.79 (s, 3 H), 2.48 (s, 3 H).

1H NMR (400 MHz, DMSO- d_6) δ 12.58 (s, 1 H), 8.72 (d, J = 7.2 Hz, 1 H), 7.90 (dd, J = 1.6, 8.0 Hz, 1 H), 7.46 - 7.34 (m, 1 H), 7.18 (t, J = 7.2 Hz, 2 H), 6.93 - 6.85 (m, 2 H), 6.79 (s, 3 H), 4.29 (m, 1 H), 3.88 - 3.69 (m, 1 H), 2.45 - 2.36 (m, 1 H), 2.04 - 1.90 (m, 2 H), 1.84 - 1.69 (m, 1 H), 1.68 - 1.60 (m, 1 H), 1.59 - 1.47 (m, 1 H).


5-hydroxy-3-methyl-1-(naphthalen-2-yl)-*N*-phenyl-1*H*-pyrazole-4-carboxamide**[0326] Compound ID: 198**

LCMS: m/z 366.0 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.73 (s, 1 H), 8.24 (s, 1 H), 8.07 (d, J = 8.8 Hz, 1 H), 8.05 - 7.94 (m, 3 H), 7.64 (d, J = 7.6 Hz, 2 H), 7.63 - 7.49 (m, 2 H), 7.32 (t, J = 8.0 Hz, 2 H), 7.03 (t, J = 7.2 Hz, 1 H), 2.58 (s, 3 H)

***N*,3-dimethyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0327] Compound ID: 199




LCMS: m/z 232.1 $[M+H]^+$;

^1H NMR (400 MHz, CHLOROFORM- d) δ 11.10 (s, 1 H), 7.96 (s, 1 H), 7.45 (m, 2 H), 7.37 (m, 2 H), 7.29 (m, 1 H), 2.78 (s, 3 H), 2.40 (s, 3 H).

***N*-isopropyl-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0328] Compound ID: 200




LCMS: m/z 260.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 12.83 (s, 1 H), 8.30 (s, 1 H), 7.70 (d, J = 7.6 Hz, 2 H), 7.47 (t, J = 8.0 Hz, 2 H), 7.27 (t, J = 7.2 Hz, 1 H), 4.00 (dt, J = 12.8, 6.4 Hz, 1 H), 2.46 (s, 3 H), 1.12 (d, J = 6.8 Hz, 6 H)

3-methyl-5-oxo-*N*-phenyl-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0329] Compound ID: 201






LCMS: m/z 362.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.56 (s, 1 H), 8.03 (d, J = 8.4 Hz, 2 H), 7.89 (d, J = 8.8 Hz, 2 H), 7.62 (dd, J = 8.8, 1.2 Hz, 2 H), 7.32 (t, J = 8.0 Hz, 2 H), 7.04 (t, J = 7.2 Hz, 1 H), 2.57 (s, 3 H)

1-(1,1-dioxido-2,3,4,5-tetrahydrothiophen-3-yl)-3-methyl-5-oxo-N-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide

[0330] Compound ID: 202




LCMS: m/z 336.0 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.54 (s, 1 H), 7.56 (d, J = 8.0 Hz, 2 H), 7.30 (t, J = 7.6 Hz, 2 H), 7.02 (t, J = 7.6 Hz, 1 H), 5.15 - 5.04 (m, 1 H), 3.58 - 3.52 (m, 1 H), 3.50 - 3.42 (m, 1 H), 3.36 - 3.20 (m, 2 H), 2.49 - 2.46 (m, 2 H), 2.44 (s, 3 H)

N-(4-acetylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide


[0331] Compound ID: 203



LCMS: m/z 336.2 $[M+H]^+$;


1H NMR (400 MHz, DMSO- d_6) δ 11.33 (s, 1 H), 7.95 - 7.85 (m, 4 H), 7.73 (d, J = 8.4 Hz, 2 H), 7.41 (t, J = 8.0 Hz, 2 H), 7.15 (t, J = 7.6 Hz, 1 H), 2.40 (s, 3 H)

N,3-dimethyl-5-oxo-N,1-diphenyl-4,5-dihydro-1H-pyrazole-4-carboxamide

[0332] Compound ID: 204


LCMS: m/z 308.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6 + D $_2$ O) δ 7.48 (d, J = 7.6 Hz, 2 H), 7.38 (t, J = 7.2 Hz, 2 H), 7.28 (t, J = 8.0 Hz, 2 H), 7.23 - 7.10 (m, 4 H), 3.31 (s, 3 H), 1.98 (s, 3 H)

N*-(4-hydroxyphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide*[0333] Compound ID: 205**


LCMS: m/z 310.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 13.07 (s, 1 H), 10.42 (s, 1 H), 9.17 (s, 1 H), 7.72 (d, J = 7.6 Hz, 2 H), 7.52 (d, J = 7.6 Hz, 2 H), 7.41 - 7.38 (m, 2 H), 7.38 - 7.31 (m, 1 H), 6.72 - 6.69 (m, 2 H), 2.53 (s, 3 H)


3-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamido)benzoate**[0334] Compound ID: 206**

LCMS: m/z 352.2 $[M+H]^+$;


1H NMR (400 MHz, DMSO- d_6) δ 11.03 (s, 1 H), 8.36 (s, 1 H), 7.83 (d, J = 6.8 Hz, 2 H), 7.76 (d, J = 8.8 Hz, 1 H), 7.59 (d, J = 7.2 Hz, 1 H), 7.48 - 7.42 (m, 3 H), 7.25 - 7.23 (m, 1 H), 3.86 (s, 3 H), 2.47 (s, 3 H).


N*-benzoyl-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0335] Compound ID: 207****LCMS:** *m/z* 322.1 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.42 (s, 1 H), 7.97 (d, *J* = 7.6 Hz, 2 H), 7.74 (d, *J* = 7.6 Hz, 2 H), 7.68 - 7.62 (m, 1 H), 7.61 - 7.55 (m, 2 H), 7.52 (t, *J* = 8.0 Hz, 2 H), 7.37 - 7.28 (m, 1 H), 2.52 (s, 3 H)

3-methyl-5-oxo-1-phenyl-*N*-(3-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0336] Compound ID: 208****LCMS:** *m/z* 362.0 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.95 (s, 1 H), 8.28 (s, 1 H), 7.72 (d, *J* = 8.0 Hz, 2 H), 7.67 (d, *J* = 8.4 Hz, 1 H), 7.57 - 7.50 (m, 3 H), 7.38 (d, *J* = 7.6 Hz, 1 H), 7.36 - 7.29 (m, 1 H), 2.55 (s, 3 H)

N*-(2,3-dihydro-1*H*-inden-5-yl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0337] Compound ID: 209**




LCMS: m/z 334.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.63 (s, 1 H), 7.75 (d, J = 7.6 Hz, 2 H), 7.58 (s, 1 H), 7.52 (t, J = 7.6 Hz, 2 H), 7.34 - 7.26 (m, 2 H), 7.14 (d, J = 8.0 Hz, 1 H), 2.87 - 2.79 (m, 4 H), 2.54 (s, 3 H), 2.06 - 1.97 (m, 2 H)

***N*-(3-chlorophenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0338] Compound ID: 210




LCMS: m/z 350.2 $[M+Na]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.84 (s, 1 H), 8.05 - 7.91 (m, 1 H), 7.79 - 7.65 (m, 2 H), 7.56 - 7.47 (m, 2 H), 7.36 - 7.26 (m, 3 H), 7.14 - 7.00 (m, 1 H), 2.54 (s, 3 H).

***N*-(3-methoxyphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**


[0339] Compound ID: 211



LCMS: m/z 324.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.71 (s, 1 H), 7.75 - 7.66 (m, 2 H), 7.52 (t, J = 7.6 Hz, 2 H), 7.39 (t, J = 2.4 Hz, 1 H), 7.36 - 7.29 (m, 1 H), 7.24 - 7.16 (m, 1 H), 7.08 - 7.04 (m, 1 H), 6.61 (dd, J = 1.6, 8.0 Hz, 1 H), 3.75 (s, 3 H), 2.54 (s, 3 H)


3-methyl-5-oxo-1-phenyl-*N*-(*m*-tolyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0340] Compound ID: 212

LCMS: m/z 308.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.72 (s, 1 H), 7.78 (d, J = 8.0 Hz, 2 H), 7.53 - 7.44 (m, 3 H), 7.40 (d, J = 8.0 Hz, 1 H), 7.27 (t, J = 8.0 Hz, 1 H), 7.17 (t, J = 7.6 Hz, 1 H), 6.83 (d, J = 7.6 Hz, 1 H), 2.53 (s, 3 H), 2.28 (s, 3 H)


3-methyl-5-oxo-1-phenyl-N-(3-(pyrazin-2-yl)phenyl)-4,5-dihydro-1H-pyrazole-4-carboxamide

[0341] Compound ID: 213

LCMS: m/z 336.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 11.81 (s, 1 H), 8.42 (d, J = 8.0 Hz, 1 H), 7.89 (dd, J = 1.2, 7.6 Hz, 1 H), 7.77 (d, J = 7.6 Hz, 2 H), 7.56 - 7.45 (m, 3 H), 7.27 (t, J = 7.2 Hz, 1 H), 7.19 - 7.10 (m, 1 H), 2.57 (s, 3H), 2.51 - 2.55 (m, 3 H)

3-methyl-5-oxo-1-phenyl-N-(pyridin-2-yl)-4,5-dihydro-1H-pyrazole-4-carboxamide

[0342] Compound ID: 214


LCMS: m/z 295.0 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 11.64 (s, 1 H), 8.27 (d, J = 4.4 Hz, 1 H), 8.11 - 8.00 (m, 1 H), 7.95 - 7.76 (m, 3 H), 7.45 (t, J = 7.6 Hz, 2 H), 7.22 (t, J = 7.6 Hz, 1 H), 7.12 (t, J = 6.8 Hz, 1 H),

2.46 (s, 3 H).

***N*-(3-bromophenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0343] Compound ID: 215




LCMS: m/z 371.9 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ = 10.84 (s, 1 H), 8.14 (s, 1 H), 7.74 (d, J = 8.0 Hz, 2 H), 7.53 (t, J = 7.6 Hz, 2 H), 7.40 (d, J = 7.6 Hz, 1 H), 7.35 - 7.19 (m, 3 H), 2.54 (s, 3 H).

3-methyl-5-oxo-1-phenyl-*N*-(pyridin-4-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0344] Compound ID: 216




LCMS: m/z 295.0 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 12.58 (s, 1 H), 8.49 (d, J = 6.8 Hz, 2 H), 8.14 - 7.97 (m, 4 H), 7.32 (t, J = 7.6 Hz, 2 H), 7.03 (t, J = 7.6 Hz, 1 H), 2.27 (s, 3 H)

^{13}C NMR (101 MHz, DMSO- d_6) δ 165.63, 163.57, 154.18, 149.06, 142.29, 141.04, 128.79, 122.97, 118.23, 113.47, 93.82, 15.84

3-methyl-5-oxo-1-phenyl-*N*-(thiazol-2-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0345] Compound ID: 217






LCMS: m/z 301.2 $[M+H]^+$;

^1H NMR (400 MHz, METHANOL- d_4) δ 7.65 (d, J = 7.6 Hz, 2 H), 7.54 (t, J = 8.0 Hz, 2H), 7.47 (d, J = 3.6 Hz, 1H), 7.43 - 7.34 (m, 1 H), 7.16 (d, J = 3.6 Hz, 1 H), 2.63 (s, 3 H).

(2S)-2-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamido)propanoic acid

[0346] Compound ID: 218




LCMS: m/z 290.4 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 12.72 (s, 1 H), 8.77 (d, J = 6.4 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2 H), 7.49 (t, J = 8.0 Hz, 2 H), 7.28 (t, J = 8.0 Hz, 1 H), 4.41 (m, 1 H), 2.47 (s, 3 H), 1.34 (d, J = 7.2 Hz, 3 H).

N-(1H-benzo[d]imidazol-5-yl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide


[0347] Compound ID: 219



LCMS: m/z 334.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ = 11.05 (d, J = 9.2 Hz, 1H), 9.49 (d, J = 14.8 Hz, 1H), 8.51 (d, J = 1.6 Hz, 1 H), 7.86 - 7.70 (m, 3 H), 7.59 - 7.44 (m, 3 H), 7.33 (t, J = 7.2 Hz, 1 H), 2.59 (d, J = 4.0 Hz, 3H).


N-(3-(dimethylcarbamoyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide

[0348] Compound ID: 220

LCMS: m/z 365.3 $[M+H]^+$;

1H NMR (400MHz, DMSO- d_6) δ 10.81 (s, 1 H), 7.79 (t, J = 1.6 Hz, 1 H), 7.76 - 7.69 (m, 2 H), 7.56 - 7.47 (m, 3 H), 7.37 (t, J = 8.0 Hz, 1 H), 7.35 - 7.29 (m, 1 H), 7.04 (d, J = 7.6 Hz, 1 H), 3.08 - 2.84 (m, 6 H), 2.54 (s, 3 H).


3-methyl-1-(1-methylpiperidin-4-yl)-5-oxo-*N*-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0349] Compound ID: 221

LCMS: m/z 315.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 11.19 (s, 1 H), 8.16 (s, 1 H), 7.52 (d, J = 7.6 Hz, 2 H), 7.19 (t, J = 7.6 Hz, 2 H), 6.84 (t, J = 7.6 Hz, 1 H), 4.25 - 4.15 (m, 1 H), 3.34 - 3.33 (m, 2 H), 2.93 (t, J = 12.0 Hz, 2 H), 2.68 (s, 3 H), 2.15 (s, 3 H), 2.14 - 2.03 (m, 2 H), 1.78 (d, J = 11.7 Hz, 2 H)

***N*-(3-hydroxyphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**


[0350] Compound ID: 222

LCMS: m/z 310.2 $[M+H]^+$;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.76 (s, 1 H), 9.28 (s, 1 H), 7.86 (d, *J* = 7.6 Hz, 2 H), 7.44 (t, *J* = 7.6 Hz, 2 H), 7.25 (t, *J* = 2.0 Hz, 1 H), 7.23 - 7.17 (m, 1 H), 7.08 - 7.02 (m, 1 H), 6.92 - 6.87 (m, 1 H), 6.39 (dd, *J* = 1.6, 7.2 Hz, 1 H), 2.45 (s, 3 H).

***N*-(3-isopropylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0351] Compound ID: 100




LCMS: *m/z* 336.1 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.68 (s, 1 H), 7.74 (d, *J* = 7.6 Hz, 2 H), 7.56 - 7.41 (m, 4 H), 7.37 - 7.29 (m, 1 H), 7.23 (t, *J* = 7.6 Hz, 1 H), 6.92 (d, *J* = 8.0 Hz, 1 H), 2.95 - 2.80 (m, 1 H), 2.55 (s, 3 H), 1.21 (d, *J* = 6.8 Hz, 6 H).

3-methyl-5-oxo-1-phenyl-*N*-(3-(thiophen-2-yl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide


[0352] Compound ID: 101



LCMS: *m/z* 376.2 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.81 (s, 1 H), 8.03 (s, 1 H), 7.74 (d, *J* = 7.6 Hz, 2 H), 7.58 - 7.45 (m, 5 H), 7.37 - 7.29 (m, 3 H), 7.14 (dd, *J* = 4.0, 5.2 Hz, 1 H), 2.56 (s, 3 H).


***N*-([1,1'-biphenyl]-3-yl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0353] Compound ID: 102

LCMS: m/z 370.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.84 (s, 1 H), 7.99 (s, 1 H), 7.75 (d, J = 7.7 Hz, 2 H), 7.65 (d, J = 7.4 Hz, 2 H), 7.56 (d, J = 8.8 Hz, 1 H), 7.54 - 7.45 (m, 4 H), 7.43 - 7.35 (m, 2 H), 7.34 - 7.28 (m, 2 H), 2.55 (s, 3 H)


***N*-(3-(methoxymethyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0354] Compound ID: 103

LCMS: m/z 338.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 11.18 (s, 1 H), 8.13 (s, 1 H), 8.06 (s, 2 H), 7.60 (s, 1 H), 7.49 (d, J = 8.0 Hz, 1 H), 7.30 (s, 2 H), 7.20 (t, J = 7.6 Hz, 1 H), 7.00 (s, 1 H), 6.84 (d, J = 7.6 Hz, 1 H), 4.37 (s, 2 H), 3.29 (s, 3 H), 2.28 (s, 3 H).

3-methyl-5-oxo-1-phenyl-*N*-(3-(pyridin-4-yl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0355] Compound ID: 104




LCMS: m/z 371.3 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.99 (s, 1 H), 8.71 (d, J = 5.2 Hz, 2 H), 8.16 (d, J = 13.8 Hz, 1 H), 7.88 - 7.78 (m, 4 H), 7.77 - 7.65 (m, 1 H), 7.53 - 7.45 (m, 4 H), 7.27 (t, J = 7.2 Hz, 1 H), 2.49 (s, 3 H).

***N*-(3-(aminomethyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0356] Compound ID: 223




LCMS: m/z 323.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.81 (s, 1 H), 8.35 (br s, 2 H), 7.80 - 7.75 (m, 2 H), 7.75 - 7.69 (m, 2 H), 7.52 (t, J = 8.0 Hz, 2 H), 7.41 - 7.29 (m, 2 H), 7.15 (d, J = 7.6 Hz, 1 H), 4.00 (d, J = 5.6 Hz, 2 H), 2.57 (s, 3 H).


***N*-(4-(*N,N*-dimethylsulfamoyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0357] Compound ID: 105




LCMS: m/z 401.2 $[M+H]^+$;


1H NMR (400 MHz, METHANOL- d_4) δ 8.16 (s, 1 H), 7.87 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 7.8 Hz, 2 H), 7.71 (d, J = 8.8 Hz, 2H), 7.43 (t, J = 8.0 Hz, 2 H), 7.27 - 7.18 (m, 1 H), 2.68 (s, 6 H), 2.47 (s, 3 H).

3-methyl-5-oxo-1-phenyl-*N*-(tetrahydrofuran-3-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0358] Compound ID: 106****LCMS:** m/z 288.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 8.62 (br s, 1 H), 7.71 (d, J = 7.6 Hz, 2 H), 7.48 (t, J = 7.6 Hz, 2 H), 7.28 (t, J = 7.6 Hz, 1 H), 4.43 (s, 1 H), 3.85 - 3.77 (m, 2 H), 3.76 - 3.69 (m, 1 H), 3.49 (dd, J = 3.6, 8.8 Hz, 1 H), 2.47 (s, 3 H), 2.23 - 2.13 (m, 1 H), 1.78 - 1.68 (m, 1 H)

N*-(3-(1*H*-imidazol-2-yl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0359] Compound ID: 107****LCMS:** m/z 360.1 $[M+H]^+$;

1H NMR (400 MHz, METHANOL- d_4) δ 8.19 (s, 1 H), 7.83 - 7.74 (d, J = 8.4 Hz, 3 H), 7.57 - 7.49 (m, 4 H), 7.43 (t, J = 7.6 Hz, 2 H), 7.22 (t, J = 7.2 Hz, 1 H), 2.47 (s, 3 H)


N*-(3-(furan-2-yl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0360] Compound ID: 108**

LCMS: m/z 360.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.82 (s, 1 H), 8.10 - 7.96 (m, 1 H), 7.86 - 7.67 (m, 3 H), 7.61 - 7.43 (m, 3 H), 7.41 - 7.34 (m, 2 H), 7.33 - 7.27 (m, 1 H), 6.94 (d, J = 3.2 Hz, 1 H), 6.60 (dd, J = 1.6, 3.2 Hz, 1 H), 2.54 (s, 3 H)

3-methyl-5-oxo-1-phenyl-*N*-(3-(pyrazin-2-yl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0361] Compound ID: 109




LCMS: m/z 372.1 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.86 (s, 1 H), 9.24 (d, J = 1.6 Hz, 1 H), 8.74 - 8.73 (m, 1 H), 8.63 (d, J = 2.4 Hz, 1 H), 8.44 (t, J = 2.0 Hz, 1 H), 7.81 (d, J = 7.6 Hz, 1 H), 7.77 - 7.73 (m, 3 H), 7.56 - 7.47 (m, 3 H), 7.34 (t, J = 7.6 Hz, 1H), 2.58 (s, 3 H).


1-(4-(*N,N*-dimethylsulfamoyl)phenyl)-3-methyl-5-oxo-*N*-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0362] Compound ID: 110




LCMS: m/z 401.2 $[M+H]^+$;


^1H NMR (400 MHz, DMSO- d_6) δ = 11.00 (s, 1 H), 8.39 (d, J = 8.8 Hz, 2 H), 7.66 (d, J = 8.8 Hz, 2 H), 7.59 (d, J = 7.6 Hz, 2 H), 7.23 (t, J = 7.6 Hz, 2 H), 6.89 (t, J = 7.2 Hz, 1 H), 2.58 (s, 6 H), 2.27 (s, 3 H).

N*-(3-(hydroxymethyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0363] Compound ID: 111****LCMS:** *m/z* 324.1 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.69 (s, 1 H), 7.72 (d, *J* = 7.6 Hz, 2 H), 7.57 - 7.54 (m, 1 H), 7.52 - 7.50 (m, 3 H), 7.34 - 7.25 (m, 1 H), 7.25 - 7.23 (m, 1 H), 6.98 (d, *J* = 7.6 Hz, 1 H), 4.48 (s, 2 H), 2.55 (s, 3 H).

3-methyl-5-oxo-1-phenyl-*N*-(tetrahydro-2*H*-pyran-4-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0364]****Compound ID: 112****LCMS:** *m/z* 302.2 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.47 (s, 1 H), 7.75 (d, *J* = 8.0 Hz, 2 H), 7.44 (t, *J* = 7.6 Hz, 2 H), 7.23 (t, *J* = 7.2 Hz, 1 H), 3.96 - 3.92 (m, 1 H), 3.83 - 3.80 (m, 2 H), 3.41 (t, *J* = 10.4 Hz, 2 H), 2.43 (s, 3 H), 1.80 (d, *J* = 10.8 Hz, 2 H), 1.45 - 1.37 (m, 2 H).


Ethyl 3-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamido)benzoate**[0365] Compound ID: 113**

LCMS: m/z 366.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.94 (s, 1 H), 8.31 (t, J = 2.0 Hz, 1 H), 7.81 - 7.76 (m, 3 H), 7.62 (d, J = 7.6 Hz, 1 H), 7.52 - 7.43 (m, 3 H), 7.29 (t, J = 7.6 Hz, 1 H), 4.33 (q, J = 7.2 Hz, 2 H), 2.52 (s, 3 H), 1.38 (t, J = 7.2 Hz, 3 H).

***N*-(3-butyrylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0366] Compound ID: 114




LCMS: m/z 364.1 $[M+H]^+$;

^1H NMR (400MHz, DMSO- d_6) δ 10.93 (s, 1 H), 8.25 (t, J = 1.6 Hz, 1 H), 7.82 (dd, J = 1.2, 8.0 Hz, 3 H), 7.62 (d, J = 8.0 Hz, 1 H), 7.51 - 7.44 (m, 3 H), 7.32 - 7.26 (m, 1 H), 2.99 (t, J = 7.2 Hz, 2H), 2.52 (s, 3 H), 1.64 (q, J = 7.2 Hz, 2 H), 0.94 (t, J = 8.0 Hz, 3 H).

***N*-(3-(tert-butyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**


[0367] Compound ID: 115



LCMS: m/z 350.3 $[M+H]^+$;


^1H NMR (400 MHz, DMSO- d_6) δ 10.72 (s, 1H), 7.76 (d, J = 7.6 Hz, 2 H), 7.58 (s, 1 H), 7.50 - 7.45 (m, 3 H), 7.27 - 7.21 (m, 1 H), 7.20 (t, J = 7.6 Hz, 1 H), 7.03 (d, J = 7.6 Hz, 1 H), 2.49 (s, 3 H), 1.27 (s, 9 H).

3-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamido)benzoic acid

[0368] Compound ID: 116


LCMS: m/z 338.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 13.12 (s, 1 H), 10.84 (s, 1 H), 8.31 (s, 1 H), 7.79 - 7.70 (m, 3 H), 7.64 - 7.59 (m, 1 H), 7.57 - 7.49 (m, 2 H), 7.44 (s, 1 H), 7.33 (s, 1 H), 2.56 (s, 3 H).

3-methyl-5-oxo-1-phenyl-N-(3-propionylphenyl)-4,5-dihydro-1H-pyrazole-4-carboxamide**[0369] Compound ID: 117**

LCMS: m/z 350.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.86 (s, 1 H), 8.21 (d, J = 1.6 Hz, 1 H), 7.80 (d, J = 7.6 Hz, 1 H), 7.74 (d, J = 7.6 Hz, 2 H), 7.60 (d, J = 8.0 Hz, 1 H), 7.49 (t, J = 7.6 Hz, 2 H), 7.44 - 7.42 (d, J = 8.0 Hz, 1 H), 7.26 (d, J = 7.6 Hz, 1 H), 3.05 (q, J = 7.2 Hz, 2 H), 2.54 (s, 3 H), 1.10 (t, J = 7.2 Hz, 3 H).

3-methyl-5-oxo-N-(3-pentylphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide**[0370] Compound ID: 118**


LCMS: m/z 364.3 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ = 10.66 (s, 1 H), 7.74 (d, J = 8.0 Hz, 2 H), 7.52 - 7.51 (m, 2 H), 7.51 - 7.49 (m, 2 H), 7.45 - 7.43 (m, 1 H), 7.24 - 7.15 (t, J = 6.8 Hz, 1 H), 6.88 - 6.81 (J =

7.2 Hz, 1 H), 2.57 - 2.52 (m, 5 H), 1.62 - 1.51 (m, 2 H), 1.35 - 1.23 (m, 4 H), 0.86 (s, 3 H).

***N*-(3-cyclopropylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0371] Compound ID: 119




LCMS: m/z 334.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.64 (s, 1 H), 7.73 (d, J = 7.6 Hz, 2 H), 7.54 - 7.49 (m, 2 H), 7.36 - 7.32 (m, 3 H), 7.17 (t, J = 8.0 Hz, 1 H), 6.75 (d, J = 7.6 Hz, 1 H), 2.54 (s, 3 H), 1.90 - 1.89 (m, 1 H), 0.95 - 0.92 (m, 2 H), 0.66 - 0.64 (m, 2 H).

4-(4-((3-acetylphenyl)carbamoyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-1-yl)benzoic acid

[0372] Compound ID: 120




LCMS: m/z 380.2 $[M+H]^+$;

^1H NMR (400 MHz, METHANOL- d_4) δ 8.35 (s, 1 H), 8.09 - 8.01 (m, 4 H), 7.83 - 7.81 (m, 1 H), 7.67 (d, J = 4.4 Hz, 1 H), 7.47 - 7.44 (m, 1 H), 2.62 (s, 3 H), 2.53 (s, 3 H).

3-methyl-5-oxo-1-phenyl-*N*-(4-piperidyl)-4*H*-pyrazole-4-carboxamide

[0373] Compound ID: 121




LCMS: m/z 301.2 $[M+H]^+$;

^1H NMR (400MHz, METHANOL- d_4) δ = 8.36 (s, 1 H), 7.73 (d, J = 8.0 Hz, 2 H), 7.40 (t, J = 7.6 Hz, 2 H), 7.28 - 7.05 (m, 1 H), 4.24 - 3.98 (m, 1 H), 3.40 - 3.34 (m, 2 H), 3.18 - 3.07 (m, 2 H), 2.40 (s, 3 H), 2.25 - 2.06 (m, 2 H), 1.87 - 1.64 (m, 2 H)

3-methyl-5-oxo-*N*-(3-oxo-1,3-dihydroisobenzofuran-5-yl)-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0374] Compound ID: 122




LCMS: m/z 350.0 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ = 10.99 (s, 1 H), 8.37 (s, 1 H), 7.80 - 7.77 (m, 3 H), 7.75 - 7.69 (m, 1 H), 7.54 - 7.49 (m, 2 H), 7.38 - 7.31 (m, 1 H), 5.36 (s, 2 H), 2.54 (s, 3 H).

3-(4-((3-acetylphenyl)carbamoyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-1-yl)benzoic acid

[0375] Compound ID: 123




LCMS: m/z 380.0 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.82 (s, 1 H), 8.38 (s, 1 H), 8.26 (t, J = 2.0 Hz, 1 H), 8.10 - 8.04 (m, 1 H), 7.85 (d, J = 8.0 Hz, 2 H), 7.64 - 7.62 (m, 2 H), 7.47 (d, J = 8.0 Hz, 1 H), 2.59 (s, 3 H), 2.56 (s, 3 H)

3-methyl-*N*-(3-(oxazol-2-yl)phenyl)-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0376] Compound ID: 124




LCMS: m/z 361.1 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.95 (s, 1 H), 8.47 (s, 1 H), 8.23 (s, 1 H), 7.78 (d, J = 8.0 Hz, 2 H), 7.62 (dd, J = 7.6, 18.4 Hz, 2 H), 7.53 - 7.44 (m, 3 H), 7.39 (s, 1 H), 7.32 - 7.26 (m, 1 H), 2.53 (s, 3 H)

***N*-(3-ethylphenyl)-3-methyl-5-oxo-1-(pyridin-4-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0377] Compound ID: 125





LCMS: m/z 323.1 $[M+H]^+$;

^1H NMR (400 MHz, METHANOL- d_4) δ 8.46 - 8.60 (m, 4 H), 7.47 (s, 1 H), 7.41 (d, J = 8.0 Hz, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 6.89 (d, J = 7.6 Hz, 1 H), 2.64 (q, J = 7.6 Hz, 2 H), 2.44 (s, 3 H), 1.25 (t, J = 7.6 Hz, 3 H)

***N*-(3-ethylphenyl)-5-oxo-1,3-diphenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0378] Compound ID: 126






LCMS: m/z 384.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 11.00 - 10.73 (s, 1 H), 7.84 (d, J = 7.6 Hz, 4 H), 7.59 - 7.46 (m, 6 H), 7.44 - 7.39 (m, 1 H), 7.38 - 7.33 (m, 1 H), 7.25 - 7.15 (m, 1 H), 6.88 (d, J = 8.0 Hz, 1 H), 2.57 (d, J = 7.6 Hz, 2 H), 1.17 (t, J = 7.6 Hz, 3H).

***N*-(3-ethylphenyl)-3-methyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0379] Compound ID: 127




LCMS: m/z 390.2 $[M+H]^+$;

^1H NMR (400 MHz, CHLOROFORM- d) δ 7.83 (s, 2 H), 7.65 (s, 2 H), 7.39 - 7.29 (m, 2 H), 7.22 (s, 1 H), 6.98 (d, J = 7.2 Hz, 1 H), 2.62 (d, J = 7.2 Hz, 2 H), 2.54 (s, 3 H), 1.22 (t, J = 7.6 Hz, 3 H).


***N*-(3-ethylphenyl)-3-isopropyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0380] Compound ID: 128




LCMS: m/z 350.3 $[M+H]^+$;


^1H NMR (400 MHz, DMSO- d_6) δ 10.90 (s, 1 H), 7.67 (d, J = 8.0 Hz, 2 H), 7.53 (t, J = 8.0 Hz, 2 H), 7.47 (s, 1 H), 7.42 (d, J = 8.0 Hz, 1 H), 7.34 (d, J = 8.0 Hz, 1 H), 7.20 (t, J = 7.6 Hz, 1 H), 6.88 (d, J = 8.0 Hz, 1 H), 3.95 - 3.91 (m, 1 H), 2.59 - 2.51 (m, 2 H), 1.32 (d, J = 7.2 Hz, 6 H), 1.18 (t, J = 7.6 Hz, 3 H).

3-benzyl-*N*-(3-ethylphenyl)-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**[0381] Compound ID: 129****LCMS:** *m/z* 398.3 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.74 (s, 1 H), 7.72 (d, *J* = 8.0 Hz, 2 H), 7.54 (t, *J* = 8.0 Hz, 2 H), 7.45 - 7.43 (m, 4 H), 7.43 - 7.41 (m, 3 H), 7.34 - 7.32 (m, 2 H), 6.88 (d, *J* = 7.8 Hz, 1 H), 4.36 (s, 2 H), 2.59 (q, *J* = 7.8 Hz, 2 H), 1.17 (t, *J* = 7.5 Hz, 3 H).

N*-(3-ethylphenyl)-5-oxo-1-phenyl-3-(trifluoromethyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0382] Compound ID: 130****LCMS:** *m/z* 376.2 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 11.03 (s, 1 H), 8.02 (d, *J* = 8.0 Hz, 2 H), 7.49 (s, 1 H), 7.42 - 7.40 (m, 3 H), 7.24 - 7.13 (m, 2 H), 6.81 - 6.79 (d, *J* = 8.0 Hz, 1 H), 2.53 - 2.61 (m, 2 H), 1.18 (t, *J* = 7.6 Hz, 3 H).


N*-(3-((dimethylamino)methyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0383] Compound ID: 131**

LCMS: m/z 351.2 $[M+H]^+$;

^1H NMR (400 MHz, METHANOL- d_4) δ 7.80 - 7.77 (m, 3 H), 7.65 - 7.58 (m, 1 H), 7.44 - 7.36 (m, 3 H), 7.23 - 7.20 (m, 1 H), 7.07 (d, J = 7.6 Hz, 1 H), 4.21 (s, 2 H), 2.80 (s, 6 H), 2.45 (s, 3 H)

3-methyl-5-oxo-1-phenyl-*N*-(3-(pyrimidin-5-yl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0384] Compound ID: 132




LCMS: m/z 372.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.83 (s, 1 H), 9.20 (s, 1 H), 9.12 (s, 2 H), 8.01 (s, 1 H), 7.74 (d, J = 7.6 Hz, 1 H), 7.74 - 7.72 (m, 2 H), 7.55 - 7.51 (t, J = 8.0 Hz, 2 H), 7.49 - 7.47 (m, 2 H), 7.47-7.34 (m, 1 H), 2.58 (s, 3 H).

***N*-(3-ethylphenyl)-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0385] Compound ID: 133




LCMS: m/z 308.0 $[M+H]^+$;

^1H NMR (400MHz, DMSO- d_6) δ 10.31 (s, 1 H), 8.28 (s, 1 H), 7.78 (d, J = 8.4 Hz, 2 H), 7.53 - 7.47 (m, 4 H), 7.32 - 7.29 (m, 1 H), 7.28 - 7.23 (m, 1 H), 6.90 (d, J = 7.6 Hz, 1 H), 2.57 (q, J = 7.6 Hz, 2 H), 1.19 (t, J = 7.6 Hz, 3 H)

1-(4-ethoxyphenyl)-*N*-(3-ethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0386] Compound ID: 134




LCMS: m/z 285.1 [M-80];

^1H NMR (400 MHz, DMSO- d_6) δ 8.51 (s, 1 H), 8.43 (s, 1 H), 7.33 (d, J = 8.8 Hz, 2 H), 7.30 (s, 1 H), 7.24 - 7.19 (m, 1 H), 7.16 (t, J = 7.6 Hz, 1 H), 6.84 (d, J = 7.2 Hz, 2 H), 6.80 (d, J = 7.6 Hz, 1 H), 3.97 (q, J = 6.8 Hz, 2 H), 2.56 (q, J = 7.6 Hz, 2 H), 2.52 (s, 3 H), 1.30 (t, J = 6.8 Hz, 3 H), 1.17 (t, J = 7.6 Hz, 3 H).

ethyl 4-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamido)picolinate

[0387] Compound ID: 135




LCMS: m/z 367.0 [M+H] $^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 11.81 (s, 1 H), 8.51 (d, J = 6.0 Hz, 1 H), 8.44 (s, 1 H), 7.87 (d, J = 7.6 Hz, 3 H), 7.44 (t, J = 7.6 Hz, 2 H), 7.20 (t, J = 7.6 Hz, 1 H), 4.39 (q, J = 6.8 Hz, 2 H), 2.43 (s, 3 H), 1.36 (t, J = 6.8 Hz, 3 H)

3-ethyl-*N*-(3-ethylphenyl)-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0388] Compound ID: 136






LCMS: m/z 336.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.74 (s, 1 H), 7.72 (d, J = 8.0 Hz, 2 H), 7.53 (t, J = 7.6 Hz, 2 H), 7.48 (s, 1 H), 7.43 (d, J = 7.6 Hz, 1 H), 7.38 - 7.30 (m, 1 H), 7.21 (t, J = 7.6 Hz, 1 H), 6.89 (d, J = 7.6 Hz, 1 H), 2.97 (q, J = 7.6 Hz, 2H), 2.59 (q, J = 7.6 Hz, 2 H), 1.28 (t, J = 7.6 Hz, 3H), 1.18 (t, J = 7.6 Hz, 3 H).

***N*-(3-ethylphenyl)-5-oxo-1-phenyl-3-(pyridin-4-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0389] Compound ID: 137




LCMS: m/z 385.3 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 11.79 (s, 1 H), 8.81 (q, J = 6.4 Hz, 4 H), 8.21 (d, J = 7.6 Hz, 2 H), 7.49-7.40 (m, 4 H), 7.18 (t, J = 7.6 Hz, 2 H), 6.81 (d, J = 7.6 Hz, 1 H), 2.58 (q, J = 7.6 Hz, 2 H), 1.19 (t, J = 7.6 Hz, 3 H).


***N*-(3-ethylphenyl)-1-(4-methoxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0390] Compound ID: 138




LCMS: m/z 352.0 $[M+H]^+$;


^1H NMR (400 MHz, CHLOROFORM- d) δ 7.39 (s, 1H), 7.31 (d, J = 7.6 Hz, 3 H), 7.21 (t, J = 7.6 Hz, 1 H), 6.94 (d, J = 7.2 Hz, 1 H), 6.81 (d, J = 7.2 Hz, 2 H), 3.74 (s, 3 H), 2.62 (q, J = 7.2 Hz, 2 H), 2.41 (s, 3H), 1.22 (t, J = 7.6 Hz, 3 H).


N*-(3-(*N,N*-dimethylsulfamoyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0391] Compound ID: 139****LCMS:** *m/z* 401.0 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98 (s, 1 H), 8.26 (t, *J* = 1.6 Hz, 1 H), 7.73 (d, *J* = 8.0 Hz, 3 H), 7.58 (t, *J* = 7.6 Hz, 1 H), 7.53 (t, *J* = 8.0 Hz, 2 H), 7.39 (d, *J* = 8.0 Hz, 1 H), 7.36 - 7.29 (m, 1 H), 2.63 (s, 6 H), 2.55 (s, 3 H).

N*-(3-propylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0392] Compound ID: 140****LCMS:** *m/z* 336.1 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.70 (s, 1 H), 7.76 (d, *J* = 7.6 Hz, 2 H), 7.51 (t, *J* = 8.0 Hz, 2 H), 7.46 (s, 1 H), 7.43 (d, *J* = 8.0 Hz, 1 H), 7.30 (t, *J* = 7.6 Hz, 1 H), 7.20 (t, *J* = 7.6 Hz, 1 H), 6.86 (d, *J* = 7.6 Hz, 1 H), 2.55 (s, 2 H), 2.53 (s, 3 H), 1.64 - 1.54 (m, 2 H), 0.90 (t, *J* = 7.6 Hz, 3 H).

N*-(3-(1,1-difluoroethyl)phenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide*[0393] Compound ID: 141**




LCMS: m/z 358.1 $[M+H]^+$;

1H NMR (400MHz, DMSO- d_6) δ 10.90 (s, 1 H), 7.95 (s, 1 H), 7.76 (d, J = 7.6 Hz, 2 H), 7.62 (d, J = 8.0 Hz, 1 H), 7.51 (t, J = 7.6 Hz, 2 H), 7.42 (t, J = 8.0 Hz, 1 H), 7.30 (t, J = 7.6 Hz, 1 H), 7.21 (d, J = 8.0 Hz, 1 H), 2.53 (s, 3 H), 1.96 (t, J = 18.8 Hz, 3 H)

***N*-(3-ethylphenyl)-1-(4-isopropoxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0394] Compound ID: 142




LCMS: m/z 380.3 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.88 (s, 1 H), 7.69 (s, 2 H), 7.45 (s, 1 H), 7.41 (d, J = 8.0 Hz, 1 H), 7.17 (t, J = 7.6 Hz, 1 H), 7.01 - 6.94 (m, 2H), 6.82 (d, J = 7.2 Hz, 1 H), 4.61 (td, J = 5.6, 11.2 Hz, 1 H), 2.62 - 2.53 (q, J = 7.6 Hz, 2 H), 2.42 (s, 3 H), 1.27 (d, J = 6.0 Hz, 6 H), 1.18 (t, J = 7.6 Hz, 3 H)

1-(4-(cyclopropylmethoxy)phenyl)-*N*-(3-ethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0395] Compound ID: 143




LCMS: m/z 392.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.77 (s, 1 H), 7.61 (d, J = 9.2 Hz, 2 H), 7.46 (s, 1 H), 7.42 (d, J = 8.0 Hz, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 7.03 (d, J = 9.2 Hz, 2 H), 6.86 (d, J = 7.6 Hz, 1 H), 3.85 (d, J = 6.8 Hz, 2 H), 2.58 (q, J = 7.6 Hz, 2 H), 2.48 (s, 3 H), 1.28-1.21 (m, 1 H), 1.18 (t, J = 7.6 Hz, 3 H), 0.63 - 0.54 (m, 2 H), 0.38 - 0.30 (m, 2 H).

1-(4-acetamidophenyl)-*N*-(3-ethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0396] Compound ID: 144




LCMS: m/z 379.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.70 (s, 1 H), 10.07 (s, 1 H), 7.69 (d, J = 8.0 Hz, 2 H), 7.62 (d, J = 8.8 Hz, 2 H), 7.46 (s, 1 H), 7.42 (d, J = 8.0 Hz, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 6.87 (d, J = 7.2 Hz, 1 H), 2.58 (q, J = 8.0 Hz, 2 H), 2.51 (s, 3 H), 2.06 (s, 3 H), 1.17 (t, J = 7.6 Hz, 3 H)

3-methyl-5-oxo-*N*-(3-(2-oxopropyl)phenyl)-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0397] Compound ID: 145




LCMS: m/z 350.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.71 (s, 1 H), 7.74 (d, J = 8.0 Hz, 2 H), 7.54 - 7.49 (t, J = 7.2 Hz, 3 H), 7.47 (s, 1 H), 7.31 (t, J = 7.6 Hz, 1 H), 7.25 (t, J = 7.6 Hz, 1 H), 6.86 (d, J = 7.6 Hz, 1 H), 3.74 (s, 2 H), 2.54 (s, 3 H), 2.13 (s, 3 H).

***N*-(3-cyclopentylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0398]






Compound ID: 146

LCMS: m/z 362.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.65 (s, 1 H), 7.79 - 7.68 (d, J = 7.8 Hz, 2 H), 7.55 - 7.51 (m, 3 H), 7.40 (d, J = 8.0 Hz, 1 H), 7.33 (d, J = 7.6 Hz, 1 H), 7.21 (t, J = 8.0 Hz, 1 H), 6.93 (d, J = 7.6 Hz, 1 H), 2.99 - 2.90 (m, 1 H), 2.55 (s, 3 H), 2.04 - 1.97 (m, 2 H), 1.82 - 1.71 (m, 2 H), 1.69 - 1.59 (m, 2 H), 1.58 - 1.48 (m, 2 H).

***N*-(3-isobutylphenyl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide**

[0399] Compound ID: 147




LCMS: m/z 350.1 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.70 (s, 1 H), 7.76 (d, J = 8.0 Hz, 2 H), 7.51 (d, J = 7.6 Hz, 2 H), 7.49 - 7.42 (m, 2 H), 7.30 - 7.25 (m, 1 H), 7.22 - 7.20 (m, 1 H), 6.83 - 6.80 (m, 1 H), 2.67 (s, 3 H), 2.42 (d, J = 7.2 Hz, 2 H), 1.85 - 1.81 (m, 1 H), 0.87 (d, J = 6.8 Hz, 6 H)

***N*-(3-(1H-imidazol-2-yl)phenyl)-3-methyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazole-4-carboxamide**

[0400] Compound ID: 148




LCMS: m/z 428.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 11.09 (s, 1 H), 8.26 (s, 1 H), 8.18 (d, J = 8.4 Hz, 2 H), 8.01 (d, J = 8.0 Hz, 1 H), 7.81 (s, 3 H), 7.80 (s, 1 H), 7.67 (d, J = 7.6 Hz, 1 H), 7.56 (t, J = 8.0 Hz, 1 H), 2.48 (s, 3 H).

***N*-(3-(1*H*-imidazol-2-yl)phenyl)-3-methyl-5-oxo-1-(3-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0401]




Compound ID: 149

LCMS: *m/z* 428.0 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98 (s, 1 H), 8.37 (s, 1 H), 8.23 (s, 1 H), 8.13 (d, *J* = 8.8 Hz, 1 H), 8.07 (d, *J* = 8.0 Hz, 1 H), 7.82 (s, 2 H), 7.74 - 7.71 (m, 2 H), 7.60 - 7.56 (m, 2 H), 2.54 (s, 3 H).

3-methyl-5-oxo-*N*-(3-(pyrazin-2-yl)phenyl)-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0402] **Compound ID: 150**




LCMS: *m/z* 440.0 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.80 (s, 1 H), 9.24 (d, *J* = 1.6 Hz, 1 H), 8.74 (dd, *J* = 1.6, 2.4 Hz, 1 H), 8.63 (d, *J* = 2.4 Hz, 1 H), 8.44 (s, 1 H), 8.08 (d, *J* = 8.8 Hz, 2 H), 7.87 (d, *J* = 8.8 Hz, 2 H), 7.83 - 7.71 (m, 2 H), 7.47 (t, *J* = 7.6 Hz, 1 H), 2.55 (s, 3 H).

3-methyl-5-oxo-*N*-(3-(pyrazin-2-yl)phenyl)-1-(3-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0403] **Compound ID: 166**






LCMS: m/z 440.2 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.81 (s, 1 H), 9.25 (d, J = 1.6 Hz, 1 H), 8.77 - 8.71 (m, 1 H), 8.63 (d, J = 2.4 Hz, 1 H), 8.44 (t, J = 1.6 Hz, 1 H), 8.28 (s, 1 H), 8.12 (d, J = 9.6 Hz, 1 H), 7.80 (dd, J = 2.0, 7.6 Hz, 2 H), 7.74 (t, J = 8.0 Hz, 1 H), 7.62 (d, J = 7.6 Hz, 1 H), 7.48 (t, J = 8.0 Hz, 1 H), 2.55 (s, 3 H).

4-((3-ethylphenyl)carbamoyl)-3-methyl-1-(4-(methylanino)phenyl)-1H-pyrazol-5-yl dimethylcarbamate

[0404] Compound ID: 224




LCMS: m/z 422.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 9.50 (s, 1 H), 7.51 (s, 1 H), 7.41 (d, J = 8.0 Hz, 1 H), 7.26 - 7.16 (m, 3 H), 6.92 (d, J = 7.6 Hz, 1 H), 6.62 (d, J = 8.8 Hz, 2 H), 6.04 - 5.97 (m, 1 H), 3.02 (s, 3 H), 2.79 (s, 3 H), 2.71 (d, J = 4.8 Hz, 3 H), 2.59 (q, J = 7.6 Hz, 2 H), 2.37 (s, 3 H), 1.18 (t, J = 7.6 Hz, 3 H).

3-methyl-5-oxo-1-phenyl-N-(3-(2,2,2-trifluoroacetyl)phenyl)-4,5-dihydro-1H-pyrazole-4-carboxamide

[0405] Compound ID: 152




LCMS: m/z 408.3 $[M+H+H_2O]^+$;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.77 (s, 1 H), 7.82 (s, 1 H), 7.74 - 7.71 (m, 2 H), 7.55 - 7.51 (m, 3 H), 7.36 - 7.32 (m, 3 H), 2.56 (s, 3 H)

¹⁹F NMR (400 MHz, DMSO-*d*₆) δ: -82.71 (s, 3 F).

***N*-(3-ethylphenyl)-3-methyl-1-(4-nitrophenyl)-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0406] Compound ID: 153




LCMS: *m/z* 367.2 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.48 (s, 1 H), 8.37 (d, *J* = 9.2 Hz, 2H), 8.12 (d, *J* = 9.6 Hz, 2 H), 7.47 (s, 1 H), 7.44 (d, *J* = 8.0 Hz, 1 H), 7.21 (t, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 7.6 Hz, 1 H), 2.58 (q, *J* = 7.6 Hz, 2 H), 2.54 (s, 3 H), 1.18 (t, *J* = 7.6 Hz, 3 H).

1-(4-aminophenyl)-*N*-(3-ethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide


[0407] Compound ID: 154



LCMS: *m/z* 337.2 [M+H]⁺;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.80 (s, 1 H), 7.45 (s, 1 H), 7.41 (d, *J* = 8.4 Hz, 1 H), 7.28 (d, *J* = 6.8 Hz, 2 H), 7.20 (t, *J* = 7.6 Hz, 1 H), 6.86 (d, *J* = 7.6 Hz, 1 H), 6.69 (d, *J* = 8.4 Hz, 2 H), 2.57 (q, *J* = 7.6 Hz, 2 H), 2.47 (s, 3 H), 1.17 (t, *J* = 7.6 Hz, 3 H)


1-(4-(3,3-dimethylureido)phenyl)-*N*-(3-ethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0408] Compound ID: 155

LCMS: m/z 408.3 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 10.90 (s, 1 H), 8.32 (s, 1 H), 7.67 (s, 2 H), 7.50 (d, J = 9.2 Hz, 2 H), 7.45 (s, 1 H), 7.41 (d, J = 8.4 Hz, 1 H), 7.16 (t, J = 7.6 Hz, 1H), 6.81 (d, J = 7.6 Hz, 1 H), 2.93 (s, 6H), 2.56 (q, J = 7.6 Hz, 2 H), 2.41 (s, 3 H), 1.17 (t, J = 7.6 Hz, 3 H).


***N*-(3-ethylphenyl)-5-oxo-1-phenyl-3-(pyridin-2-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0409] Compound ID: 156

LCMS: m/z 385.1 $[M+H]^+$;

1H NMR (400 MHz, DMSO- d_6) δ 12.03 (s, 1 H), 9.00 (s, 1 H), 8.65 (d, J = 7.6 Hz, 1 H), 8.49 (t, J = 7.6 Hz, 1 H), 8.21 (d, J = 8.0 Hz, 2 H), 7.90 (t, J = 2.4 Hz, 1 H), 7.53 (d, J = 8.0 Hz, 1 H), 7.50 - 7.46 (m, 3 H), 7.30 (t, J = 7.6 Hz, 1 H), 7.25 (t, J = 7.6 Hz, 1 H), 6.98 (d, J = 7.6 Hz, 1 H), 2.66 - 2.60 (q, J = 7.6 Hz, 2 H), 1.21 (t, J = 7.6 Hz, 3 H).

***N*-(3-ethylphenyl)-5-oxo-1-phenyl-3-(pyridin-3-yl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**


[0410] Compound ID: 157

LCMS: m/z 385.2 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 11.66 (s, 1 H), 9.68 (s, 1 H), 9.11 (d, J = 8.0 Hz, 1 H), 8.81 (d, J = 5.2 Hz, 1 H), 8.20 (d, J = 7.6 Hz, 2 H), 8.04 (dd, J = 5.6, 8.0 Hz, 1 H), 7.49 (s, 1 H), 7.47 - 7.37 (m, 3 H), 7.16 (td, J = 7.6, 10.0 Hz, 2H), 6.81 (d, J = 7.6 Hz, 1 H), 2.58 (q, J = 7.6 Hz, 2 H), 1.19 (t, J = 7.6 Hz, 3 H).

***N*-(3-ethylphenyl)-3-methyl-5-oxo-1-(4-propoxyphenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0411] Compound ID: 158




LCMS: m/z 380.1 $[M+H]^+$;

^1H NMR (400MHz, DMSO- d_6) δ 13.24 (s, 1 H), 10.71 (s, 1 H), 7.56 (d, J = 9.2 Hz, 2 H), 7.47 - 7.45 (m, 1 H), 7.43 - 7.41 (m, 1 H), 7.22 - 7.20 (m, 1 H), 7.07 (d, J = 8.8 Hz, 2 H), 6.88 (d, J = 7.6 Hz, 1 H), 3.97 (t, J = 6.4 Hz, 2 H), 2.61 - 2.58 (m, 2 H), 2.57 (s, 3 H), 1.76 (t, J = 6.8 Hz, 2 H), 1.18 (t, J = 7.6 Hz, 3H), 0.99 (t, J = 7.6 Hz, 3 H).

3-(4-((3-(furan-2-yl)phenyl)carbamoyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazol-1-yl)benzoic acid

[0412] Compound ID: 159




LCMS: m/z 404.0 $[M+H]^+$;

^1H NMR (400 MHz, METHANOL- d_4) δ 8.33 (s, 1 H), 7.89 - 8.10 (m, 3 H), 7.66 - 7.63 (m, 1 H), 7.55 (d, J = 1.2 Hz, 1 H), 7.48 - 7.40 (m, 2 H), 7.36 - 7.34 (m, 1 H), 6.78 (d, J = 3.2 Hz, 1 H), 6.52 - 6.50 (m, 1 H), 2.63 (s, 3 H).

1-(4-(*N,N*-dimethylsulfamoyl)phenyl)-*N*-(3-(furan-2-yl)phenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide

[0413] Compound ID: 160




LCMS: m/z 467.1 $[M+H]^+$;

^1H NMR (400 MHz, METHANOL- d_4) δ 8.19 - 8.05 (m, 3 H), 7.88 (d, J = 8.4 Hz, 2 H), 7.57 (d, J = 1.2 Hz, 1 H), 7.50 (d, J = 7.6 Hz, 1 H), 7.45 - 7.39 (m, 1 H), 7.38 - 7.31 (m, 1 H), 6.80 (d, J = 3.2 Hz, 1H), 6.54 (dd, J = 1.6, 3.2 Hz, 1 H), 2.73 (s, 6 H), 2.58 (s, 3 H).

3-methyl-5-oxo-1-phenyl-*N*-(3-(2,2,2-trifluoroethyl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide


[0414] Compound ID: 161



LCMS: m/z 376.0 $[M+H]^+$;

^1H NMR (400 MHz, DMSO- d_6) δ 10.83 (s, 1 H), 7.78 (d, J = 7.6 Hz, 2 H), 7.67 (s, 1 H), 7.60 (d, J = 8.0 Hz, 1 H), 7.50 (t, J = 8.0 Hz, 2 H), 7.34 - 7.25 (m, 2 H), 7.01 (d, J = 7.6 Hz, 1 H), 3.63 (q, J = 11.6 Hz, 2 H), 2.52 (s, 3 H).

[0415] *N*-(3-(furan-2-yl)phenyl)-3-methyl-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazole-4-carboxamide




Compound ID: 162

LCMS: m/z 428.0 $[M+H]^+$;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.74 (s, 1 H), 8.10 (d, *J* = 8.0 Hz, 2 H), 8.06 (s, 1 H), 7.86 (s, 2 H), 7.75 (s, 1 H), 7.48 (s, 1 H), 7.35 (s, 2 H), 6.97 - 6.89 (m, 1 H), 6.60 (s, 1 H), 2.53 (s, 3 H).

***N*-(3-(1*H*-imidazol-2-yl)phenyl)-1-(4-(*N,N*-dimethylsulfamoyl)phenyl)-3-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-4-carboxamide**

[0416] Compound ID: 173



LCMS: *m/z* 467.1 [M+H]⁺;

¹H NMR (400MHz, METHANOL-*d*₄) δ 8.35 (s, 1 H), 7.99 (q, *J* = 8.8 Hz, 4 H), 7.90 - 7.86 (m, 1 H), 7.69 (s, 2 H), 7.66 - 7.61 (m, 2 H), 2.75 (s, 6 H), 2.72 (s, 3 H)

EXAMPLE 2

Biological activity of compounds of the invention

ACSS2 cell-free activity assay (Cell-free IC₅₀)

[0417] The assay is based on a coupling reaction with Pyrophosphatase: ACSS2 is converting ATP+CoA+Acetate => AMP+ pyrophosphate + Acetyl-CoA (Ac-CoA). Pyrophosphatase converts pyrophosphate, a product of the ACSS2 reaction, to phosphate which can be detected by measuring the absorbance at 620 nm after incubation with the Biomol green reagent (Enzo life Science, BML-AK111).

Cell-free IC₅₀ determination:

[0418] 10nM of human ACSS2 protein (OriGene Technologies, Inc) was incubated for 90 minutes at 37C with various compounds' concentrations in a reaction containing 50 mM Hepes

pH 7.5, 10 mM DTT, 90 mM KCl, 0.006 % Tween-20, 0.1 mg/ml BSA, 2 mM MgCl₂, 10 μ M CoA, 5 mM NaAc, 300 μ M ATP and 0.5U/ml Pyrophosphatase (Sigma). At the end of the reaction, Biomol Green was added for 30 minutes at RT and the activity was measured by reading the absorbance at 620nm. IC₅₀ values were calculated using non-linear regression curve fit with 0% and 100% constrains (CDD Vault, Collaborative Drug Discovery, Inc.).

Results:

[0419] The results are presented in Table 2 below:

Table 2. ACSS2 cell-free activity assay results (Cell-free IC₅₀).

ACSS2 PPase IC ₅₀ assay: IC ₅₀ (uM)	From 1E-5 μ M to 6E-3 μ M	From 6E-3 μ M to 0.1 μ M	From 0.1 μ M to 1 μ M	From 1 μ M to 100uM	Above 100uM
Compounds number	226	159	233	111	180
	261	168	123	118	186
	271	237	146	131	187
	242	142	125	122	190
	228	259	173	105	192
	265	244	132	116	193
	269	255	100	179	194
	250	263	135	126	195
	247	149	174	121	196
	246	231	153	112	199
	141	251	144	104	200
	230	257	155	128	202
	236	107	154	129	204
	266	169	254	130	213
	253	138	147	134	214
	229	240	110	136	217
	264	124	270	137	221
	164	170	103	152	106
	275	274	260	156	
	165	235	133	157	
	252	184	139	176	
	166	171	120	239	
	108	277	115	268	
	227	245	209		

ACSS2 PPase IC ₅₀ assay: IC ₅₀ (uM)	From 1E-5 μM to 6E-3 μM	From 6E-3 μM to 0.1 μM	From 0.1 μM to 1 μM	From 1μM to 100uM	Above 100uM
	258	158	102		
	241	272	283	182	
	249	143	284	185	
	220	215	285	188	
	117	114	288	189	
	243	238	290	191	
	248	162	302	197	
	145	127	329	198	
	119	232	339	201	
	234	113	340	203	
	167	256	341	205	
	276	150	345	207	
	109	267	346	212	
	206	172	347	216	
	280	273	349	218	
	281	262	350	222	
	282	148	358	223	
	286	101		224	
	287	160		278	
	289	103			
	291	161			
	292	183			
	297	208			
	298	210			
	300	211			
	301	215			
	303	140			
	304	279			
	305	293			
	306	294			
	307	295			
	308	296			
	309	299			

ACSS2 PPase IC ₅₀ assay: IC ₅₀ (uM)	From 1E-5 μM to 6E-3 μM	From 6E-3 μM to 0.1 μM	From 0.1 μM to 1 μM	From 1μM to 100uM	Above 100uM
	310	333			
	311	335			
	312	337			
	313	338			
	314	348			
	315	354			
	316	356			
	317				
	318				
	319				
	320				
	321				
	322				
	323				
	324				
	325				
	326				
	327				
	328				
	330				
	331				
	332				
	334				
	336				
	342				
	343				
	344				
	351				
	352				
	353				
	355				
	357				

ACSS2 cellular activity assay (Cellular IC50)

[0420] The cellular activity of ACSS2 was based on tracing the incorporation of carbons from ^{13}C -Acetate into fatty-acids.

Cell treatment:

[0421] BT474/MDA-MB-468 cells growing in DMEM +25mM D-glucose+ 1mM sodium pyruvate+10% FBS+ 2mM glutamine were plated in 12-well plates at 0.4×10^6 cells/well. The cells were then incubated at CO_2 incubator for 24hrs at hypoxic conditions (1% O_2) before treated with compounds. At day 2, the medium was replaced to DMEM medium containing 15mM Glucose, 1mM Pyruvate, 0.65mM Glutamine, 1% Dialyzed serum, 3.5ug/ml Biotin, 0.2mM ^{13}C -Acetate and various concentrations of the compounds. The cells were incubated for 5 hours at CO_2 incubator in hypoxic conditions (1% O_2). At the end of the 5 hours' incubation, the cells were washed twice with cold PBS, harvested in 1 ml PBS and transfer into V-shaped HPLC glass vials and centrifuge for 10 min at 600g at 4C. The supernatant was removed, and the cells' pellets were stored at -80°C until taken for saponification.

Saponification assay

[0422] The cells pellets were resuspended with 0.5 ml of the 90% Methanol, 10% H_2O , 0.3M NaOH mixture and incubated at 80°C for 60 min. Following the incubation, 50 μl formic acid and 0.4 ml hexane were added and the mixture was vortexed for 2 minutes. The vials were left few minutes for phases separation and then 200 μl of the top hexane phase extracted to a new glass vial. The hexane was dried under nitrogen and reconstituted in 100 μl of Methanol: Acetonitrile 5:3 mixture. The solution transferred to Eppendorf tubes, spun down at 17000G for 20 min and transferred to LC-MS vials.

LCMS method

[0423] The analysis was performed with Thermo Q Exactive mass spectrometer with HESI probe and Dionex Ultimate 3000 UHPLC system. The separations were performed on Phenomenex Kintex 2.6u XB-C18 100A 150x2.10mm column by injecting 5ul of each sample. The chromatography started with a linear gradient from 85% to 100% of organic solvent (Methanol: Acetonitrile 1: 1) versus 10mM Ammonium Acetate buffer pH 4.7 for 3.5 minutes, followed by 4.5 minutes of isocratic 100% organic solvent and then 3 minutes of isocratic initial conditions, at a flow rate of 0.3ul/min. The MS source conditions that were used: capillary

temperature 325°C, sheath flow 25, aux flow 15, spray voltage 3.8kV, aux temperature 300 °C. The data collected from Negative ion mode at resolution of 70000 at Full-MS mode in 75-1000m/z range.

LCMS results analysis

[0424] The analysis of ^{13}C acetate incorporation into fatty acids (palmitate, myristate and stearate) performed on TraceFinder 3.2.512.0. The negative control areas and ^{13}C isotopic theoretical natural abundance were subtracted from the samples areas. Total ^{13}C incorporation for each fatty-acid (palmitate, myristate and stearate) was calculated and presented as percentage of the total amount. Cellular EC_{50} values were calculated using a non-linear regression curve fit with 0% and 100% constrains (CDD Vault, Collaborative Drug Discovery, Inc.)

Results:

[0425] The results are presented in Tables 3 and 4 below:

Table 3. ^{13}C acetate incorporation into fatty acids (BT474 cells).

<i>IC₅₀ (nM) BT474</i>			
	Myristate	Palmitate	Stearate
< 100nM	141, 108	141, 108, 117	141, 117, 108
$100\text{nM} < \text{IC}_{50} < 1000\text{nM}$	117, 138, 140, 142,	138, 140, 142, 119, 109, 220, 206, 124	138, 140, 142, 119, 109, 220, 206, 124, 107, 114, 208, 215, 184
$\geq 1000\text{nM}$		107, 114, 208, 215, 184, 183	183

Table 4. ^{13}C acetate incorporation into fatty acids (BT474 cells).

<i>IC₅₀(nM) MDA-468</i>			
	Myristate	Palmitate	Stearate
< 100nM	141, 108, 165, 119, 117, 138, 145, 164, 109, 167	141, 108, 165, 119, 117, 138, 145, 164, 109, 220, 167, 166	141, 108, 165, 119, 117, 138, 145, 164, 109, 220, 167, 166, 140
$100\text{nM} < \text{IC}_{50} < 1000\text{nM}$	220, 166, 140, 107, 142, 124, 168, 208	140, 107, 142, 124, 168, 208	107, 142, 124, 168, 208
$\geq 1000\text{nM}$	159, 169	159, 169	159, 169

Fatty-acid assay

[0426] Testing the inhibitory effect of compounds on the cellular activity of ACSS2 was done by tracing the incorporation of ^{13}C from ^{13}C -acetate into fatty-acids in MDA-MB-468 cells under hypoxic conditions of 1% O_2 . The assay was done for 5 hours in DMEM with 5.5mM glucose, 1mM sodium Pyruvate, 0.65mM Glutamine, 3.5ug/ml Biotin, 1% dialyzed serum, 0.5mM ^{13}C -acetate and with different concentrations of the inhibitors. At the end of the incubation, the cells were washed with cold PBS, harvested into glass tubes and undergo saponification. The level of ^{13}C incorporation into Palmitate was done by LC-MS analysis and the level of inhibition was calculated with PRISM software.

Table 5. Fatty-acid assay: Incorporation of ^{13}C -Acetate for compounds of the invention.

Compound	FA IC50 MDA468 (nM)
107	46.3
108	15.5
109	76.0
117	20.7
119	19.4
124	187.3
138	18.6
140	111.8
141	4.0
142	97.4
145	53.4
149	96.1
159	2414.0
164	62.2
165	9.5
166	78.7
167	78.1
168	17.1
169	3200.0
206	34.2
208	481.8
220	97.3
226	46.9
227	48.3

Compound	FA IC50 MDA468 (nM)
228	8.2
229	53.8
230	6.1
231	271.5
234	134.3
235	328.5
236	9.8
237	85.3
241	46.0
242	5.0
243	135
244	448.7
246	3.9
247	8.4
248	56.6
249	28.3
250	8.9
251	70.5
252	71.9
253	26.6
255	178.4
257	159.1
258	583.7
259	127.1
261	3.8
263	8.8
264	15.1
265	4.5
266	3.2
269	2.1
271	6.1
279	103.5
280	25.3
282	3.157

Compound	FA IC50 MDA468 (nM)
286	11.6
287	1.0
289	6.8
291	3.8
292	20.74
297	1496
298	2.66
300	3.9
301	1.1
303	2.9
304	8.1
305	48390
306	30.5
307	45110
308	19.68
309	11.2
310	0.33
311	2.80
312	5.63
313	2.53
314	6.6
315	2.35, 0.23, 0.0028, 0.082, 0.25
316	3.3
317	1.4
318	7.049
319	8.026
320	3.243
321	1.76
322	9.719
323	22.73
324	4.71
325	1.287
326	14.44
327	4.697 0.7642
328	5.092 0.9079

Compound	FA IC50 MDA468 (nM)
330	1.207 0.4626
331	5.4
332	9.092 3.042

EXAMPLE 3

In-vivo efficacy study of compound 265 in MDA-MB-468 breast cancer cells xenograft

[0427] An *in-vivo* efficacy study was carried out by Charles-River Laboratories at the Freiburg, Germany site.

[0428] Tumor pieces from Breast cancer cell line MDA-MB-468 passaged as subcutaneous xenograft were subcutaneously implanted into female NMRI nude mice (CrI:NMRI-Foxn1nu). The animals were randomized into groups when tumors volume reached 50 to 250 mm³. Vehicle control or compound **265** at 100 mg/kg were dosed orally once daily. Body weights and tumor volume [mm³] by caliper were measured twice weekly.

[0429] The results show a significant tumor growth delay in the group that was treated with 100mg/kg of compound-265 (Figure 4).

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description


- [WO2015175845A \[0014\]](#)

Non-patent literature cited in the description

- Cancer Facts & Figures American Cancer Society: Atlanta, GA, 2008, [0002]
- COMERFORD Cell, 2014, [0006]
- MASHIMO Cell, 2014, [0006]
- SCHUG et al. Cancer Cell, 2015, [0006]
- SCHUG Cancer Cell, 2015, vol. 27, 157-71 [0006]
- WAKIL SJABU-ELHEIGA LA Fatty acid metabolism: Target for metabolic syndrome. J. Lipid Res, 2009, [0011]
- HARRIMAN G Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats PNAS, 2016, [0011]
- MEWS P et al. Nature, 2017, vol. 546, 381- [0012] [0294]
- GRAFF, J et al. Histone acetylation: molecular mnemonics on chromatin Nat Rev. Neurosci., 2013, vol. 14, 97-111 [0012] [0294]
- LI, X et al. Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis and Autophagy Molecular Cell, 2017, vol. 66, 1-14 [0013] [0245]
- CHEN, R. et al. Coordinate regulation of stress signaling and epigenetic events by ACSS2 and HIF-2 in cancer cells Plos One, 2017, vol. 12, 121-31 [0013]
- CHEN, R et al. Coordinate regulation of stress signaling and epigenetic events by Acss2 and HIF-2 in cancer cells Plos One, 2017, vol. 12, 121-31 [0239]
- Z. HUANG et al. ACSS2 promotes systemic fat storage and utilization through selective regulation of genes involved in lipid metabolism PNAS, 2018, vol. 115, 40E9499-E9506 [0288]

Patentkrav

1. Forbindelse repræsenteret med strukturen af formel (I):



5 hvor


ringe **A** og **B** er hver uafhængigt et enkelt eller fusioneret aromatisk eller heteroaromatisk ringsystem, eller en enkelt eller fusioneret C₃-C₁₀-cycloalkyl eller en enkelt eller fusioneret C₃-C₁₀-heterocyklisk ring;

- R₁** og **R₂** er hver uafhængigt H, F, Cl, Br, I, OH, SH, R₈-OH, R₈-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R_gCN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁) B(OH)₂, -OC(O)CF₃, -OCH₂Ph, NHC(O)-R₁₀ NHCO-N(R₁₀)(R₁₁) COOH, -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ lineær eller forgrenet C(O)-halogenalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁), lineær eller forgrenet, substitueret eller ikke-substitueret C₁-C₅-alkyl, lineær eller forgrenet C₁-C₅-halogenalkyl, lineær, forgrenet eller cyklisk C₁-C₅-alkoxy eventuelt hvor mindst en methylen-gruppe (CH₂) i alkoxyen er erstattet med et oxygenatom, lineær eller forgrenet C₁-C₅-thioalkoxy, lineær eller forgrenet C₁-C₅-halogenalkoxy, lineær eller forgrenet C₁-C₅-alkoxyalkyl, substitueret eller ikke-substitueret C₂-C₈-cycloalkyl, substitueret eller ikke-substitueret C₂-C₈ heterocyklisk ring, substitueret eller ikke-substitueret aryl (hvor substitutioner inkluderer: F, Cl, Br, I, lineær eller forgrenet C₁-C₅-alkyl, OH, alkoxy, N(R)₂, CF₃, CN eller NO₂), CH(CF₃)(NH-R₁₀);
- eller **R₂** og **R₁** er forbundet for at danne en 5- eller 6-leddet substitueret eller ikke-substitueret, alifatisk eller aromatisk, carbocyklisk eller heterocyklisk ring;
- R₃** er lineær eller forgrenet C₂-C₅-halogenalkyl, CF₂CH₃, CH₂CF₃, CF₂CH₂CH₃, CH₂CH₂CF₃, CF₂CH(CH₃)₂, CF(CH₃)-CH(CH₃)₂, substitueret eller ikke-substitueret C₃-C₈-cycloalkyl, substitueret eller ikke-substitueret C₃-C₈ heterocyklisk ring (hvor substitutioner inkluderer: F, Cl, Br, I, lineær eller forgrenet C₁-C₅-alkyl, OH, alkoxy, N(R)₂, CF₃, CN eller NO₂);

- R₄** er H, F, Cl, Br, I, OH, SH, R₈-OH, R₈-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R_gCN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀, NHCO-N(R₁₀)(R₁₁), COOH, -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ lineær eller forgrenet C(O)-halogenalkyl, -
- 5 C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁), lineær eller forgrenet, substitueret eller ikke-substitueret C₁-C₅-alkyl, lineær eller forgrenet C₁-C₅-halogenalkyl, lineær, forgrenet eller cyklisk C₁-C₅-alkoxy, lineær eller forgrenet C₁-C₅-thioalkoxy, lineær eller forgrenet C₁-C₅-halogenalkoxy, lineær eller forgrenet C₁-C₅-alkoxyalkyl, substitueret eller ikke-substitueret C₃-C₈-cycloalkyl,
- 10 substitueret eller ikke-substitueret C₃-C₈ heterocyklisk ring, substitueret eller ikke-substitueret aryl, (hvor substitutioner inkluderer: F, Cl, Br, I, lineær eller forgrenet C₁-C₅-alkyl, OH, alkoxy, N(R)₂, CF₃, CN eller NO₂), CH(CF₃)(NH-R₁₀); eller **R₃** og **R₄** er forbundet for at danne en 5- eller 6-leddet substitueret eller ikke-substitueret, alifatisk eller aromatisk, carbocyklisk eller heterocyklisk ring;
- 15 **R₅** er H, lineær eller forgrenet, substitueret eller ikke-substitueret C₁-C₅-alkyl, lineær eller forgrenet C₁-C₅-halogenalkyl, R₈-aryl, substitueret eller ikke-substitueret aryl, substitueret eller ikke-substitueret heteroaryl (hvor substitutioner inkluderer: F, Cl, Br, I, lineær eller forgrenet C₁-C₅-alkyl, OH, alkoxy, N(R)₂, CF₃, CN eller NO₂);
- 20 **R₆** er H, C₁-C₅ lineær eller forgrenet alkyl;
R₈ er [CH₂]_p
hvor **p** er mellem 1 og 10;
R₉ er [CH]_q, [C]_q
hvor **q** er mellem 2 og 10;
- 25 **R₁₀** og **R₁₁** er hvert uafhængigt H, lineær eller forgrenet C₁-C₅-alkyl, C(O)R eller S(O)₂R;
R er H, lineær eller forgrenet C₁-C₅-alkyl, lineær eller forgrenet C₁-C₅-alkoxy, phenyl, aryl eller heteroaryl, eller to gem R substituenten er forbundet for at danne en 5- eller 6-leddet heterocyklisk ring;
- 30 **m**, **n** og **k** er hver uafhængigt et heltal mellem 0 og 4;
l er et heltal mellem 1 og 4;
Q₁ og **Q₂** er hvert uafhængigt S eller O;
eller dens farmaceutisk acceptable salt, optisk isomer, tautomer, hydrat, *N*-oxid, isotopisk variant, PROTAC, farmaceutisk produkt eller en hvilken som helst

kombination deraf.

2. Forbindelsen ifølge krav 1, repræsenteret med strukturen af formel (II):




5 hvor

R₁, R₂, R₃, R₄, R₅, R₆, R₈, R₁₀, R₁₁, R, m, n, l, k, Q₁ og Q₂ er som defineret i krav 1; og

$X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9$ eller X_{10} er hver uafhængigt C eller N.

10

3. Forbindelsen ifølge krav 1 eller 2, repræsenteret med strukturen af formel (IV):



hvor

R₁, R₂, R₃, R₄, og **R₈** er som defineret i krav 1; og






15 $\mathbf{X}_3, \mathbf{X}_4, \mathbf{X}_7$, og $\mathbf{X}_8$ er hver uafhængigt C eller N;








hvor, hvis $\mathbf{X}_3$ er N, så er $\mathbf{R}_4$ fraværende; og








hvor, hvis X_8 er N, så er R_2 fraværende.







4. Forbindelsen ifølge krav 1, valgt fra følgende:







20







Forbindelsesnavn	Struktur
101	
104	
107	
109	
119	
122	







Forbindelsesnavn	Struktur
124	
132	
141	
146	
148	
149	
150	








Forbindelsesnavn	Struktur
159	
160	
161	
162	
164	
165	
166	

Forbindelsesnavn	Struktur
167	 <chem>COC(=O)c1ccc(cc1)N2C(=O)C(=CN2C3C(=O)NC(N3)c4ccc(cc4)c5c[nH]cn5)C</chem>
169	 <chem>OC(=O)c1ccc(cc1)N2C(=O)C(=CN2C3C(=O)NC(N3)c4ccc(cc4)c5c[nH]cn5)C</chem>
170	 <chem>OC(=O)c1ccc(cc1)N2C(=O)C(=CN2C3C(=O)NC(N3)c4ccc(cc4)c5oc[nH]5)C</chem>
171	 <chem>CN(C)S(=O)(=O)c1ccc(cc1)N2C(=O)C(=CN2C3C(=O)NC(N3)c4ccc(cc4)c5c[nH]cn5)C</chem>
172	 <chem>OC(=O)c1ccc(cc1)N2C(=O)C(=CN2C3C(=O)NC(N3)c4ccc(cc4)c5c[nH]cn5)C</chem>
173	 <chem>CN(C)S(=O)(=O)c1ccc(cc1)N2C(=O)C(=CN2C3C(=O)NC(N3)c4ccc(cc4)c5c[nH]cn5)C</chem>








Forbindelsesnavn	Struktur
174	
176	
185	
209	
219	
226	








Forbindelsesnavn	Struktur
227	
228	
229	
230	
231	
232	







Forbindelsesnavn	Struktur
233	
234	
235	
236	
237	
238	






Forbindelsesnavn	Struktur
239	
240	
241	
242	
243	
244	
245	






Forbindelsesnavn	Struktur
246	 <chem>COc1ccc(cc1)N2C(=O)C(=O)N(C2)c3ccc(cc3)C(=O)Nc4ccc(cc4)c5ccoc5</chem>
247	 <chem>COc1ccc(cc1)N2C(=O)C(=O)N(C2)c3ccc(cc3)C(=O)Nc4ccc(cc4)c5ccoc5</chem>
248	 <chem>COc1ccc(cc1)N2C(=O)C(=O)N(C2)c3ccc(cc3)C(=O)Nc4ccc(cc4)c5ccoc5</chem>
249	 <chem>COc1ccc(cc1)N2C(=O)C(=O)N(C2)c3ccc(cc3)C(=O)Nc4ccc(cc4)c5ccoc5</chem>
250	 <chem>COc1ccc(cc1)N2C(=O)C(=O)N(C2)c3ccc(cc3)C(=O)Nc4ccc(cc4)c5ccoc5</chem>
251	 <chem>COc1ccc(cc1)N2C(=O)C(=O)N(C2)c3ccc(cc3)C(=O)Nc4ccc(cc4)c5ccoc5</chem>





Forbindelsesnavn	Struktur
252	
253	
254	
255	
256	
257	
258	

Forbindelsesnavn	Struktur
259	
261	
262	
263	
264	
265	
266	





Forbindelsesnavn	Struktur
269	
270	
271	
272	
273	
274	






Forbindelsesnavn	Struktur
275	
276	
277	
278	
279	

Forbindelsesnavn	Struktur
280	 <chem>CC1=CC=C(C=C1C(=O)Nc2c(C)cnc2Nc3ccc(cc3c4nn(C)c4)C(F)(F)F)C(F)(F)F</chem>
281	 <chem>COc1ccc(cc1Nc2c(C)cnc2C(=O)Nc3ccc(cc3C(F)(F)F)C(F)(F)F)C(F)(F)F</chem>
282	 <chem>CC1=CC=C(C=C1C(=O)Nc2c(C)cnc2Nc3ccc(cc3c4nn(C)c4)C(F)(F)F)C(F)(F)F</chem>
286	 <chem>FC(F)(F)C(F)(F)Fc1ccc(cc1Oc2ccc(cc2Nc3c(C)cnc3C(=O)Nc4ccc(cc4C(F)(F)F)C(F)(F)F)C(F)(F)F)C(F)(F)F</chem>
287	 <chem>COC1=CC=C(C=C1C(=O)Nc2c(C)cnc2Nc3ccc(cc3c4cc(OC)cc4OC)C(F)(F)F)C(F)(F)F</chem>






Forbindelsesnavn	Struktur
289	
291	
292	
293	





Forbindelsesnavn	Struktur
294	 <chem>CC1=C(C(=O)N(C1=O)C(=O)NC2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)C(F)(F)F</chem>
295	 <chem>CC1=C(C(=O)N(C1=O)C(=O)NC2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)C(F)(F)F</chem>
296	 <chem>CC1=C(C(=O)N(C1=O)C(=O)NC2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)C(F)(F)F</chem>
297	 <chem>CC1=C(C(=O)N(C1=O)C(=O)NC2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)C(F)(F)F</chem>
298	 <chem>CC1=C(C(=O)N(C1=O)C(=O)NC2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)C(F)(F)F</chem>






Forbindelsesnavn	Struktur
299	
300	
301	
302	






Forbindelsesnavn	Struktur
303	
304	
305	
306	
308	

Forbindelsesnavn	Struktur
309	<chem>COc1cc(NC(=O)c2nc3cc(C(F)(F)F)ccc3n2)ccc1OC(F)(F)F</chem>
310	<chem>COc1cc(NC(=O)c2nc3cc(C(F)(F)F)ccc3n2)ccc1OC(F)(F)F</chem>
311	<chem>COc1cc(NC(=O)c2nc3cc(C(F)(F)F)ccc3n2)ccc1OC(F)(F)F</chem>
312	<chem>COc1cc(NC(=O)c2nc3cc(C(F)(F)F)ccc3n2)ccc1OC(F)(F)F</chem>
313	<chem>COc1cc(NC(=O)c2nc3cc(C(F)(F)F)ccc3n2)ccc1OC(F)(F)F</chem>








Forbindelsesnavn	Struktur
314	 <chem>COc1ccc(N2C(=O)C(C)=NC2C(=O)Nc3ccc(F)cc3)cc4ccc(C(F)(F)F)cc4</chem>
315	 <chem>CC1=CN(C(=O)Nc2ccc(OCCF)cc2C3=CC=CC=N3)C(=O)Nc4ccc(C(F)(F)F)cc4</chem>
316	 <chem>CC1=CN(C(=O)Nc2ccc(OCC(F)(F)F)cc2C3=CC=CC=N3)C(=O)Nc4ccc(C(F)(F)F)cc4</chem>
317	 <chem>CCOC1=CC=C(N2C(=O)C(C)=NC2C(=O)Nc3ccc(C(F)(F)F)cc3)C=C1</chem>
318	 <chem>CC(C)OC1=CC=C(N2C(=O)C(C)=NC2C(=O)Nc3ccc(C(F)(F)F)cc3)C=C1</chem>








Forbindelsesnavn	Struktur
319	
320	
321	
322	





Forbindelsesnavn	Struktur
323	
324	
325	
326	
327	

Forbindelsesnavn	Struktur
328	
329	
330	
331	
332	

Forbindelsesnavn	Struktur
333	<chem>CC1=NC(=O)N(C1)c2cc(ccc2C(F)(F)F)C(F)(F)F</chem>
334	<chem>CC1=NC(=O)N(C1)c2cc(ccc2C(F)(F)F)C(F)(F)F</chem>
335	<chem>CC1=NC(=O)N(C1)c2cc(ccc2C(F)(F)F)C(F)(F)F</chem>
336	<chem>CC1=NC(=O)N(C1)c2cc(ccc2C(F)(F)F)C(F)(F)F</chem>
338	<chem>CC1=NC(=O)N(C1)c2cc(ccc2C(F)(F)F)C(F)(F)F</chem>
339	<chem>CC1=NC(=O)N(C1)c2cc(ccc2C(F)(F)F)C(F)(F)F</chem>

Forbindelsesnavn	Struktur
340	
341	
342	
343	
344	
345	
346	


Forbindelsesnavn	Struktur
347	
348	
349	
350	
351	
352	
353	







Forbindelsesnavn	Struktur
354	
355	
356	 HCl
357	








eller dens farmaceutisk acceptable salt, optisk isomer, tautomer, hydrat, *N*-oxid, isotopiske varianter (f.eks., deuteret analog), PROTAC, farmaceutisk produkt eller en hvilken som helst kombination deraf.








5







5. Forbindelse repræsenteret af en hvilken som helst af de følgende strukturer:








Forbindelsesnavn	Struktur
100	







Forbindelsesnavn	Struktur
102	
103	
105	
106	
108	
110	
111	

Forbindelsesnavn	Struktur
112	
113	
114	
115	
116	
117	
118	





Forbindelsesnavn	Struktur
120	
121	
123	
125	
126	
127	
128	








Forbindelsesnavn	Struktur
129	
130	
131	
133	
134	
135	








Forbindelsesnavn	Struktur
136	
137	
138	
139	
140	
142	
143	







Forbindelsesnavn	Struktur
144	
145	
147	
152	
153	
154	
155	







Forbindelsesnavn	Struktur
156	<chem>CC1=CC=C(NC(=O)C2=C(C(=O)N3C=CC=CC3)N=CC=C2)C=C1</chem>
157	<chem>CC1=CC=C(NC(=O)C2=C(C(=O)N3C=CC=CC3)N=CC=C2)C=C1</chem>
158	<chem>CC1=CC=C(NC(=O)C2=C(C(=O)N3C=CC=CC3)N=CC=C2)C=C1</chem>
168	<chem>CC1=CC=C(NC(=O)C2=C(C(=O)N3C=CC=CC3)N=CC=C2)C=C1</chem>
176	<chem>CC1=CC=C(NC(=O)C2=C(C(=O)N3C=CC=CC3)N=CC=C2)C=C1</chem>
183	<chem>CC1=CC=C(NC(=O)C2=C(C(=O)N3C=CC=CC3)N=CC=C2)C=C1</chem>






Forbindelsesnavn	Struktur
184	
186	
187	
190	
191	
192	
193	

Forbindelsesnavn	Struktur
194	
195	
196	
198	
201	
202	
203	

Forbindelsesnavn	Struktur
204	
206	
207	
209	
213	
214	
215	

Forbindelsesnavn	Struktur
216	 <chem>Cc1nn(c2ccccc2)c(=O)c1NC(=O)c3ccncc3</chem>
217	 <chem>Cc1nn(c2ccccc2)c(=O)c1NC(=O)c3cc[nH]s3</chem>
218	 <chem>C[C@H](C(=O)O)NC(=O)c1c(C)nnc1C(=O)Nc2ccccc2</chem>
220	 <chem>Cc1nn(c2ccccc2)c(=O)c1NC(=O)Nc3ccccc3C(=O)N(C)C</chem>
221	 <chem>Cc1nn(c2ccccc2)c(=O)c1NC(=O)Nc3ccccc3C(=O)N(C)C4CCN(C)CC4</chem>
222	 <chem>Cc1nn(c2ccccc2)c(=O)c1NC(=O)Nc3cc(O)ccc3</chem>

Forbindelsesnavn	Struktur
223	 <chem>Cc1nc2ccccc2n1C(=O)Nc3ccc(CN)cc3</chem>
224	 <chem>CN(C)c1ccc(NC2=CN3C(=O)N(C)C(=O)N3C2=O)cc1C(=O)Nc4ccc(cc4)C5OC(C)OC5OC</chem>
260	 <chem>CCc1cc(C)sc1NC(=O)c2c(C)n(c3ccccc32)C(=O)N3C=CC=C3</chem>
267	 <chem>CCc1ccc(NC(=O)c2c(C)n(c3ccc4ccncc4c3)C(=O)N3C=CC=C3)cc1</chem>
268	 <chem>CC1=CN(C(=O)Nc2ccccc2C1=O)C=C3C=CC=N3C</chem>
283	 <chem>Cc1cc(C)sc1NC(=O)c2c(C)n(c3ccccc32)C(=O)N3C=CC=C3</chem>

Forbindelsesnavn	Struktur
284	
285	
288	
290	
307	

Forbindelsesnavn	Struktur
337	

eller dens farmaceutisk acceptable salt, optisk isomer, tautomer, hydrat, *N*-oxid, isotopiske varianter (f.eks., deuteret analog), PROTAC, farmaceutisk produkt eller en hvilken som helst kombination deraf.

5


6. Forbindelsen ifølge et hvilket som helst af de foregående krav, hvor forbindelsen er en inhibitor af Acyl-CoA Synthetase Short-Chain Family Member 2 (ACSS2).

10 **7.** Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1 til 6 og en farmaceutisk acceptabel bærer.

8. Forbindelse ifølge et hvilket som helst af kravene 1-6 til anvendelse som et medikament.

15

9. Forbindelse repræsenteret med strukturen af formel (I):



hvor

ringe **A** og **B** er hver uafhængigt et enkelt eller fusioneret aromatisk eller

20 heteroaromatisk ringsystem, eller en enkelt eller fusioneret C₃-C₁₀-cycloalkyl eller en enkelt eller fusioneret C₃-C₁₀ heterocyklisk ring;

R₁ og **R₂** er hver uafhængigt H, F, Cl, Br, I, OH, SH, R₈-OH, R₈-SH, -R₈-O-R₁₀, CF₃, CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₉CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-N(R₁₀)(R₁₁) B(OH)₂, -OC(O)CF₃, -OCH₂Ph, NHC(O)-R₁₀ NHCO-N(R₁₀)(R₁₁) COOH, -

25 C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ lineær eller forgrenet

- C(O)-halogenalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁),
 lineær eller forgrenet, substitueret eller ikke-substitueret C₁-C₅-alkyl, lineær eller
 forgrenet C₁-C₅-halogenalkyl, lineær, forgrenet eller cyklisk C₁-C₅-alkoxy eventuelt
 hvor mindst en methylen gruppe (CH₂) i alkoxyen er erstattet med et oxygenatom,
- 5 lineær eller forgrenet C₁-C₅-thioalkoxy, lineær eller forgrenet C₁-C₅-halogenalkoxy,
 lineær eller forgrenet C₁-C₅-alkoxyalkyl, substitueret eller ikke-substitueret C₃-C₈-
 cycloalkyl, substitueret eller ikke-substitueret C₃-C₈ heterocyklisk ring,
 substitueret eller ikke-substitueret aryl (hvor substitutioner inkluderer: F, Cl, Br, I,
 lineær eller forgrenet C₁-C₅-alkyl, OH, alkoxy, N(R)₂, CF₃, CN eller NO₂),
- 10 CH(CF₃)(NH-R₁₀);
 eller **R₂** og **R₁** er forbundet for at danne en 5- eller 6-leddet substitueret eller
 ikke-substitueret, alifatisk eller aromatisk, carbocyklisk eller heterocyklisk ring;
R₃ og **R₄** er hver uafhængigt H, F, Cl, Br, I, OH, SH, R₈-OH, R₈-SH, -R₈-O-R₁₀, CF₃,
 CD₃, OCD₃, CN, NO₂, -CH₂CN, -R₈CN, NH₂, NHR, N(R)₂, R₈-N(R₁₀)(R₁₁), R₉-R₈-
- 15 N(R₁₀)(R₁₁), B(OH)₂, -OC(O)CF₃, -OCH₂Ph, -NHCO-R₁₀, NHCO-N(R₁₀)(R₁₁), COOH,
 -C(O)Ph, C(O)O-R₁₀, R₈-C(O)-R₁₀, C(O)H, C(O)-R₁₀, C₁-C₅ lineær eller forgrenet
 C(O)-halogenalkyl, -C(O)NH₂, C(O)NHR, C(O)N(R₁₀)(R₁₁), SO₂R, SO₂N(R₁₀)(R₁₁),
 lineær eller forgrenet, substitueret eller ikke-substitueret C₁-C₅-alkyl, lineær eller
 forgrenet C₁-C₅-halogenalkyl, lineær, forgrenet eller cyklisk C₁-C₅-alkoxy, lineær
- 20 eller forgrenet C₁-C₅-thioalkoxy, lineær eller forgrenet C₁-C₅-halogenalkoxy, lineær
 eller forgrenet C₁-C₅-alkoxyalkyl, substitueret eller ikke-substitueret C₃-C₈-
 cycloalkyl, substitueret eller ikke-substitueret C₃-C₈ heterocyklisk ring,
 substitueret eller ikke-substitueret aryl, (hvor substitutioner inkluderer: F, Cl, Br,
 I, lineær eller forgrenet C₁-C₅-alkyl, OH, alkoxy, N(R)₂, CF₃, CN eller NO₂),
- 25 CH(CF₃)(NH-R₁₀);
 eller **R₃** og **R₄** er forbundet for at danne en 5- eller 6-leddet substitueret eller
 ikke-substitueret, alifatisk eller aromatisk, carbocyklisk eller heterocyklisk ring;
R₅ er H, lineær eller forgrenet, substitueret eller ikke-substitueret C₁-C₅-alkyl,
 lineær eller forgrenet C₁-C₅-halogenalkyl, R₈-aryl, substitueret eller ikke-
- 30 substitueret aryl, substitueret eller ikke-substitueret heteroaryl (hvor
 substitutioner inkluderer: F, Cl, Br, I, lineær eller forgrenet C₁-C₅-alkyl, OH,
 alkoxy, N(R)₂, CF₃, CN eller NO₂);
R₆ er H, lineær eller forgrenet C₁-C₅-alkyl;
R₈ er [CH₂]_p
- 35 hvor **p** er mellem 1 og 10;

R₉ er [CH]_q, [C]_q

hvor **q** er mellem 2 og 10;

R₁₀ og **R₁₁** er hvert uafhængigt H, lineær eller forgrenet C₁-C₅-alkyl, C(O)R eller S(O)₂R;

- 5 **R** er H, lineær eller forgrenet C₁-C₅-alkyl, lineær eller forgrenet C₁-C₅-alkoxy, phenyl, aryl eller heteroaryl, eller to gem R-substituenten er forbundet for at danne en 5- eller 6-leddet heterocyklisk ring;

m, **n**, **l** og **k** er hver uafhængigt et heltal mellem 0 og 4;

Q₁ og **Q₂** er hvert uafhængigt S eller O;

- 10 eller dens farmaceutisk acceptable salt, optisk isomer, tautomer, hydrat, *N*-oxid, isotopisk variant, PROTAC, farmaceutisk produkt eller en hvilken som helst kombination deraf,
til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen for at udvikle eller inhibere kræft hos et individ.

15

10. Forbindelsen til anvendelse ifølge krav 9, hvor kræftformen er valgt fra hepatocellulært karcinom, melanom (f.eks., BRAF mutant melanom), glioblastom, brystkræft (f.eks., invasive ductale karcinomer i brystet, triple-negativ brystkræft), prostatakkræft, leverkræft, hjernekræft, æggestokkræft, lungekræft,

- 20 Lewis lungekarcinom (LLC), kolonkarcinom, bugspytkirtelkræft, nyrecellekarcinom og brystkarcinom, og/eller
hvor kræftformen er tidlig kræft, fremskreden kræft, invasiv kræft, metastatisk kræft, lægemiddelresistent kræft eller en hvilken som helst kombination deraf.

- 25 **11.** Forbindelsen til anvendelse ifølge krav 9 eller 10, hvor individet tidligere er blevet behandlet med kemoterapi, immunoterapi, radioterapi, biologisk terapi, kirurgisk indgreb eller en hvilken som helst kombination deraf.

- 12.** Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 9 til 11, hvor
30 forbindelsen indgives i kombination med en kræft hæmmende terapi, såsom kemoterapi, immunoterapi, radioterapi, biologisk terapi, kirurgisk indgreb eller en hvilken som helst kombination deraf.

13. Forbindelse repræsenteret med strukturen af formel (I) som defineret i krav 9, til anvendelse til at dæmpe, reducere eller inhibere tumorvækst hos et individ.

14. Forbindelsen til anvendelse ifølge krav 13, hvor tumorvæksten er forøget ved
 5 øget acetatoptagelse af kræftceller af nævnte kræft, for eksempel:
 hvor den øgede acetatoptagelse er medieret af ACSS2, og/eller
 hvor tumorcellerne er under hypoksisk stress, eller
 hvor tumorvæksten er dæmpet på grund af suppression af lipidsyntese (f.eks.,
 fedtsyre) og/eller regulering af acetylering og funktion af histoner induceret af
 10 ACSS2-medieret acetatmetabolisme over for acetyl-CoA.

15. In vitro fremgangsmåde til at dæmpe, reducere eller inhibere lipidsyntese
 og/er regulere acetylering og funktion af histoner i en celle såsom en kræftcelle;
 eller
 15 at dæmpe, reducere eller inhibere acetyl-CoA-syntese, såsom ACSS2-medieret
 acetyl-CoA-syntese, fra acetat i en celle såsom en kræftcelle; eller
 at dæmpe, reducere eller inhibere acetatmetabolisme, såsom ACSS2-medieret
 acetatmetabolisme, i kræftcelle, eventuelt hvor kræftcellen er under hypoksisk
 stress,
 20 hvilken fremgangsmåde omfatter at bringe cellen i kontakt med en forbindelse
 repræsenteret med strukturen af formel (I) som defineret i krav 9.


16. In vitro fremgangsmåde til at binde en ACSS2-inhibitorforbindelse til et
 ACSS2-enzym, omfattende trinnet at bringe et ACSS2-enzym i kontakt med en
 25 ACSS2-inhibitorforbindelse repræsenteret med strukturen af formel (I) som
 defineret i krav 9, i en mængde der er effektiv til at binde ACSS2-inhibitor-
 forbindelsen til ACSS2-enzymet.








17. Forbindelse repræsenteret med strukturen af formel (I) som defineret i krav
 30 9, til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen
 for at udvikle eller inhibere human alkoholisme hos et individ, eller
 til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen for
 at udvikle eller inhibere en virusinfektion, såsom en infektion med humant
 cytomegalovirus (HCMV), hos et individ, eller


- til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen for at udvikle eller inhibere alkoholisk steatohepatitis (ASH) hos et individ, eller til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen for at udvikle eller inhibere non-alkoholisk fedtleversygdom (NAFLD) hos et individ,
- 5 eller
- til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen for at udvikle eller inhibere non-alkoholisk steatohepatitis (NASH) hos et individ, eller til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen for at udvikle eller inhibere en metabolisk lidelse såsom fedme, vægtforøgelse,
- 10 hepatisk steatose og fedtleversygdom hos et individ, eller
- til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen for at udvikle eller inhibere en neuropsykiatrisk sygdom eller lidelse såsom angst, depression, skizofreni, autisme og post-traumatisk stresslidelse hos et individ, eller
- 15 til anvendelse til at behandle, dæmpe, reducere sværheden, reducere risikoen for at udvikle eller inhibere en autoimmunsygdom eller -lidelse hos et individ.

18. Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 9-14 eller 17, eller *in vitro* fremgangsmåden ifølge et hvilket som helst af kravene 15 eller 20 16, hvor forbindelsen repræsenteret med strukturen af formel (I) er som defineret i et hvilket som helst af kravene 1-6.

19. Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 9-14 eller 17, eller *in vitro* fremgangsmåden ifølge et hvilket som helst af kravene 15 eller 25 16, hvor forbindelsen repræsenteret med strukturen af formel (I) er repræsenteret med en hvilken som helst af de følgende strukturer:

Forbindelsesnummer	Forbindelsesstruktur
182	

Forbindelsesnummer	Forbindelsesstruktur
188	
189	
197	
205	
208	
210	
211	

Forbindelsesnummer	Forbindelsesstruktur
212	 <chem>CN1C(=O)c2ccccc2C(=O)N1c3ccccc3</chem>

DRAWINGS

Drawing




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4